



(19) Eur pâisches Patentamt  
Eur pean Pat nt Offic  
Office européen des brevets



(11) Publication number:

**0 516 069 A1**

(22)

## EUROPEAN PATENT APPLICATION

(21) Application number: 92108916.5

(51) Int. Cl. 5: **C07D 213/81, C07D 277/46,  
C07D 401/06, C07D 401/12,  
C07D 401/14, C07D 417/12,  
C07D 417/14, C07D 241/24,  
C07C 233/82, A61K 31/44,  
A61K 31/425**

(22) Date of filing: 27.05.92

(35) Priority: 31.05.91 JP 157725/91

(21) Applicant: **SUMITOMO PHARMACEUTICALS  
COMPANY, LIMITED  
2-8, Doshomachi 2-chome, Chuo-ku  
Osaka-shi Osaka 541(JP)**

(43) Date of publication of application:  
02.12.92 Bulletin 92/49


(72) Inventor: Nagata, Hideo  
2-29-7, Ooike  
Ibaraki-shi, Osaka 567(JP)  
Inventor: Kawakami, Hajime  
6-32-702, Fukazu-cho  
Nishinomiya-shi, Hyogo 663(JP)

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI NL PT SE**

(24) Representative: von Kreisler, Alek,  
Dipl.-Chem. et al  
Patentanwälte Von Kreisler-Selting-Werner,  
Delchmannhaus am Hauptbahnhof  
W-5000 Köln 1(DE)

(54) Leukotriene B<sub>4</sub> antagonist.

(57) Leukotriene B<sub>4</sub> antagonists of the formula:



wherein each symbol is as defined in the specification, processes for producing them, and pharmaceutical compositions containing them. The compounds of the present invention are very useful as the drugs for the treatment of allergic and inflammatory diseases.

**EP 0 516 069 A1**

BACKGROUND OF THE INVENTIONTECHNICAL FIELD

5 The present invention relates to compounds effective as leukotriene B<sub>4</sub> antagonists.

More particularly, this invention relates to leukotriene B<sub>4</sub> antagonists, to processes for producing them and to pharmaceutical compositions containing at least one of those leukotriene B<sub>4</sub> antagonists, which have excellent anti-leukotriene B<sub>4</sub> activity and are useful as an anti-allergic agent or an anti-inflammatory agent.


10 PRIOR ART

In 1979 B. Samuelsson reported the isolation and biological effects of leukotrienes (B. Samuelsson et al. (1980): Advances in Prostaglandin and Thromboxane Research, Vol. 6, edited by B. Samuelsson, R. Ramwell, and R. Paletti, P. I. Raven Press, New York).

15 Since then, a tremendous amount of research in the synthetic organic chemistry and pharmacology of leukotriene A<sub>4</sub>, B<sub>4</sub>, C<sub>4</sub>, D<sub>4</sub>, etc. has been performed.

Leukotrienes induce an increase in capillary permeability and cause smooth muscle contraction. Leukotriene B<sub>4</sub>, one of leukotrienes which is shown below, has different pharmacological properties from the others. It is chemotactic for macrophages and neutrophils at concentrations of ~ 1 ng/ml (greater than any other known lipid chemotactic factor). It is detected in the synovia of patients with rheumatoid arthritis or 20 gouty arthritis, and in the sputum of obstructive airways diseases which suggest that it is a primary mediator of inflammatory and allergic states.

25


Leukotriene B<sub>4</sub>

30

35

In recent research some compounds having an antagonism on LTB<sub>4</sub> have been reported. For example,  
1) EP-A-0183177 (SUMITOMO PHARMACEUTICALS CO.)


40




2) EP-A-276065 (ELI LILLY & CO)

50

55




3) EP-A-276064 (ELI LILLY & CO)



4) EP-A-0405116 (ONO PHARMACEUTICAL CO)

10

15




20

5) EP-A-292977 (SEARLE G D &amp; CO)

25

30



6) WO-A-8805045 (UPJOHN CO)

35

B-C-C≡CH<sub>2</sub>C(M<sub>2</sub>)-C≡C-Y-C(M<sub>1</sub>)-A  
B-C-C≡CH<sub>2</sub>C(M<sub>2</sub>)-C≡C-P-R<sub>5</sub>-A


SUMMARY OF THE INVENTION

40 In accordance with the present invention, leukotriene B<sub>4</sub> antagonists of the following general formula [I] and their non-toxic pharmaceutically acceptable salts are provided, which have potent anti-leukotriene B<sub>4</sub> activity which include suppression of chemotaxis, degranulation and O<sub>2</sub>-production of leukocytes, and modulation of lymphocytes activity, etc. This action may render these compounds very useful as the drugs for the treatment of inflammatory states or immunological disorders such as allergy, rheumatoid arthritis, inflammatory bowel disease.

DISCLOSURE OF THE INVENTION

50 The novel leukotriene B<sub>4</sub> antagonists provided by the present invention are those represented by the formula [I]:

55



10

wherein

A is a C<sub>1</sub>-C<sub>5</sub> alkylene chain;

B is a phenylene or 6 membered heteroaromatic group which is constituted by carbon atoms and one or two nitrogen atoms, and B may be, optionally substituted with one or two substituents selected from the 15 group, consisting of a C<sub>1</sub>-C<sub>5</sub> alkyl group, a C<sub>1</sub>-C<sub>5</sub> alkoxy group, a hydroxyl group, a carboxyl group, a nitro group and a halogen atom;

R<sup>1</sup> is a C<sub>1</sub>-C<sub>5</sub> alkyl group;R<sup>2</sup> is a hydroxyl group or a C<sub>1</sub>-C<sub>5</sub> alkoxy group;R<sup>3</sup> and R<sup>4</sup> are each independently a hydrogen atom, a C<sub>1</sub>-C<sub>5</sub> alkyl group, a C<sub>2</sub>-C<sub>5</sub> alkenyl group or a20 C<sub>2</sub>-C<sub>5</sub> alkynyl group;R<sup>5</sup> is a hydrogen atom, a C<sub>1</sub>-C<sub>5</sub> alkyl group or a hydroxy C<sub>1</sub>-C<sub>5</sub> alkyl group;R<sup>6</sup> is a group of the formula: $-\text{X}-\text{Y}-\text{Z}-\text{R}^6$ 

25

wherein X is a phenylene group or a monocyclic 5- 6 membered hetero aromatic group, and X is optionally substituted with one or two substituents selected from the group consisting of a C<sub>1</sub>-C<sub>5</sub>alkyl group, a hydroxyl group, a carboxyl group, a nitro group and a halogen atom;

Y is a single bond or an oxygen atom;

30 Z is a single bond or a C<sub>1</sub>-C<sub>5</sub> alkylene chain;

provided that when Y is an oxygen atom,

X is a phenylene group and Z is a C<sub>1</sub>-C<sub>5</sub> alkylene chain;R<sup>6</sup> is a COOR<sup>7</sup> group,a CONR<sup>8</sup>R<sup>9</sup> group,35 a CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOR<sup>7</sup> group,a CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>CONR<sup>8</sup>R<sup>9</sup> group,a CONHCHR<sup>20</sup>CONHCHR<sup>22</sup>CO<sub>2</sub>R<sup>7</sup> group or

a sulfamoyl group,

wherein R<sup>7</sup> is a hydrogen atom, a benzyl group, a C<sub>1</sub>-C<sub>5</sub> alkyl group or an C<sub>1</sub>-C<sub>5</sub> alkyl group

40 substituted with an aminoheteroaromatic group wherein the heteroaromatic group is a monocyclic 5-6 membered heteroaromatic group;

R<sup>8</sup> and R<sup>9</sup> are each independently a hydrogen atom, a C<sub>1</sub>-C<sub>5</sub> alkyl group, hydroxy C<sub>1</sub>-C<sub>5</sub> alkyl group, a hydroxyethylpyridyl group or a hydroxyethylthiazolyl group, or the group of the formula:

45  $-\text{NR}^8\text{R}^9$ 

represents a pyrrolidino, a piperidino or a morpholino group;

R<sup>20</sup> is a hydrogen atom, a hydroxyl group, a C<sub>1</sub>-C<sub>5</sub> alkyl group, a phenyl group, a hydroxyphenyl group, a benzyl group, a hydroxy benzyl group or a substituted C<sub>1</sub>-C<sub>5</sub> alkyl group wherein the substituent is 50 selected from the group consisting of a hydroxyl group, a C<sub>1</sub>-C<sub>5</sub> alkoxy group, a mercapto group, a methylthio group, an amino group, an indolyl group, an imidazolyl group, a carboxyl group, a C<sub>1</sub>-C<sub>5</sub> alkoxycarbonyl group, a carbamoyl group and a guanidino group;

n is 0, 1, 2, 3, 4 or 5; and

R<sup>22</sup> is a hydrogen atom, a C<sub>1</sub>-C<sub>5</sub> alkyl group or a C<sub>1</sub>-C<sub>5</sub> hydroxyalkyl group;55 or R<sup>6</sup> is a CHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOR<sup>7</sup> group,a CH<sub>2</sub>CHR<sup>20</sup>COOR<sup>7</sup> group,a CHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>CONR<sup>8</sup>R<sup>9</sup> group,a CH<sub>2</sub>CHR<sup>20</sup>CONR<sup>8</sup>R<sup>9</sup> group,

- a  $\text{CHR}^{20}(\text{CH}_2)_n\text{OH}$  group,  
 a  $\text{CR}^{20}\text{R}^{22}(\text{CH}_2)_n\text{OH}$  group,  
 a  $\text{CH}_2\text{CHR}^{20}\text{OH}$  group, or  
 a  $\text{CHR}^{20}\text{CONHCHR}^{22}\text{CO}_2\text{R}^7$  group,  
 5 wherein  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{20}$ ,  $\text{R}^{22}$  and  $n$  are as defined above, or the group of the formula:

10



represents an azetidino group, pyrrolidino group, a piperidino group or a homopiperidino group, which is optionally substituted with one to two substituents selected from the group consisting of a hydroxyl group, a 15  $\text{C}_1\text{-C}_5$  hydroxyalkyl group, carboxyl group,  $\text{C}_1\text{-C}_5$  alkoxycarbonyl group and benzyloxycarbonyl group; or pharmaceutically acceptable salts thereof.

In the definitions as used above, the term " $\text{C}_1\text{-C}_5$  alkylene" means a straight or branched chain  $\text{C}_1\text{-C}_5$  alkylene (e.g. methylene, ethylene, trimethylene, tetramethylene, pentamethylene, 1-methylethylene, 2-ethyltrimethylene, etc.).

20 The term " $\text{C}_1\text{-C}_5$  alkyl" means a straight or branched chain  $\text{C}_1\text{-C}_5$  alkyl (e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl, neo-pentyl, etc.).

The term " $\text{C}_2\text{-C}_5$  alkenyl" means a straight or branched chain  $\text{C}_2\text{-C}_5$  alkenyl (e.g. 1-methylethethyl, 1-ethylethethyl, 1-propenyl, 2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1-n-butenyl, 2-n-butenyl, 3-n-butenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, etc.).

25 The term " $\text{C}_2\text{-C}_5$  alkynyl" means a straight or branched chain  $\text{C}_2\text{-C}_5$  alkynyl (e.g. ethynyl, 1-propynyl, 2-propynyl, 1-methyl-2-propynyl, 1-n-butyynyl, 2-n-butyynyl, 3-n-butyynyl, 3-methyl-1-butyynyl, 1-methyl-2-butyynyl, 2-methyl-3-butyynyl, 1-pentynyl 2-pentynyl 3-pentynyl, 4-pentynyl, etc.).




30 The term " $\text{C}_1\text{-C}_5$  alkoxy" means alkoxy having  $\text{C}_1\text{-C}_5$  alkyl moiety (e.g. methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxyl, iso-pentoxyl, sec-pentoxyl, neo-pentoxyl, etc.).

The term "6 membered heteroaromatic group which is constituted by carbon atoms and one or two nitrogen atoms" includes pyridinediyl, pyrazinediyl, pyrimidinediyl, etc.




35 The term "monocyclic 5-6 membered heteroaromatic group" contains, for example, 1-3 hetero atoms which can be a nitrogen, oxygen or sulfur atom, or an oxydized nitrogen atom ( $\text{N} \rightarrow \text{O}$ ), and examples of the monocyclic 5-6 membered heteroaromatic group are a pyridinediyl group and any one of the group of the formula (i)-(viii):

40



45



50



55



The term "hydroxyphenyl group" may be a 2-hydroxyphenyl, a 3-hydroxyphenyl or a 4-hydroxyphenyl group.

The term "hydroxybenzyl group" may be a 2-hydroxybenzyl, a 3-hydroxybenzyl or a 4-hydroxybenzyl group.

5 The term "halogen" may be a chlorine, a bromine or a fluorine atom.



The term "indolyl group" may be a 2-indolyl or 3-indolyl group.


The term "imidazolyl group" may be a 4-imidazolyl group.

A basic object of the present invention is to provide novel compounds effective as leukotriene B<sub>4</sub> antagonists [I] having excellent pharmacological activities.

Another object of the present invention is to provide processes for producing those compounds [I]. A further object of the present invention is to provide a pharmaceutical composition containing a compound of the formula [I]. These and other objects will be apparent to those skilled in the art to which the present invention pertains from the foregoing and subsequent descriptions.


The novel leukotriene B<sub>4</sub> antagonists [I] of the invention can be prepared by the following methods:





10


15



20

25

30





35





40

45

50

55





(wherein A, B, R¹, R², R³, R⁴, R⁵, R⁶', X, Y, Z and R²⁰ are as defined above, and  
 R¹¹ is the same as R⁶', but it does not mean free carboxylic group;  
 R¹² is a group of the formula:

- 50    X-Y-Z-COOR⁷',  
 · X-Y-Z-CONHCHR²⁰(CH₂)ₙ COOR⁷',  
 · X-Y-Z-CONHCHR²⁰CONHCHR²²CO₂R⁷',  
 · CHR²⁰(CH₂)ₙCOOR⁷',  
 · CH₂CHR²⁰COOR⁷', or  
 55    CHR²⁰CONHCHR²²COOR⁷',

wherein X, Y, Z, R²⁰, R²² and n are as defined above, and R⁷' is the same as R⁷ but it does not mean a hydrogen atom,

$R^{13}$  is a group of the formula:

- X-Y-Z-COOH,
- X-Y-Z-CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub> COOH,
- 5 X-Y-Z-CONHCHR<sup>20</sup>CONHCHR<sup>22</sup>CO<sub>2</sub>H,
- CHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOH,
- CH<sub>2</sub>CHR<sup>20</sup>COOH, or
- CHR<sup>20</sup>CONHCHR<sup>22</sup>COOH,
- 10 wherein X, Y, Z, R<sup>20</sup>, R<sup>22</sup> and n are as defined above.

$R^{14}$  is a group of the formula:

(CH<sub>2</sub>)<sub>n</sub>COOR<sup>7</sup>, or  
CONHCHR<sup>22</sup>COOR<sup>7</sup>,

- 15 wherein R<sup>7</sup>, R<sup>22</sup> and n are as defined above.

$R^{15}$  is a group of the formula:

- COOR<sup>7</sup>,
- 20 CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOR<sup>7</sup>, or  
CONHCHR<sup>20</sup>CONHCHR<sup>22</sup>CO<sub>2</sub>R<sup>7</sup>,
- wherein R<sup>7</sup>, R<sup>20</sup>, R<sup>22</sup> and n are as defined above.

$R^{16}$  is a group of the formula:

- 25 COOH,
- CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOH, or  
CONHCHR<sup>20</sup>CONHCHR<sup>22</sup>CO<sub>2</sub>H,
- 30 wherein R<sup>20</sup>, R<sup>22</sup> and n are as defined above.

$R^{26}$  is a group of the formula:

(CH<sub>2</sub>)<sub>n</sub>COOH, or  
CONHCHR<sup>22</sup>COOH,

- 35 wherein R<sup>22</sup> and n are as defined above.

#### Method A

- 40 The amide compound [IV] or [IX] can be prepared from an acid compound [II] or [VII] by reacting an amine compound [III] or [VIII] in the presence of a condensing agent (e.g. dicyclohexylcarbodiimide, ethyldimethylaminopropylcarbodiimide hydrochloride, etc.), hydroxybenzotriazole and a tertiary amine (e.g. triethylamine, 4-dimethylaminopyridine, etc.) in an inert solvent (e.g. dichloromethane, mixed solvent of dichloromethane and N,N-dimethylformamide, etc.) at a temperature in the range from 0 °C to the boiling temperature of the solvent.
- 45 If a substituent of R<sup>20</sup> of compound [VIII] is an impediment group (e.g. mercapto, carboxyl, amino group, etc.), the compound is previously protected by a protecting group (e.g. benzyl, benzyloxycarbonyl, t-butoxycarbonyl group, etc.), and after the reaction is carried out, the protecting group is eliminated. The protection and deprotection of R<sup>20</sup> can be carried out by the conventional procedure. [Protective Group in
- 50 Organic Chemistry, Edited by J. F. W. McOmic (1973) 95 - 143].

#### Method B

- The amide compound [IV] or [IX] can be obtained from an acid chloride or an acid anhydride of an acid compound [II] or [VII] by reacting with an amine compound [III] or [VIII] in the presence of a tertiary amine (e.g. triethylamine, etc.), or by reacting with a salt of an amine compound [III] or [VIII] (e.g. sodium salt, potassium salt, etc.) in the absence of amine in an inert solvent (e.g. tetrahydrofuran, etc.) at a temperature in the range from 0 °C to a boiling temperature of the solvent.

**EP 0 516 069 A1**

The transformation of an acid group to an acid chloride group can be carried out by treating the acid compound with phosphorous oxychloride or thionyl chloride in an inert solvent (e.g. chloroform, etc.) or in the absence of solvent at a temperature in the range of from -40 °C to the boiling temperature of the reaction mixture.

5 The transformation of an acid group to an acid anhydride group can be carried out by treating the acid compound with chloroformate ester (e.g. ethyl chloroformate, etc.) in the presence of a tertiary amine (e.g. triethylamine, etc.) in an inert solvent (e.g. chloroform, etc.) at a temperature in the range of from -40 °C to the boiling temperature of the solvent.

If a substituent of R<sup>20</sup> of compound [VIII] is a impeditment group (e.g. mercapto, carboxyl, amino group, etc.), the compound is previously protected by a protecting group (e.g. benzyl group, benzyloxycarbonyl group, t-butoxycarbonyl group, etc.), and after the reaction is carried out, the protecting group is eliminated.

10 The protection and deprotection of R<sup>20</sup> can be carried out by the conventional procedure [Protective Group in Organic Chemistry, Edited by J. F. W. McOmic (1973) 95 - 143].

15 **Method C**

The acid compound [VI], [X] or [XIV] can be prepared by hydrolysis of the ester compound [V], [IX] or [XIII] by treating with an aqueous alkali (e.g. sodium hydroxide, lithium hydroxide) in an inert solvent (e.g. tetrahydrofuran, methanol, ethanol, etc.).

20 **Method D**

The N-oxide compound [XII] can be prepared from pyridine compound [XI] by treating with an oxidizing agent (e.g. m-chloroperbenzoic acid, etc.) in an inert solvent (e.g. methylene chloride, etc.).

25 The amine compounds [III] and [VIII] are known compounds or easily obtained as described in e.g. J. Goto, K. Sakane, Y. Nakai, T. Teraji, The journal of antibiotics, 37, 532 (1984), I. Csendes, B. W. Müller, W. Tosch, The journal of antibiotics, 36, 1020 (1983), M. Ohta, Yakugaku zassi, 72, 1536 (1983), JP-A-58-23697. And, the starting compounds [II], [II-1] and [II-2] can be obtained by the following method.

30


35

40

45

50

55



(wherein A, B, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined above, R<sup>17</sup> is a C<sub>1</sub>-C<sub>5</sub> alkyl group, R<sup>18</sup> is a C<sub>1</sub>-C<sub>5</sub> alkyl group, Hal is a chlorine or bromine atom)

Alkylation of the compound [XV] into the compound [XVII] can be accomplished by treating the former with the compound [XVI] in an inert solvent (e.g. N,N-dimethylformamide, etc.) in the presence of a base (e.g. anhydrous potassium carbonate, etc.). Optionally, the compound [XVII] can be alkylated to produce the compound [XVIII] by the same procedure as used in the synthesis of the compound [XVII] from the compound [XV]. And, the compound (II-1) and (II-2), respectively, can be prepared from the compound [XVII] and [XVIII] by hydrolysis (Method C).


The compound [XV] is a known compound or easily obtained as described in e.g. J. Hurst, J. Wibberley, Journal of Chemical Society, 1962, 119.

The compound [XVI] is obtained by;

(1) In the case where both Hal and B of compound [XVI] are jointed to the same carbon atom:

the compound [XVI] is a known compound or easily obtained as described in e.g. J. Hurst, J. Wibberley, Journal of Chemical Society, 1962, 119, etc.

(2) In the case that there are two carbon atoms between Hal and B in compound [XVI]:



(wherein A, B and Hal are as defined above,  $\text{R}^{19}$  is a  $\text{C}_1\text{-}\text{C}_5$  alkyl group (but, there is at least one hydrogen atom at the  $\alpha$  carbon bonded to B),  $\text{R}^{21}, \text{R}^{23}$  are each independently a hydrogen atom or a  $\text{C}_1\text{-}\text{C}_5$  alkyl group,  $\text{R}^{24}$  is a  $\text{C}_1\text{-}\text{C}_5$  alkyl group, and  $\text{R}^{25}$  is a  $\text{C}_1\text{-}\text{C}_5$  alkyl group or phenyl group)

the compound [XVI] is prepared in the following way:

first step: the carboxylic acid group of a compound [XX] is protected to yield a 4,4-dimethyl-2-oxazoline compound,

second step: the 4,4-dimethyl-2-oxazoline compound is treated with a base to deprotonate a hydrogen atom attached to a carbon atom adjacent to B group (e.g. sodium amide, n-butyl lithium, etc.),

third step: the deprotected compound is reacted with the compound of the formula [XXI] (aldehyde or ketone) to yield a hydroxy compound,

fourth step: the hydroxyl compound is alkylated by reacting with a compound of the formula  $\text{R}^{24}\text{-Hal}$ ,


fifth step: the alkylated compound is treated with halogenated hydrogen (e.g. hydrogen chloride, hydrogen bromide, etc.) in the alcohol represented by  $\text{R}^{17}\text{OH}$ .

(3) In the case that there are 3 or more carbon atoms between Hal and B in the compound [XVI]:  
 the compound [XVI] is prepared in the same way, except modifying the alkylation reaction, as described  
 in above (2), i.e., the compound [XX] is protected and deprotonated, and then alkylated by alkylhalide  
 [XXII]. The alkylated product is treated with halogenated hydrogen (e.g. hydrogen chloride, hydrogen  
 bromide, etc.) in the alcohol represented by R<sup>17</sup>OH.

5 Specific examples of the leukotriene B<sub>4</sub> antagonists are as follows:

Table 1

10



20

25

30

35


R <sup>3</sup>	H	H	H	n-Pr	H	H	H	H	H
R <sup>4</sup>	Me	n-Pr	n-Pr	H	Et	Et	Et	Et	Et
R <sup>5</sup>	H	H	H	H	CH <sub>3</sub>	Et	n-Pr	i-Pr	H
R <sup>6</sup>	CONH <sub>2</sub>	CONHMe							

Table 2

40

45

55




50

55

A	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -	-(CH <sub>2</sub> ) <sub>5</sub> -				
R <sup>6</sup>	CONMe <sub>2</sub>	CONH <i>i</i> Pr	O-C-N-C(=O)-	O-C-N-C(=O)-	O-C-N-C(=O)-	CONH <sub>2</sub>	CONH <sub>2</sub>	CONH <sub>2</sub>	CONH <sub>2</sub>

Table 3




A	-CHMe-	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -
B									
Z	-CH <sub>2</sub> -	single bond	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -	-(CH <sub>2</sub> ) <sub>5</sub> -	-CH <sub>2</sub> -	single bond

15

20

Table 4



B									
Z	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -	single bond	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -

40

45

50

55

Table 5

5

10

B								
X								

15

20

Table 6

30


35

B								
X								
Z	single bond	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -	single bond	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -

40

45


Table 7



B									
X									
Z	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -	single bond	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	single bond	-CH <sub>2</sub> -

25

Table 8




B									
X									
Z	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -	-CH <sub>2</sub> -	single bond	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -	-CMe <sub>2</sub> -

55

Table 9

5



10

15

20

X									
Z	single bond	single bond	single bond	single bond	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -
R <sup>6</sup>	CONH <sub>2</sub>	CONH <sub>2</sub>	SO <sub>2</sub> NH <sub>2</sub>	SO <sub>2</sub> NH <sub>2</sub>	CONH <sub>2</sub>	CONH <sub>2</sub>	SO <sub>2</sub> NH <sub>2</sub>	SO <sub>2</sub> NH <sub>2</sub>	SO <sub>2</sub> NH <sub>2</sub>

Table 10

25

30

35

40

45

50

R <sup>2</sup>	OH	OH	OH	OH	OMe	OH	OH	OH	OH
R <sup>5</sup>	H	H	H	H	H	H	Me	Et	n-Pr
X									
Y	-O-	-O-	-O-	-O-	single bond				
Z	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -				
R <sup>6</sup>	CONH <sub>2</sub>	CONH <sub>2</sub>	CONH <sub>2</sub>	CONH <sub>2</sub>	CONH <sub>2</sub>	CO <sub>2</sub> Et	CO <sub>2</sub> Et	CO <sub>2</sub> Et	CO <sub>2</sub> Et

55

Table 11


5

10

15

20

25



A	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -	-(CH <sub>2</sub> ) <sub>5</sub> -	-CHMe-	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -
B									
R <sup>5</sup>	i-Pr	H	H	H	H	H	H	H	H
Z	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -

30


Table 12

35

40

45


50



B									
X									
Z	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -

55


Table 13



10

B								
X								
Z	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -


Table 14



35


B								
X								
Z	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -

Table 15



X								
Y	-O-	-O-	-O-	-O-	single bond	single bond	single bond	single bond
Z	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	single bond	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -
R <sup>6'</sup>	CO <sub>2</sub> Et	CO <sub>2</sub> Et	CO <sub>2</sub> Et	CO <sub>2</sub> Et	CO <sub>2</sub> H	CO <sub>2</sub> H	CO <sub>2</sub> H	CO <sub>2</sub> H

Table 16



X								
Z	-(CH <sub>2</sub> ) <sub>5</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -

50

55

Table 17


5

10

15

20

25



X									
Z	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	single bond	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-(CH <sub>2</sub> ) <sub>4</sub> -	-(CH <sub>2</sub> ) <sub>5</sub> -	single bond

Table 18

30


35

40

45

50

55



R <sup>5</sup>	H	H	H	Me	Et	n-Pr	i-Pr	n-Bu	i-Bu
X									
Z	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -					

Table 19

5

10

15

20

25

30

B									
X									
Z	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -




Table 20


35

40

45

50


B									
X									
Z	-(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>3</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -



55

EP 0 516 069 A1


Table 21



B									
X									
Z	$-(CH_2)_3-$	$-CH_2-$	$-(CH_2)_2-$	$-(CH_2)_3-$	$-CH_2-$	$-(CH_2)_2-$	$-(CH_2)_3-$	$-CH_2-$	$-(CH_2)_2-$

25

Table 22




A	$-CH_2-$	$-CH_2-$	$-CH_2-$	$-CH_2-$	$-CH_2-$	$-CH_2-$	$-CH_2-$	$-(CH_2)_2-$	$-(CH_2)_3-$
B									
X									
Z	$-(CH_2)_3-$	$-CH_2-$	$-(CH_2)_2-$	$-(CH_2)_3-$	$-CH_2-$	$-(CH_2)_2-$	$-(CH_2)_3-$	$-CH_2-$	$-CH_2-$

55

## EP 0 516 069 A1

Table 23




10

R <sup>4</sup>	Et	Et	Et	Me	Et	n-Pr	n-Bu	-CH <sub>2</sub> CH=CH <sub>2</sub>	CH <sub>2</sub> C≡CH
A	-(CH <sub>2</sub> ) <sub>4</sub> -	-(CH <sub>2</sub> ) <sub>5</sub> -	-CHMe-	-CH <sub>2</sub> -	-CH <sub>2</sub> -				

20

Table 24



30

R <sup>3</sup>	Me	Et	n-Pr	n-Bu	n-Pentyl	-CH <sub>2</sub> CH=CH <sub>2</sub>	CH <sub>2</sub> C≡CH	Me	Et
R <sup>4</sup>	Et	Et	Et	Et	Et	Et	Et	H	H

35


40

45

50

55

Table 25




R <sup>1</sup>	Me	Me	Me	Me	Me	Me	Me	Et	n-Pr
R <sup>2</sup>	OH	OH	OH	OH	OMe	OEt	O-n-Pr	OH	OH
R <sup>3</sup>	i-Pr	i-Bu	n-Bu	n-Pentyl	H	H	H	H	H
R <sup>4</sup>	H	H	H	H	Et	Et	Et	Et	Et

15

20

25

Table 26



R <sup>1</sup>	n-Bu	n-Pentyl	Me	Me	Me
R <sup>6</sup>	CO <sub>2</sub> H	CO <sub>2</sub> H	<sup>O</sup> CN-CH <sub>2</sub> CO <sub>2</sub> Me H	<sup>O</sup> CN-(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> Me H	<sup>O</sup> CN-CH <sub>2</sub> CO <sub>2</sub> H H

40

45


50

55

Table 27

5

10



15

20

X					
R <sup>6</sup>	$\text{O} \begin{matrix} \text{CN}-(\text{CH}_2)_2\text{CO}_2\text{H} \\ \text{H} \end{matrix}$	$\text{O} \begin{matrix} \text{CN} \cdot \text{CH}_2\text{CO}_2\text{Me} \\ \text{H} \end{matrix}$	$\text{O} \begin{matrix} \text{CN}-(\text{CH}_2)_2\text{CO}_2\text{Me} \\ \text{H} \end{matrix}$	$\text{O} \begin{matrix} \text{CN} \cdot \text{CH}_2\text{CO}_2\text{H} \\ \text{H} \end{matrix}$	$\text{O} \begin{matrix} \text{CN}-(\text{CH}_2)_2\text{CO}_2\text{H} \\ \text{H} \end{matrix}$


25

30

Table 28

35

40



45

50


X					
R <sup>6</sup>	$\text{O} \begin{matrix} \text{CN}-(\text{CH}_2)_2\text{CO}_2\text{H} \\ \text{H} \end{matrix}$	$\text{O} \begin{matrix} \text{iPr} \\ \text{CN} \cdot \text{CHCO}_2\text{Me} \\ \text{H} \end{matrix}$	$\text{O} \begin{matrix} \text{CH}_2\text{CO}_2\text{H} \\ \text{CN} \cdot \text{CHCC}_2\text{H} \\ \text{H} \end{matrix}$	$\text{O} \begin{matrix} (\text{CH}_2)_4\text{NH}_2 \\ \text{CN} \cdot \text{CHCO}_2\text{H} \\ \text{H} \end{matrix}$	$\text{O} \begin{matrix} \text{CH}_2\text{OH} \\ \text{CN} \cdot \text{CHCO}_2\text{H} \\ \text{H} \end{matrix}$

55

Table 29

5

10



15

20

$\text{R}^6$	$\text{CH}_2\text{CO}_2\text{H}$	$(\text{CH}_2)_2\text{CO}_2\text{H}$	$(\text{CH}_2)_3\text{CO}_2\text{H}$	$(\text{CH}_2)_4\text{CO}_2\text{H}$	$\text{CH}_2\text{CO}_2\text{Me}$
--------------	----------------------------------	--------------------------------------	--------------------------------------	--------------------------------------	-----------------------------------

25

30

Table 30

35

40

45


$\text{R}^6$	$\text{CH}_2\text{CO}_2\text{Et}$	$\text{CH}_2\text{CO}_2\text{CH}_2-\text{C}_6\text{H}_4-$	$\text{CH}_3-\text{CH}(\text{CO}_2\text{H})_2$	$\text{CH}_3-\text{CH}(\text{CO}_2\text{H})_2$	$\text{CH}_3-\text{CH}(\text{CO}_2\text{H})_2$
--------------	-----------------------------------	---	--	--	--

50

55

Table 31

5



10


R <sup>6</sup>	CHOO <sub>2</sub> H Cyclohexyl	CHCO <sub>2</sub> H Benzyl	CHCO <sub>2</sub> H 4-Methylbenzyl	CHCO <sub>2</sub> H 4-Hydroxybenzyl	CHCO <sub>2</sub> H 2-Hydroxybenzyl
----------------	-----------------------------------	-------------------------------	---------------------------------------	--	--

20

25

Table 32

30



35

40

45

R <sup>6</sup>	CH <sub>2</sub> CO <sub>2</sub> H 2-Hydroxyethyl	CH <sub>2</sub> CO <sub>2</sub> H 3-Hydroxypropyl	CH <sub>2</sub> CO <sub>2</sub> H 3-Mercaptopropyl	CH <sub>2</sub> CO <sub>2</sub> H 2-Mercaptoethyl	CH <sub>2</sub> CO <sub>2</sub> H (CH <sub>2</sub> ) <sub>4</sub> NH <sub>2</sub>
----------------	---	--	---	--	--


50

55

Table 33

5

10



15

20

R <sup>6</sup>	<chem>CC(=O)c1ccccc1</chem>	<chem>CC(=O)c1ccncc1</chem>	<chem>CC(=O)c1cc(C(=O)O)cc1</chem>	<chem>CC(=O)c1cc(C(=O)OCC(=O)O)cc1</chem>	<chem>CC(=O)c1cc(C(=O)OCC(=O)N)cc1</chem>
----------------	-----------------------------	-----------------------------	------------------------------------	---	---

25

30

Table 34

35

40

45

R <sup>6</sup>	<chem>CC(=O)NC(=O)C</chem>	<chem>CC(=O)NCCCCN</chem>	<chem>CC(=O)NHC</chem>	<chem>CC(=O)NHCCH3</chem>	<chem>CC(=O)NHC(=O)C</chem>
----------------	----------------------------	---------------------------	------------------------	---------------------------	-----------------------------


50

55

Table 35

5

10



15

20

R <sup>6</sup>	(CH <sub>2</sub> ) <sub>2</sub> CONH <sub>2</sub>	(CH <sub>2</sub> ) <sub>2</sub> CONMe <sub>2</sub>	CH <sub>2</sub> CONCyclohexyl	CH <sub>2</sub> CONCyclopentylO	CH <sub>2</sub> CONCyclopentyl
----------------	---	--	-------------------------------	---------------------------------	--------------------------------

25

30

Table 36

35

40

45

R <sup>6</sup>	CHCOONH <sub>2</sub> CH <sub>3</sub>	CHCOONH <sub>2</sub> Cyclopropyl	CHCOONMe <sub>2</sub> Cyclohexyl	CHCOONMe <sub>2</sub> Cyclopentyl-OH	CHCOONHMe Cyclopentyl-OH
----------------	---	-------------------------------------	-------------------------------------	---	-----------------------------

50

55


## EP 0 516 069 A1

Table 37



15					
----	--	--	--	--	--


Table 38



30	R <sup>1</sup>	Et	n-Pr	Me	Me	Me
35	R <sup>2</sup>	OH	OH	OMe	OEt	OH
40	R <sup>3</sup>	H	H	H	H	n-Pr
45	R <sup>4</sup>	Et	Et	Et	Et	H

55

Table 39




R <sup>2</sup>	OH	OMe	OMe	OH	OH
R <sup>3</sup>	n-Pr	n-Pr	n-Pr	H	H
R <sup>4</sup>	H	H	H	Et	Et
A	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-CH <sub>2</sub> -	-(CH <sub>2</sub> ) <sub>2</sub> -	-CH <sub>2</sub> -
R <sup>5</sup>	H	H	H	H	Me
R <sup>6</sup>	CHOO <sub>2</sub> H CH <sub>3</sub>	CHOO <sub>2</sub> H CH <sub>3</sub>	(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H	(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H	(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H

Table 40

5

10



15


R <sup>5</sup>	Et	n-Pr	isoBu	sec-Bu	(CH <sub>2</sub> ) <sub>2</sub> OH
----------------	----	------	-------	--------	------------------------------------

20

Table 41

25

30



35

40


45

50

R <sup>3</sup>	H	H	H	H	n-Pr
R <sup>4</sup>	Et	Et	Et	Et	H
R <sup>5</sup>	(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H	CHCO <sub>2</sub> H CH <sub>3</sub>	CHCO <sub>2</sub> H OH	CHCO <sub>2</sub> H CH <sub>2</sub> CO <sub>2</sub> H	CHCO <sub>2</sub> H CH <sub>2</sub> CO <sub>2</sub> H

55

Table 42




R <sup>1</sup>	OMe	OH	OH	OH	OH
R <sup>2</sup>	n-Pr	H	H	H	H
R <sup>4</sup>	H	Et	Et	Et	Et
B					
R <sup>6</sup>	CHCO <sub>2</sub> H CH <sub>2</sub> CO <sub>2</sub> H	(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H	CHCO <sub>2</sub> H CH <sub>3</sub>	CHCO <sub>2</sub> H OH	CHCO <sub>2</sub> H CH <sub>2</sub> CO <sub>2</sub> H

45

50

55

Table 43



$\text{R}^2$	OH	O <i>Me</i>	OH	OH	OH
$\text{R}^3$	n-Pr	n-Pr	H	H	H
$\text{R}^4$	H	H	Et	Et	Et
B					
$\text{R}^6$	$\text{CHOO}_2\text{H}$ $\text{CH}_2\text{CO}_2\text{H}$	$\text{CHOO}_2\text{H}$ $\text{CH}_2\text{CO}_2\text{H}$	$(\text{CH}_2)_2\text{CO}_2\text{H}$	$\text{CHOO}_2\text{H}$ $\text{CH}_3$	$\text{CHOO}_2\text{H}$ 


40

45

50


55

Table 44



R <sup>2</sup>	OH	OH	O <sub>Me</sub>	OH	OH
R <sup>3</sup>	H	n-Pr	n-Pr	H	H
R <sup>4</sup>	Et	H	H	Et	Et
R <sup>5</sup>	CHOO <sub>2</sub> H CH <sub>2</sub> CO <sub>2</sub> H	CHOO <sub>2</sub> H CH <sub>2</sub> CO <sub>2</sub> H	CHOO <sub>2</sub> H CH <sub>2</sub> CO <sub>2</sub> H	CHOO <sub>2</sub> H CH <sub>3</sub>	CHOO <sub>2</sub> H CH <sub>3</sub>

Table 45




R <sup>6</sup>	CHOO <sub>2</sub> H CH <sub>3</sub>				

50


55

Table 46



R <sup>1</sup>	Me	Et	Me	Me	Me
R <sup>6</sup>	(CH <sub>2</sub> ) <sub>2</sub> OH	(CH <sub>2</sub> ) <sub>3</sub> OH	(CH <sub>2</sub> ) <sub>4</sub> OH	CH(CH <sub>2</sub> OH) <sub>2</sub> CH <sub>3</sub>	CH(CH <sub>2</sub> OH) <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>

Table 47



R <sup>2</sup>	OH	O- <sub>n</sub> -Pr	OH	OH	OH
R <sup>3</sup>	Me	H	H	H	H
R <sup>4</sup>	Me	H	Et	Et	Et
R <sup>5</sup>	H	H	H	Me	H
R <sup>6</sup>	(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H	(CH <sub>2</sub> ) <sub>2</sub> CO <sub>2</sub> H	CH(CH <sub>2</sub> OH) <sub>2</sub>	CH(CH <sub>2</sub> OH) <sub>2</sub>	CH <sub>2</sub> CONHCH <sub>2</sub> CO <sub>2</sub> H

Among the leukotriene B<sub>4</sub> antagonists thus obtained, the compound [I] can be converted to a pharmaceutically acceptable salt form. The pharmaceutically acceptable salts of these leukotriene B<sub>4</sub> antagonists can be formed with pharmaceutically acceptable metal cation such as sodium, potassium, magnesium and calcium, ammonium or amine cations.

The preparations of pharmaceutical compositions can be carried out by conventional methods. For

example, leukotriene B<sub>4</sub> antagonists [I] may be mixed with carriers, diluents, lubricants, fillers and/or binders such as lactose, sucrose, calcium phosphate, starch, talcum, casein, magnesium stearate, methyl cellulose, polyglycols, tragacanth and the like, sometimes together with stabilizers and emulsifying agents. The resulting mixture may be processed in a usual manner to tablets, capsules, pills, injections, ointment,  
5 suppositories and the like. In a clinical practice, the leukotriene B<sub>4</sub> antagonists [I] can be administered orally, intranasally, intradermally or the like.

The daily dosage may vary depending upon the administration route, symptom, age or weight of the patient, and the usual oral dosage of the active ingredient is between about 1 mg and about 1000 mg daily for human beings.

10

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

Practical and preferred embodiments of the present invention are illustrated in the following examples, which are not intended to limit the scope of the invention.

15

##### Reference Example 1

5-Ethyl-2,4-dihydroxyacetophenone (0.97 g, 5.0 mmol) and methyl 6-bromomethylpyridine-2-carboxylate (1.38 g, 5.8 mmol) were dissolved in an N,N-dimethylformamide solution (50 ml), and anhydrous potassium carbonate (480 mg) was added to the above solution, and the mixture was stirred at room temperature for  
20 16 hours. The reaction mixture was poured into water and extracted with ethyl acetate (100 ml × 3).

The extract was dried, concentrated and chromatographed on silica gel to give methyl 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylate.

25

##### Reference Example 2

Methyl 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy) methyl]pyridine-2-carboxylate (38 mg, 12 mmol) was dissolved in a methanol solution (2 ml), and one normal sodium hydroxide (1 ml) was added to the above solution at 0 °C, and the mixture was stirred at room temperature for 1 hour. One-tenth normal potassium bisulfate was titrated to the above solution until it became pH2. Then, precipitated white crystals were filtered off, and washed with water, and dried to give 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylic acid.

##### Reference Example 3

35

3-n-Propyl-2,4-dihydroxyacetophenone (816 mg, 4.2 mmol) was added to a methanol solution (10 ml), sodium metal was added to the solution at 0 °C, and the mixture was stirred for 30 min, and evaporated under reduced pressure, and dried to give a sodium salt of 3-n-propyl-2,4-dihydroxyacetophenone. The salt was dissolved in N,N-dimethylformamide (10 ml), and it was added to a N,N-dimethylformamide solution (10 ml) of methyl-6-bromo-methylpyridine-2-carboxylate (920 mg, 4.0 mmol) at room temperature, and the mixture was stirred for 1 hour.

The reaction mixture was poured into water, and normal potassium bisulfate was titrated until it became pH3, and extracted with ethyl acetate (100 ml × 3). The extract was dried, concentrated and chromatographed on silica gel to give methyl 6-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]pyridine-2-carboxylate.

45

##### Reference Example 4

According to the procedure of Reference Example 2, 6-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]pyridine-2-carboxylic acid was obtained by hydrolysis of methyl 6-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)-  
50 methyl]pyridine-2-carboxylate.

##### Reference Example 5

Anhydrous potassium carbonate (1.0 g) was added to a N,N-dimethylformamide solution (10 ml) of methyl 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylate (500 mg, 1.4 mmol) and methyl iodide (5 ml), and the mixture was stirred at 70 °C for 2 hours.

The reaction mixture was poured into water and extracted with ethyl acetate and washed with saturated aqueous sodium chloride. Then, the extract was dried, concentrated and chromatographed on silica gel to

give methyl 6-[(4-acetyl-2-ethyl-5-methoxyphenoxy)methyl]pyridine-2-carboxylate.

Reference Example 6

- 5 According to the procedure of Reference Example 2, 6-[(4-acetyl-2-ethyl-5-methoxyphenoxy)methyl]-  
pyridine-2-carboxylic acid was obtained by hydrolysis of methyl 6-[(4-acetyl-2-ethyl-5-methoxy-phenoxy)-  
methyl]pyridine-2-carboxylate.

Reference Example 7

- 10 According to the procedure of Reference Example 5, methyl 6-[(4-acetyl-2-n-propyl-3-methoxy-  
phenoxy)methyl]pyridine-2-carboxylate was obtained from methyl 6-[(4-acetyl-3-hydroxy-2-n-propyl-  
phenoxy)methyl]pyridine-2-carboxylate.

15 Reference Example 8

According to the procedure of Reference Example 2, 6-[(4-acetyl-2-n-propyl-3-methoxyphenoxy)-  
methyl]pyridine-2-carboxylic acid was obtained by hydrolysis of methyl 6-[(4-acetyl-2-n-propyl-3-metho-  
xyphenoxy)methyl]pyridine-2-carboxylate.

20 Reference Example 9 (a compound included in formula [XVI])

A mixture of 6-methylpyridine-2-carboxylic acid (13.7 g, 100 mmol) and thionyl chloride (40 ml) was  
stirred at 70 °C for 1 hour. The mixture was dried, and dichloromethane (40 ml) was added to the residue.  
25 The solution was added to a dichloromethane solution of 2-amino-2-methyl-propanol (36.0 g, 400 mmol),  
and stirred. The mixture was washed with water, and dried over anhydrous magnesium sulfate. The extract  
was concentrated and chromatographed on silica gel to give an amide compound. 4,4-Dimethyl-2-oxazoline  
30 compound was obtained by reacting the amide compound and thionyl chloride in dichloromethane. 4,4-  
Dimethyl-2-oxazoline compound was reacted with n-butyl lithium at 78 °C in anhydrous tetrahydrofuran, and  
chlorophenyl ether (782 mg, 5 mmol) was added. Purified alkylated compound was treated with ethanol  
saturated with HCl to give ethyl 6-(3-chloropropyl)-pyridine-2-carboxylate.

Reference Example 10 (a compound included in formula [II])

35 According to the procedure of Reference Examples 1,2, 6-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)-  
propyl]pyridine-2-carboxylic acid was obtained from ethyl 6-(3-chloropropyl)pyridine-2-carboxylate and 5-  
ethyl-2,4-dihydroxyacetophenone.





40

45

50

55

Table 48

5	
10	
15	
20	
25	
30	
35	
40	
45	
50	

**EP 0 516 069 A1**

Table 49

	<sup>1</sup> H-NMR	$\delta$ ppm
5	1 (solvent:CDCL <sub>3</sub> ) 0.99(3H,t,J = 7.4Hz), 1.62(2H,tq,J = 7.4Hz,J = 7.4Hz ), 2.57(3H,s), 2.76(2H,t,J = 7.4Hz), 4.04(3H,s), 5.39(2H,s), 6.46(1H,d,J = 8.9Hz), 7.59(1H,d,J = 8.9Hz), 7.79(1H,d,J = 6.6Hz), 7.92(1H,dd,J = 6.6Hz,J = 7.9Hz), 8.10(1H,d,J = 7.9Hz)	
10	2 (solvent:CDCL <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 2.59(3H,S), 2.68(2H,q,J = 7.6Hz), 5.30(2H,s), 6.43(1H,s), 7.51(1H,s), 7.78(1H,d,J = 6.9Hz), 8.04(1H,dd,J = 6.9Hz,J = 7.9Hz), 8.22(1H,d,J = 7.9Hz)	
15	3 (solvent:CDCL <sub>3</sub> ) 0.99(3H,t,J = 7.4Hz), 1.62(2H,tq,J = 7.4Hz,J = 7.4Hz ), 2.57(3H,s), 2.76(2H,t,J = 7.4Hz), 4.04(3H,s), 5.39(2H,s), 6.46(1H,d,J = 8.9Hz), 7.59(1H,d,J = 8.9Hz), 7.79(1H,d,J = 6.6Hz), 7.92(1H,dd,J = 6.6Hz,J = 7.9Hz), 8.10(1H,d,J = 7.9Hz)	
	4 (solvent:CDCL <sub>3</sub> ) 0.99(3H,t,J = 7.4Hz), 1.62(2H,tq,J = 7.4Hz,J = 7.4Hz ), 2.57(3H,s), 2.76(2H,t,J = 7.4Hz), 5.34(2H,s), 6.45(1H,d,J = 8.9 Hz), 7.60(1H,d,J = 8.9Hz), 7.79(1H,dd,J = 1.0Hz,J = 6.9Hz), 8.04(1H, dd,J = 6.9Hz,J = 7.4Hz), 8.21(1H,dd J = 1.0Hz, J = 7.4Hz)	

20

25

30

35





40

45

50

55

Table 50

5	
6	
7	
8	

50

55

Table 51

	<sup>1</sup> H-NMR	$\delta$ ppm
5	(solvent:CDCl <sub>3</sub> ) 1.24(3H,t,J = 7.6Hz), 2.58(3H,s), 2.70(2H,q,J = 7.6Hz), 3.86(3H,s), 4.04(3H,s), 5.40(2H,s), 7.72(1H,s), 7.79(1H,d,J = 7.9Hz), 7.94(1H,dd,J = 7.9Hz,J = 7.6Hz), 8.11(1H,d,J = 7.6Hz)	
10	(solvent:CDCl <sub>3</sub> ) 1.24(3H,t,J = 7.4Hz), 2.57(3H,s), 2.69(2H,q,J = 7.4Hz), 3.90(3H,s), 5.40(2H,s), 6.64(1H,s), 7.65(1H,s), 7.80(1H,d,J = 7.3Hz), 8.01(1H,dd,J = 7.6Hz,J = 7.6Hz), 8.13(1H,d,J = 7.9Hz)	
15	(solvent:CDCl <sub>3</sub> ) 1.02(3H,t,J = 7.5Hz), 1.66(2H,q,J = 7.6Hz), 2.61(3H,s), 2.75(2H,t,J = 7.8Hz), 3.78(3H,s), 5.31(2H,s), 6.70(1H,d,J = 8.6Hz), 7.56(1H,d,J = 8.9Hz), 7.90(1H,d,J = 7.9Hz), 8.04(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.21(1H,d,J = 7.6Hz)	
20	(solvent:CDCl <sub>3</sub> ) 1.02(3H,t,J = 7.6Hz), 1.65(2H,q,J = 7.7Hz), 2.62(3H,s), 2.75(2H,t,J = 7.8Hz), 3.78(3H,s), 5.31(2H,s), 6.70(1H,d,J = 8.6Hz), 7.56(1H,d,J = 8.9Hz), 7.90(1H,d,J = 7.9Hz), 8.04(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.21(1H,d,J = 7.6Hz)	

Example 1

25 A mixture of 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylic acid (63 mg, 0.20 mmol), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (40 mg, 0.20 mmol), 1-hydroxybenzotriazole (30 ml, 0.22 mmol), 2-aminothiazole-4-carboxamide (35 mg, 0.24 mg) and triethylamine (20 mg, 0.20 mmol) in a mixed solution of dichloromethane (2 ml) and N,N-dimethylformamide (2 ml) was stirred at room temperature for 44 hours. The reaction mixture was poured into water and extracted with ethyl acetate (80 ml×3). The extract was dried over anhydrous magnesium sulfate, concentrated under reduced pressure and chromatographed on silica gel to give 2[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)-methyl]pyridine-2-carboxamide]thiazol-4-ylcarboxamide.

Example 2~35,62,88,90,92

35 According to the procedure of Example 1, the compounds (Example 2~ 35,62,88,90,92) were obtained.

Example 36

40 Ethyl 2-[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxamide]thiazole-4-ylcarboxylate (24 mg, 0.05 mmol) was suspended in methanol (1.5 ml), followed by addition of one-second normal sodium hydroxide (1.0 ml).

After the solution was stirred for 2 hr, it was made acidic with one-second normal potassium bisulfate. Precipitated crystals were separated by filtration, and washed with water, and dried to give 2-[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxamide]thizaol-4-ylcarboxylic acid.

Example 37~52,61,87,89,91

50 According to the procedure of Example 36, the compounds (Example 37 ~52, 61, 87, 89, 91) were obtained.

Example 54~56,64,67,68,70,72,74,76,78,80,82,84,86,94,96,100, 102,104,106,108,112,114,115,116-121,123,126,127,138,141

55 According to the procedure of Example 1, the title compounds were obtained.

Example 53,57~60,63,65,69,71,73,75,77,79,81,83,85,93,95,99, 101,105,107,111,113,122,130

According to the procedure of Example 36, the title compounds were obtained.

**Example 98**

5 Ethyl 2-[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxamide]pyridine-6-ylcarboxylate (280 mg, 0.60 mM) was dissolved in dichloromethane (5 ml), followed by addition of m-chloroperbenzoic acid (124 mg, 0.72 mM). After being stirred at room temperature for 16 hours, the reaction mixture was washed with aqueous sodium sulfite-sodium bicarbonate, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give ethyl 2-[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxamide]pyridine-N-oxide-6-ylcarboxylate.

10 **Example 110,125,129,131,134,136,139,142**

According to the procedure of Example 98, the title compounds were obtained.

**Example 97,109,124,128,132,133,135,137,140**

15 According to the procedure of Example 36, the title compounds were obtained.

**Example 143~178, 212,214,216,218,222,225,226**

20 According to the procedure of Example 1, the title compounds were obtained.

**Example 179~211,213,215,223,224**

25 According to the procedure of Example 36, the title compounds were obtained.

30

35






40

45

50

55

Table 52

Ex. No.	Structural formula
1	
2	
3	
4	
5	

50

55

**EP 0 516 069 A1**

Table 53

		<sup>1</sup> H-NMR	$\delta$ ppm
5	1	(solvent:CDCL <sub>3</sub> ) 1.28(3H,t,J = 7.6Hz), 2.60(3H,s), 2.71(2H,q,J = 7.6Hz), 5.34(1H,s), 5.55(1H,bs), 6.48(1H,s), 7.05(1H,bs), 7.52(1H,s), 7.77(1H,d,J = 7.3Hz), 9.90(1H,s), 8.04 (1H,dd,J = 6.6Hz, J = 7.3Hz), 8.28(1H,d,J = 7.3Hz), 10.98(1H,bs), 12.70(1H,s)	
10	2	(solvent:CDCL <sub>3</sub> ) 1.27(3H,J = 7.6Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 3.69(2H,s), 5.32(2H,s), 5.43(1H,bs), 6.45(1H,s), 6.60(1H,bs), 6.86(1H,s), 7.51(1H,s), 7.74(1H,d,J = 6.9Hz), 8.02(1H,t,J = 6.9Hz), 8.27(1H,d,J = 6.9Hz), 12.68(1H,s)	
15	3	(solvent:CDCL <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 2.58(3H,s), 2.69(2H,q,J = 7.6Hz), 3.70(2H,s), 3.81(3H,s), 5.39(1H,s), 5.43(1H,bs), 6.46(1H,s), 6.70(1H,bs), 6.88(1H,s), 7.49(1H,s), 7.64(1H,dd,J = 1.0Hz,J = 7.9Hz), 7.79(1H,dd,J = 7.6Hz,J = 7.9Hz), 7.95(1H,dd,J = 1.0Hz,J = 7.6Hz), 12.65(1H,s)	
20	4	(solvent:CDCL <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.44(3H,t,J = 6.9Hz), 2.58(3H,s), 2.69(2H,q,J = 7.6Hz), 3.69(2H,S), 4.36(2H,q,J = 6.9Hz) 5.25(1H,s), 5.44(1H,bs), 6.43(1H,s), 6.67(1H,bs), 6.89(1H,s), 7.49(1H,s), 7.64(1H,d,J = 7.9Hz), 7.74(1H,d,J = 6.9Hz), 7.94(1H,dd,J = 6.9Hz),J = 7.9Hz), 12.66(1H,s)	
25	5	(solvent:CDCL <sub>3</sub> ) 0.78(6H,d,J = 6.6Hz), 1.26(3H,t,J = 7.6Hz), 2.0-2.2(1H,m), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.66(2H,s), 4.33(2H,d,J = 7.3Hz), 5.21(2H,s), 5.84(1H,bs), 6.42(1H,s), 6.60(1H,bs), 6.88(1H,s), 7.49(1H,s), 7.62(1H,d,J = 7.6Hz), 7.74(1H,d,J = 7.9Hz), 7.93(1H,dd,J = 6Hz,J = 7.9Hz), 12.66(1H,s)	

30

35


40

45

50

55

Table 54

Ex. No.	Structural formula
6	
7	
8	
9	
10	

50

55

**EP 0 516 069 A1**

Table 55

		<sup>1</sup> H-NMR	$\delta$ ppm
5	6	(solvent:CDCL <sub>3</sub> ) 1.28(3H,t,J = 7.6Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 2.84(3H,d,J = 5.0Hz), 3.67(2H,s), 5.33(2H,s), 6.45(1H,s), 6.48(1H,bs), 6.85(1H,s), 7.51(1H,s), 7.74(1H,d,J = 6.6Hz), 8.02(1H,t,J = 6.6Hz), 8.27(1H,d,J = 6.6Hz), 11.06(1H,bs), 12.70(1H,s)	
10	7	(solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 3.01(3H,s), 3.11(1H,s), 3.83(2H,s), 5.28(2H,s), 6.43(1H,s), 6.86(1H,b), 7.51(1H,s), 7.72(1H,dd,J = 1.0Hz,J = 7.9Hz), 8.00(1H,t,J = 7.9Hz), 8.25(1H,dd,J = 1.0Hz,J = 7.9Hz), 11.08(1H,bs), 12.70(1H,s)	
15	8	(solvent:CDCL <sub>3</sub> ) 1.15(6H,d,J = 6.6Hz), 1.27(3H,t,J = 7.6Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 3.63(2H,s), 4.0-4.2(1H,m), 5.32(1H,s), 6.06(1H,bs), 6.45(1H,s), 6.85(1H,s), 7.51(1H,s), 7.74(1H,d,J = 7.9Hz), 8.02(1H,t,J = 7.9Hz), 8.27(1H,d,J = 7.9Hz), 11.06(1H,bs), 12.70(1H,s)	
20	9	(solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.31(3H,s), 1.34(3H,s), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 3.1-3.2(1H,m), 5.30(2H,s), 6.44(1H,s), 6.62(1H,s), 7.51(1H,s), 7.71(1H,d,J = 7.9Hz), 7.99(1H,dd,J = 6.6Hz,J = 7.9Hz), 8.26(1H,d,J = 6.6Hz), 11.05(1H,bs), 12.67(1H,s)	
	10	(solvent:CDCL <sub>3</sub> ) 1.23(3H,t,J = 7.6Hz), 2.60(3H,s), 2.65(2H,q,J = 7.6Hz), 5.49(2H,s), 6.64(1H,s), 7.35-7.55(2H,m), 7.6-7.8(3H,m), 8.0-8.3(5H,m), 10.59(1H,bs), 12.60(1H,s)	

25

30

35

40

45

50

55

Table 56

Ex. No.	Structural formula
1 1	
1 2	
1 3	
1 4	
1 5	

50

55

**EP 0 516 069 A1**

Table 57

	<sup>1</sup> H-NMR	$\delta$ ppm
5	11 (solvent:CDCL <sub>3</sub> ) 1.22(3H,t,J = 7.6Hz), 2.58(3H,s), 2.67(2H,q,J = 7.6Hz), 5.49(1H,s), 6.64(1H,s), 7.53(1H,bs), 7.71(1H,s), 7.80-7.85(1H,m), 8.1-8.4(5H,m), 8.85-8.90(1H,m), 10.63(1H,bs), 12.56(1H,s)	
	12 (solvent:CDCL <sub>3</sub> ) 1.20(3H,t,J = 7.6Hz), 2.58(2H,s), 2.64(2H,q,J = 7.6Hz), 5.47(2H,s), 6.62(1H,s), 7.30(2H,s), 7.71(1H,s), 7.75-7.90(3H,m), 8.0-8.2(4H,m), 10.75(1H,bs), 12.56(1H,s)	
10	13 (solvent:CDCL <sub>3</sub> ) 1.00(3H,t,J = 7.4Hz), 1.63(2H,tq,J = 7.4Hz,J = 7.4Hz), 2.58(3H,s), 2.77(2H,t,J = 7.4Hz), 3.69(2H,s), 5.36(2H,s), 5.40(1H,bs), 6.47(1H,d,J = 9.2Hz), 6.50(1H,bs), 6.87(1H,s), 7.62(1H,d,J = 9.2Hz), 7.76(1H,d,J = 7.9Hz, 8.02(1H,dd,J = 7.9Hz, J = 7.9Hz), 8.26(1H,d,J = 7.9Hz)	
15	14 (solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.43(3H,t,J = 7.1Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 4.45(2H,q,J = 7.1Hz), 5.28(1H,s) 6.43(1H,s), 7.52(1H,s), 7.73(1H,d,J = 7.9Hz), 7.94(1H,d,J = 0.7Hz) 8.01(1H,t,J = 7.9Hz), 8.25(1H,d,J = 7.9Hz), 11.32(1H,bs), 12.66(1H,s)	
20	15 (solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.30(3H,t,J = 7.3Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 3.76(2H,d,J = 0.7Hz), 4.22(2H,q,J = 7.3Hz), 5.28(1H,s), 6.43(1H,s), 6.90(1H,d,J = 0.7 Hz), 7.51(1H,s), 7.72(1H,d,J = 7.9Hz), 8.00(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.25(1H,d,J = 7.6Hz), 11.11(1H,bs), 12.67(1H,s)	

25

30

35

40

45

50

55

Table 58

Ex. No.	Structural formula
1 6	
1 7	
1 8	
1 9	
2 0	

**EP 0 516 069 A1**

Table 59

	<sup>1</sup> H-NMR	$\delta$ ppm
5	<b>16</b> (solvent:CDCL <sub>3</sub> ) 1.25(3H,t,J = 7.3Hz), 1.27(3H,t,J = 7.4Hz), 2.59(3H,s), 2.65-2.80(4H,m), 3.05(2H,t,J = 7.3Hz), 4.15(2H,q,J = 7.3Hz), 5.30(2H,s), 6.44(1H,s), 6.69(1H,s), 7.51 (1H,s), 7.71(1H,d,J = 7.7Hz), 7.97(1H,t,J = 7.7Hz), 8.24(1H,d,J = 7.7Hz), 11.05(1H,bs), 12.67(1H,s)	
10	<b>17</b> (solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.43(3H,t,J = 7.1Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 4.45(2H,q,J = 7.1Hz), 5.28(1H,s) 6.43(1H,s), 7.52(1H,s), 7.73(1H,d,J = 7.9Hz), 7.94(1H,d,J = 0.7Hz) , 8.01(1H,t,J = 7.9Hz), 8.25(1H,d,J = 7.9Hz), 11.32(1H,bs), 12.66(1H,s)	
15	<b>18</b> (solvent:CDCL <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.28(3H,t,J = 7.1Hz), 1.40(3H,t,J = 6.9Hz), 2.58(3H,s), 2.69(2H,q,J = 7.6Hz), 3.76(2H,d,J = 0.7Hz), 4.20(2H,q,J = 7.1Hz), 4.32(2H,q,J = 6.9Hz), 5.25(1H,s), 6.44(1H,s), 6.92(1H,s), 7.49(1H,s), 7.62(1H,d,J = 7.6Hz), 7.70(1H,d,J = 6.9Hz), 7.92(1H,dd,J = 6.9Hz,J = 7.6Hz), 12.65(1H,s)	
20	<b>19</b> (solvent:CDCL <sub>3</sub> ) 0.76(6H,d,J = 6.6Hz), 1.26(3H,t,J = 7.6Hz), 1.27(3H,t,J = 7.1Hz), 2.0-2.2(1H,m), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.74(2H,s), 4.18(2H,d,J = 7.1Hz), 4.28(2H,d,J = 6.9Hz), 5.21(2H,s), 6.43(1H,s), 6.91(1H,s), 7.49(1H,s), 7.58(1H,d,J = 7.9Hz), 7.71(1H,d,J = 7.9Hz), 7.90(1H,t,J = 7.9Hz), 12.63(1H,s)	
25	<b>20</b> (solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.4Hz), 1.29(3H,t,J = 7.3Hz), 2.33(3H,s), 2.59(3H,s), 2.69(2H,q,J = 7.4Hz), 3.73(2H,s), 4.20(2H,q,J = 7.3Hz), 5.27(2H,s), 6.43(1H,s), 7.51(1H,s), 7.71(1H,d,J = 7.9Hz), 7.99(1H,t,J = 7.9Hz), 8.24(1H,d,J = 7.9Hz), 10.98(1H,bs), 12.67(1H,s)	

25

30

35






40

45

50

55

Table 60

Ex. No.	Structural formula
2 1	
2 2	
2 3	
2 4	
2 5	

50

55

**EP 0 516 069 A1**

Table 61

	<sup>1</sup> H-NMR	$\delta$ ppm
5	21 (solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.32(3H,t,J = 7.1Hz), 2.59(3H,s), 2.71(2H,q,J = 7.1Hz), 4.16(2H,s), 4.27(2H,q,J = 7.6Hz) 5.32(2H,s), 6.44(1H,s), 7.52(1H,s), 7.75(1H,d,J = 7.6Hz), 8.02(1H,t,J = 7.6Hz), 8.26(1H,d,J = 7.6Hz), 11.21(1H,bs), 12.67(1H,s)	
10	22 (solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.4Hz), 2.58(3H,s), 2.70(2H,q,J = 7.4Hz), 2.93(2H,t,J = 7.3Hz), 3.40(2H,t,J = 7.3Hz), 3.73(3H,s), 5.32(2H,s), 6.43(1H,s), 7.51(1H,s), 7.75(1H,d,J = 7.9Hz), 8.01(1H,t,J = 7.9Hz), 8.24(1H,d,J = 7.9Hz), 11.18(1H,bs), 12.66(1H,s)	
15	23 (solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.3Hz), 1.27(3H,t,J = 7.3Hz), 2.59(3H,s), 2.70(2H,q,J = 7.3Hz), 3.66(2H,s), 4.17(2H,q,J = 7.3Hz) 5.32(2H,s), 6.52(1H,s), 7.0-7.1(1H,m), 7.3-7.4(1H,m), 7.51(1H,s), 7.65-7.7(2H,m), 7.97(1H,t,J = 7.7Hz), 8.26(1H,dd,J = 1.0Hz,J = 7.7Hz), 9.92(1H,bs), 12.68(1H,s)	
20	24 (solvent:CDCL <sub>3</sub> ) 1.26(3H,t,J = 7.1Hz), 1.27(3H,t,J = 7.6Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 3.62(2H,s), 4.16(2H,q,J = 7.1Hz) 5.32(2H,s), 6.51(1H,s), 7.32(1H,d,J = 8.6Hz), 7.51(1H,s), 7.67(1H,d,J = 7.3Hz), 7.75(1H,d,J = 8.6Hz), 7.98(1H,dd,J = 7.3Hz,J = 7.6Hz), 8.27(1H,d,J = 7.6Hz), 9.90(1H,bs), 12.68(1H,s)	
25	25 (solvent:CDCL <sub>3</sub> ) 1.28(3H,t,J = 7.6Hz), 1.29(3H,t,J = 7.3Hz), 2.59(3H,s), 2.71(2H,q,J = 7.6Hz), 3.80(2H,s), 4.21(2H,q,J = 7.3Hz) 5.34(2H,s), 6.47(1H,s), 7.09(1H,d,J = 6.9Hz), 7.51(1H,s), 7.65-7.85(2H,m), 7.97(1H,t,J = 7.6Hz), 8.26(1H,t,J = 7.6Hz), 8.30(1H,t,J = 7.6Hz), 10.37(1H,bs), 12.66(1H,s)	

25

30

35

40

45

50

55

Table 62






Ex. No.	Structural formula
2 6	
2 7	
2 8	
2 9	
3 0	

Table 63

	<sup>1</sup> H-NMR	δ ppm
26	(solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.3Hz), 1.30(3H,t,J = 7.3Hz), 2.59(3H,s), 2.71(2H,q,J = 7.5Hz), 3.77(2H,s), 3.92(2H,s), 4.22(2H,q,J = 7.5Hz), 5.32(2H,s), 6.50(1H,s), 6.91(1H,s), 7.73(1H,s), 7.80(1H,d,J = 7.8Hz), 8.03(1H,dd,J = 7.9Hz,J = 7.6Hz), 8.24(1H,d,J = 7.6Hz), 11.18(1H,s)	
27	(solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.28(3H,t,J = 7.4Hz), 2.59(3H,s), 2.72(2H,q,J = 7.5Hz), 3.80(2H,s), 3.92(3H,s), 4.21(2H,q,J = 7.5Hz), 5.38(2H,s), 6.57(1H,s), 7.10(1H,dd,J = 7.0Hz,J = 0.7Hz), 7.73(1H,s), 7.76(1H,dd,J = 8.3Hz, J = 7.9Hz), 7.77(1H,dd,J = 7.9Hz,J = 1.0Hz), 8.00(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.27(1H,dd,J = 7.9Hz,J = 1.0Hz), 8.37(1H,d,J = 8.3Hz), 10.40(1H,s)	
28	(solvent:CDCl <sub>3</sub> ) 1.00(3H,t,J = 7.4Hz), 1.30(3H,t,J = 7.1Hz), 1.63(2H,qq,J = 7.9Hz, J = 7.3Hz), 2.58(3H,s), 2.77(2H,t,J = 7.6Hz), 3.77(2H,s), 4.22(2H,q,J = 7.0Hz), 5.32(1H,s), 6.48(1H,d,J = 8.9Hz), 6.91(1H,s), 7.62(1H,d,J = 8.9Hz), 7.74(1H,d,J = 7.9Hz), 8.00(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.24(1H,dd,J = 7.6Hz, J = 0.6Hz)	
29	(solvent:CDCl <sub>3</sub> ) 1.00(3H,t,J = 7.4Hz), 1.29(3H,t,J = 7.2Hz), 1.64(2H,qq,J = 7.6Hz, J = 7.2Hz), 2.58(3H,s), 2.78(2H,t,J = 7.2Hz), 3.81(2H,s), 4.21(2H,q,J = 7.0Hz), 5.38(2H,s), 6.50(1H,d,J = 8.9Hz), 7.10(1H,dd,J = 7.3Hz,J = 0.7Hz), 7.62(1H,d,J = 8.9Hz), 7.62(1H,d,J = 8.9Hz), 7.70(1H,d,J = 7.9Hz), 7.76(1H,dd,J = 8.0Hz,J = 7.9Hz), 7.97(1H,dd,J = 7.9Hz,J = 7.6Hz), 8.25(1H,d,J = 6.9Hz), 8.36(1H,d,J = 7.6Hz)	
30	(solvent:CDCl <sub>3</sub> ) 1.03(3H,t,J = 7.3Hz), 1.64(2H,qq,J = 7.8Hz, J = 7.8Hz), 2.59(3H,s), 2.74(2H,t,J = 8.0Hz), 3.78(3H,s), 3.82(2H,s), 5.31(2H,s), 6.71(1H,d,J = 8.9Hz), 6.88(1H,s), 7.53(1H,d,J = 8.9Hz), 7.70(1H,d,J = 7.6Hz), 7.97(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.19(1H,d,J = 7.6Hz)	






Table 64

Ex. No.	Structural formula
3 1	
3 2	
3 3	
3 4	
3 5	

Table 65

	<sup>1</sup> H-NMR	δ ppm
31	(solvent:CDCl <sub>3</sub> ) 1.03(3H,t,J = 7.3Hz), 1.65(2H,(q,J = 7.6Hz,J = 7.9Hz), 2.63(3H,s), 2.76(2H,t,J = 7.6Hz), 3.79(3H,s), 3.90(2H,s), 5.37(2H,s), 6.81(1H,d,J = 8.6Hz), 7.06(1H,d,J = 7.6Hz), 7.59(1H,d,J = 8.9Hz), 7.75(1H,d,J = 6.9Hz), 7.83(1H,dd,J = 7.9Hz,J = 7.9Hz), 8.01(1H,dd,J = 7.9Hz,J = 7.9Hz), 8.28(1H,d,J = 6.9Hz), 8.37(1H,d,J = 7.9Hz)	
32	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.28(3H,t,J = 7.1Hz), 2.59(3H,s), 2.71(2H,q,J = 7.6Hz), 3.72(2H,s), 4.17(2H,q,J = 7.3Hz), 5.32(2H,s), 6.43(1H,s), 6.89(1H,s), 7.51(1H,s), 7.67(1H,dd,J = 0.7Hz,J = 8.2Hz), 8.29(1H,dd,J = 2.3Hz,J = 8.2Hz), 9.14(1H,dd,J = 0.7Hz,J = 2.3Hz), 9.58(1H,bs), 12.66(1H,s)	
33	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.32(3H,t,J = 7.3Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 4.30(2H,q,J = 7.3Hz), 4.68(2H,s), 5.32(2H,s), 6.51(1H,s), 6.70-6.80(1H,m), 7.25-7.35(2H,m) 7.51(1H,s), 7.55-7.65(1H,m), 7.68(1H,d,J = 7.6Hz), 7.98(1H,dd,J = 6.6Hz,J = 7.6Hz), 8.26(1H,d,J = 6.6Hz), 9.90(1H,bs), 12.67(1H,s)	
34	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.31(3H,t,J = 7.3Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 4.26(2H,q,J = 7.3Hz), 4.63(2H,s), 5.31(2H,s), 6.51(1H,s), 6.96(2H,d,J = 9.1Hz), 7.51(1H,s), 7.66(1H,d,J = 8.6Hz), 7.71(2H,d,J = 9.1Hz), 7.97(1H,dd,J = 7.6Hz,J = 8.6Hz), 8.26(1H,d,J = 7.6Hz), 9.82(1H,s), 12.67(1H,s)	
35	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.3Hz), 1.27(3H,t,J = 7.3Hz), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 3.73(2H,s), 4.07(2H,d,J = 5.3Hz), 4.20(2H,q,J = 7.3Hz), 5.32(2H,s), 6.45(1H,s), 7.03(1H,d), 7.51(1H,s), 7.74(1H,dd,J = 1.0Hz,J = 7.6Hz), 8.01(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.25(1H,dd,J = 1.0Hz,J = 7.9Hz), 11.08(1H,bs), 12.67(1H,s)	

Table 66

Ex. No.	Structural formula
3 6	
3 7	
3 8	
3 9	
4 0	

**EP 0 516 069 A1**

**Table 67**

	<sup>1</sup> H-NMR	$\delta$ ppm
5	36 (solvent:DMSO-d <sub>6</sub> ) 1.20(3H,t,J = 7.6Hz), 2.59(3H,s), 2.63(2H,q,J = 7.6Hz), 5.44(2H,s), 6.71(1H,s), 7.45(1H,s), 7.66(1H,s), 7.7-7.8(1H,m), 8.10-8.20(2H,m), 12.60(1H,bs)	
	37 (solvent:DMSO-d <sub>6</sub> ) 1.21(3H,t,J = 6Hz), 2.58(3H,s), 2.65(2H,q,J = 7.6Hz), 3.67(2H,s), 5.46(2H,s), 6.63(1H,s), 7.11(1H,s), 7.70(1H,s), 7.78(1H,dd,J = 1.3Hz,J = 7.3Hz), 12.04(1H,bs), 12.55(1H,s)	
10	38 (solvent:DMSO-d <sub>6</sub> ) 1.21(3H,t,J = 7.4Hz), 2.59(3H,s), 2.55-2.75(4H,m), 2.89(2H,t,J = 7.6Hz), 5.47(2H,s), 6.63(1H,s), 6.95 (1H,s), 7.70(1H,s), 7.78(1H,d,J = 7.3Hz), 8.10-8.20(2H,m), 11.94(1H,bs), 12.57(1H,s)	
	39 (solvent:DMSO-d <sub>6</sub> ) 1.21(3H,t,J = 7.4Hz), 2.58(3H,s), 2.65(2H,q,J = 7.4Hz), 4.15(2H,s), 5.47(2H,s), 6.63(1H,s), 7.70(1H,s), 7.80(1H,d,J = 6.9Hz), 8.10-8.20(2H,m), 12.50(1H,bs), 12.56(1H,s)	
15	40 (solvent:DMSO-d <sub>6</sub> ) 1.21(3H,t,J = 7.4Hz), 2.59(3H,s), 2.55-2.75(4H,m), 2.89(2H,t,J = 7.6Hz), 5.47(2H,s), 6.63(1H,s), 6.95(1H,s), 7.70(1H,s), 7.78(1H,d,J = 7.3Hz), 8.10-8.20 (2H,m), 11.94(1H,bs), 12.57(1H,s)	

20

25

30

35

40

45

50

55

Table 68

Ex. No.	Structural formula
4 1	
4 2	
4 3	
4 4	
4 5	

**EP 0 516 069 A1**

Table 69

	<sup>1</sup> H-NMR	δppm
5	<b>41</b> (solvent:DMSO-d <sub>6</sub> ) 1.20(3H,t,J = 7.6Hz), 2.58(3H,s), 2.65(2H,q,J = 7.6Hz), 3.58(1H,s), 5.47(2H,s), 6.63(1H,s), 7.04(1H,d,J = 7.9Hz), 7.33(1H,m), 7.7-7.8(4H,m), 8.1-8.2(2H,m), 10.41(1H,s), 12.56(1H,s)	
10	<b>42</b> (solvent:DMSO-d <sub>6</sub> ) 1.20(3H,t,J = 7.6Hz), 2.58(3H,s), 2.65(2H,q,J = 7.6Hz), 5.46(2H,s), 6.62(1H,s), 7.27(2H,d,J = 8.2Hz) 7.65-7.85(4H,m), 8.05-8.20(2H,m), 8.10-8.20(2H,m), 10.40(1H,s), 12.56(1H,bs)	
15	<b>43</b> (solvent:DMSO-d <sub>6</sub> ) 1.23(3H,t,J = 7.6Hz), 2.58(3H,s), 2.67(2H,q,J = 7.6Hz), 3.71(2H,s), 5.49(2H,s), 6.65(1H,s), 7.17(1H,d,J = 6.9Hz), 7.69(1H,s), 7.75-7.95(2H,m), 8.10-8.20 (3H,m), 10.33(1H,s), 12.55(1H,bs)	
20	<b>44</b> (solvent:CDCL <sub>3</sub> ) 1.25(3H,t,J = 7.4Hz), 2.57(3H,s), 2.70(2H,q,J = 7.2Hz), 3.83(2H,s), 3.89(3H,s), 5.35(2H,s), 6.52(1H,s), 6.88(1H,s), 7.70(1H,s), 7.81(1H,d,J = 7.6Hz), 8.03(1H,dd,J = 7.9Hz,J = 7.6Hz), 8.24(1H,d,J = 7.6Hz)	
	<b>45</b> (solvent:CDCL <sub>3</sub> ) 1.26(3H,t,J = 6.7Hz), 2.59(3H,s), 2.72(2H,q,J = 6.9Hz), 3.91(2H,s), 3.93(3H,s), 5.39(2H,s), 6.55(1H,s), 7.07(1H,d,J = 7.3Hz), 7.74(1H,s), 7.83(1H,d,J = 6.6Hz) 7.86(1H,dd,J = 7.8Hz,J = 7.6Hz), 8.04(1H,dd,J = 7.9Hz,J = 7.9Hz), 8.29(1H,d,J = 6.6Hz), 8.41(1H,d,J = 8.3Hz)	

25

30

35






40

45

50

55

Table 70

Ex. No.	Structural formula
4 6	
4 7	
4 8	
4 9	
5 0	

50

55

**EP 0 516 069 A1**

Table 71

	<sup>1</sup> H-NMR	$\delta$ ppm
5	46 (solvent:DMSO-d <sub>6</sub> ) 0.92(3H,t,J = 7.3Hz), 1.55(2H,tq,J = 6.9Hz, J = 7.7Hz), 2.52(3H,s), 2.67(2H,t,J = 7.6Hz), 3.67(2H,s), 5.50(2H,s), 6.77(1H,d,J = 9.2Hz), 7.11(1H,s), 7.76(1H,d,J = 7.2Hz) 7.81(1H,d,J = 8.9Hz), 8.11(1H,dd,J = 7.6Hz,J = 7.6Hz), 8.13(1H,d,J = 7.6Hz)	
10	47 (solvent:CDCL <sub>3</sub> ) 1.00(3H,t,J = 7.4Hz), 1.64(2H,tq,J = 7.6Hz, J = 7.3Hz), 2.59(3H,s), 2.78(2H,t,J = 7.6Hz), 3.91(2H,s), 5.40(2H,s), 6.55(1H,d,J = 8.9Hz), 7.07(1H,d,J = 6.6Hz), 7.63(1H,d,J = 8.2Hz), 7.77(1H,d,J = 6.9Hz), 7.85(1H,dd,J = 7.9Hz,J = 7.9Hz), 8.02(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.27(H,d,J = 6.9Hz), 8.39(1H,d,J = 8.3Hz)	
15	48 (solvent:CDCL <sub>3</sub> ) 1.03(3H,t,J = 7.3Hz), 1.64(2H,tq,J = 7.6Hz,J = 7.8Hz), 2.59(3H,s), 2.74(2H,t,J = 8.0Hz), 3.78(3H,s), 3.82(2H,s) 5.31(2H,s), 6.71(1H,d,J = 8.9Hz), 6.83(1H,s), 7.53(1H,d,J = 8.9Hz), 7.70(1H,d,J = 7.6Hz), 7.97(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.19(1H,d,J = 7.6Hz)	
20	49 (solvent:CDCL <sub>3</sub> ) 1.03(3H,t,J = 7.3Hz), 1.65(2H,tq,J = 7.6Hz,J = 7.9Hz ), 2.63(3H,s), 2.76(2H,t,J = 7.6Hz), 3.79(3H,s), 3.90(2H,s), 5.37(2H,s), 6.81(1H,d,J = 8.6Hz), 7.06(1H,d,J = 7.6Hz), 7.59(1H,d, J = 8.9Hz), 7.75(1H,d,J = 6.9Hz), 7.83(1H,dd,J = 7.9Hz, J = 7.9Hz), 8.01(1H,dd,J = 7.9Hz,J = 7.9Hz), 8.28(1H,d,J = 6.9Hz) 8.37(1H,d,J = 7.9Hz)	
	50 (solvent:DMSO-d <sub>6</sub> ) 1.20(3H,t,J = 7.6Hz), 2.58(3H,s), 2.64(2H,q,J = 7.6Hz), 3.66(2H,s), 5.38(2H,s), 6.57(1H,s), 7.06(1H,s), 7.66(1H,d,J = 8.6Hz), 7.69(1H,s), 8.48(1H,dd,J = 2.0Hz,J = 8.6Hz), 9.22(1H,d,J = 2.0Hz), 12.54(1H,s)	

25

30

35






40

45

50

55

Table 72

Ex. No.	Structural formula
5 1	
5 2	
5 3	
5 4	
5 5	

50

55

**EP 0 516 069 A1**

Table 73

		<sup>1</sup> H-NMR	$\delta$ ppm
5	51	(solvent:DMSO-d <sub>6</sub> ) 1.19(3H,t,J = 7.6Hz), 2.58(3H,s), 2.64(2H,q,J = 7.6Hz), 4.64(2H,s), 5.45(2H,s), 6.62(1H,s), 6.93(2H,d,J = 8.2Hz), 7.65-7.85(4H,m), 8.05-8.20(2H,m), 10.35(1H,s), 12.55(1H,s)	
	52	(solvent:DMSO-d <sub>6</sub> ) 1.20(3H,t,J = 7.6Hz), 2.58(3H,s), 2.64(2H,q,J = 7.6Hz), 4.66(2H,s), 5.46(2H,s), 6.62(1H,s), 6.65-6.75(1H,m), 7.20-7.80(5H,m), 8.05-8.20(2H,m), 10.41(1H,s) 12.56(1H,s),	
10	58	(solvent:DMSO-d <sub>6</sub> ) 1.21(3H,t,J = 7.3Hz), 2.58(3H,s), 2.65(2H,q,J = 7.3Hz), 3.60(2H,s), 3.79(2H,d,J = 5.6Hz), 5.46(2H,s) 6.63(1H,s), 7.09(1H,s), 7.70(1H,s), 7.75-7.85(1H,m), 8.1-8.4(3H,m), 12.04(1H,bs), 12.56(1H,s)	
15	54	(solvent:CDCL <sub>3</sub> ) 1.31(3H,t,J = 7.6Hz), 1.52(2H,d,J = 6.9Hz), 2.57(3H,s), 2.74(2H,q,J = 7.6Hz), 3.71(2H,s), 4.60(1H,dq,J = 7.6Hz,J = 7.9Hz), 5.49(2H,s), 6.84(1H,s), 7.01(1H,d,J = 7.3Hz), 7.51(1H,s), 7.63(1H,d,J = 7.6Hz), 7.75(1H,dd,J = 7.6Hz,J = 8.2Hz), 7.93(1H,dd,J = 7.6Hz,J = 7.6Hz), 8.22(1H,d,J = 7.9Hz), 8.33(1H,d,J = 8.3Hz)	
20	55	(solvent:CDCL <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.43(2H,d,J = 7.3Hz), 2.59(3H,s), 2.71(2H,q,J = 7.3Hz), 3.72(3H,s), 3.74(2H,s), 4.61(2H,dq,J = 6.9Hz,J = 7.2Hz), 5.39(2H,s), 6.49(1H,s), 7.06(1H,d,J = 7.6Hz), 7.51(1H,s), 7.72(1H,d,J = 7.6Hz), 7.76(1H,dd,J = 7.2Hz,J = 3.4Hz), 8.00(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.27(1H,d,J = 7.9Hz), 8.34(1H,d,J = 8.6Hz)	

25

30

35

40

45

50

55

Table 74

Ex. No.	Structural formula
5 6	
5 7	
5 8	
5 9	
6 0	






50

55

Table 75

	<sup>1</sup> H-NMR	δ ppm
56 (solvent:CDCl <sub>3</sub> )	1.28(3H,t,J = 7.4Hz), 2.59(3H,s), 2.54(2H,t,J = 6.1Hz), 2.70(2H,t,J = 7.4Hz), 3.55(3H,s), 3.56(2H,dd,J = 5.9Hz), J = 6.3Hz, J = 7.9Hz, 3.69(2H,s), 5.39(2H,s), 6.50(1H,s), 7.06(1H,d,J = 7.6Hz), 7.51(1H,s), 7.73(1H,dd,J = 7.9Hz,J = 1.0Hz), 7.75(1H,dd,J = 7.6Hz,J = 7.9Hz), 7.99(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.30(1H,d, J = 7.9Hz, J = 1.0Hz), 8.32(1H,d,J = 8.3Hz)	
57 (solvent:CDCl <sub>3</sub> )	1.28(3H,t,J = 7.6Hz), 2.60(3H,s), 2.72(2H,q, J = 7.5Hz), 3.76(2H,s), 5.40(2H,s), 6.55(1H,s), 7.13(1H,d,J = 7.3Hz), 7.54(1H,s), 7.76(1H,dd,J = 7.3Hz, J = 7.6Hz), 7.81(1H,d,J = 7.6Hz), 8.02(1H,dd,J = 7.9Hz, J = 7.9Hz), 8.25(1H,d,J = 7.3Hz), 8.31(1H,d,J = 8.2Hz)	
58 (solvent:CDCl <sub>3</sub> )	1.31(3H,t,J = 7.6Hz), 1.52(2H,d,J = 6.9Hz), 2.57(3H,s), 2.74(2H,q,J = 7.6Hz), 3.71(2H,s), 4.60(1H,dq,J = 7.6Hz,J = 7.9Hz), 5.49(2H,s), 6.84(1H,s), 7.0(1H,d,J = 7.3Hz), 7.51(1H,s), 7.63(1H,d,J = 7.6Hz), 7.75(1H,dd,J = 7.6Hz,J = 8.2Hz), 7.93(1H,dd,J = 7.6Hz), 8.22(1H,d,J = 7.9Hz), 8.33(1H,d,J = 8.3Hz)	
59 (solvent:CDCl <sub>3</sub> )	1.28(3H,t,J = 7.6Hz), 2.58(3H,s), 2.60(2H,q,J = 5.9Hz), 2.71(2H,q,J = 7.9Hz), 3.70(2H,s), 3.60(2H,q,J = 5.7Hz), 5.44(1H,s), 6.74(1H,s), 7.03(1H,d,J = 7.6Hz), 7.50(1H,s), 7.73(1H,d,J = 7.3Hz), 7.74(1H,dd,J = 8.5Hz,J = 3Hz), 8.00(1H,dd,J = 7.9Hz), 8.25(1H,d,J = 7.6Hz), 8.31(1H,d,J = 8.2Hz)	
60 (solvent:CDCl <sub>3</sub> )	1.29(3H,t,J = 7.6Hz), 2.60(3H,s), 2.73(2H,q, J = 7.5Hz), 2.85(1H,dd,J = 17.2Hz,J = 5.3Hz), 3.00(1H,dd,J = 14.2Hz,J = 4.6Hz), 4.78(1H,t,J = 5.0Hz), 5.4(2H,s), 6.55(1H,s), 7.13(1H,d,J = 7.6Hz), 7.55(1H,s), 7.74(1H,d,J = 7.8Hz), 7.79(1H,dd,J = 7.6Hz), 8.02(1H,dd,J = 7.6Hz,J = 7.9Hz), 8.23(1H,d,J = 6.9Hz), 8.30(1H,d,J = 8.6Hz)	

Table 76

Ex. No.	Structural formula
6 1	
6 2	
6 3	
6 4	
6 5	

**EP 0 516 069 A1**

Table 77

	<sup>1</sup> H-NMR	$\delta$ ppm
5	<b>61</b> (solvent:DMSO-d <sub>6</sub> ) 1.19(3H,t,J = 7.6Hz), 2.59(3H,s), 2.64(2H,q,J = 7.6Hz), 3.67(2H,s), 5.49(2H,s), 6.69(1H,s), 7.12(1H,s), 7.71 (1H,s), 9.04(1H,s), 9.27(1H,s), 10.06(1H,s), 12.58(1H,br)	
10	<b>62</b> (solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.30(3H,t,J = 7.3Hz), 2.60 (3H,s), 2.69(2H,q,J = 7.6Hz), 3.76(2H,d,J = 0.7Hz), 4.22(2H,q,J = 7.3Hz), 5.33(2H,s), 6.47(1H,s), 6.94(1H,s), 7.53(1H,s), 9.08 (1H,s), 9.48(1H,s), 10.90(1H, br), 12.70(1H,s)	
15	<b>63</b> (solvent:DMSO-d <sub>6</sub> ) 1.19(3H,t,J = 7.6Hz), 2.59(3H,s), 2.66(2H,q,J = 7.6Hz), 2.89(1H,dd,J = 8.3Hz,15.0Hz), 3.00(1H,dd,J = 5.3Hz,15.0 Hz), 3.58(2H,s), 4.4-4.5(1H,m), 5.49(2H,s), 6.68(1H,s), 6.94 (1H,s), 7.00(1H,s), 7.71(1H,s), 7.87(1H,s), 8.33(1H,d,J = 7.6 Hz), 9.05(1H,s), 9.27(1H,s), 12.60(1H,br)	
20	<b>64</b> (solvent:CDCl <sub>3</sub> ) 1.20(3H,t,J = 7.3Hz), 2.60(3H,s), 2.70(2H,q,J = 7.3Hz), 3.1-3.2(2H,m), 3.72(3H,s), 3.75(2H,s), 4.8-4.9(1H,m), 5.36(2H,s), 6.48(1H,s), 6.79(1H,s), 6.91(1H,s), 7.53(1H,s), 7.56(1H,s), 9.10(1H,s), 9.48(1H,s), 12.78(1H,br)	
	<b>65</b> (solvent:DMSO-d <sub>6</sub> ) 1.19(3H,t,J = 7.6Hz), 2.59(3H,s), 2.6-2.7(4H, m), 3.61(2H,s), 4.5-4.6(1H,m), 5.49(2H,s), 6.69(1H,s), 7.08(1H, s), 8.35(1H,d,J = 7.6Hz), 9.05(1H,s), 9.27(1H,s), 12.60(1H,s),	

25

30

35

40

45

50

55

Table 78

Ex. No.	Structural formula
6 6	
6 7	
6 8	
6 9	
7 0	

50

55

**EP 0 516 069 A1**

Table 79

		<sup>1</sup> H-NMR	$\delta$ ppm
5	66	(solvent:CDCl <sub>3</sub> ) 1.16(3H,t,J = 7.6Hz), 1.25(3H,t,J = 7.6Hz), 1.26 (3H,t,J = 7.6Hz), 2.59(3H,s), 2.69(2H,q,J = 7.6Hz), 2.8-3.1(2H,m), 3.71(2H,s), 4.11(2H,q,J = 7.6Hz), 4.21(2H,q,J = 7.6Hz), 4.8-4.9 1H,m), 5.37(2H,s), 6.47(1H,s), 6.91(1H,s), 7.52(1H,s), 8.03 (1H,s), 9.08(1H,s), 9.49(1H,s), 12.68(1H,s)	
10	67	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 2.59(3H,t), 2.70(2H,q,J = 7.6Hz), 3.76(2H,s), 3.78(2H,d,J = 0.7Hz), 5.28(2H,s), 6.43(1H, s), 7.51(1H,s), 6.90(1H,s), 7.72(1H,dd,J = 7.9, 1.0Hz), 8.00(1H, dd,J = 7.9, 7.6Hz), 8.25(1H,d,J = 7.9Hz)	
15	68	(solvent:CDCl <sub>3</sub> ) 1.28(3H,t,J = 7.4Hz), 2.58(3H,s), 2.72(2H,q,J = 7.5Hz), 3.77(2H,s), 4.05(2H,d,J = 5.0Hz), 5.46(2H,s), 6.89(1H, s), 7.03(1H,d,J = 6.6Hz), 7.5(1H,s), 7.72(1H,d,J = 7.9Hz), 7.76 (1H,dd,J = 7.6, 7.9Hz), 7.99(1H,dd,J = 7.6, 7.9Hz), 8.24(1H,d,J = 7.6Hz), 8.30(1H,d,J = 8.3Hz)	
20	69	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 2.59(3H,s), 2.70(2H,q,J = 7.3Hz), 3.72(2H,s), 3.8-4.0(2H,m), 4.58(3H,t,J = 3.8Hz), 5.33 (2H,s), 6.48(1H,s), 6.94(1H,s), 7.52(1H,s), 7.76(1H,d,J = 7.6 Hz), 8.03(1H,dd,J = 7.9, 7.9Hz), 8.25(1H,d,J = 7.9Hz)	
25	70	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.4Hz), 2.60(3H,s), 2.71(2H,q,J = 7.5Hz), 3.37(2H,s), 3.73(3H,s), 3.87(1H,dd,J = 11.5, 3,3Hz), 3.97 (1H,dd,11.5, 3,3Hz), 4.6-4.7(1H,m), 5.34(2H,s), 6.48(1H, s), 6.96(1H,s), 7.54(1H,s), 7.77(1H,d,J = 7.6Hz), 8.04(1H,dd,J = 7.9, 7.9Hz), 8.25(1H,d,J = 7.6Hz)	

30

35

40

45

50

55

Table 80

Ex. No.	Structural formula
7 1	
7 2	
7 3	
7 4	
7 5	

50

55

Table 81

	<sup>1</sup> H-NMR	$\delta$ ppm
71	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.5-2.2(4H,m), 2.59(3H,s), 2.70(2H,q,J = 7.6Hz), 3.5-3.7(2H,m), 3.85(2H,d,J = 2.3Hz), 4.6-4.7 (1H,m), 5.32(2H,s), 6.49(1H,s), 6.92(1H,s), 7.5(1H,s), 7.73 (1H,d,J = 7.9Hz), 7.99(1H,dd,J = 7.9, 7.9Hz), 8.23(1H,d,J = 7.9Hz)	
72	(solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.9-2.3(4H,m), 2.59(3H,s), 2.70(2H,q,J = 7.5Hz), 3.6-3.8(2H,m), 3.82(2H,s), 4.12(2H,q,J = 7.2Hz), 4.63(1H,dd,J = 8.3, 3.6Hz), 5.18(2H,d,J = 7.9Hz), 5.27(2H, s), 6.44(1H,s), 6.94(1H,s), 7.35(5H,m), 7.5(1H,s), 7.72(1H,d, J = 6.9Hz), 8.00(1H,dd,J = 7.9, 7.9Hz), 8.25(1H,d,J = 7.9Hz)	
73	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 2.60(3H,s), 2.71(2H,q,J = 7.3Hz), 2.8-3.1(2H,m), 3.37(2H,d,J = 5.0Hz), 3.71(2H,s), 4.80 (1H,t,J = 4.8Hz), 5.35(2H,s), 6.49(1H,s), 6.93(1H,s), 7.54(1H, s), 7.76(1H,d,J = 7.9Hz), 8.03(1H,dd,J = 7.9, 7.9Hz), 8.23(1H,d,J = 7.9Hz)	
74	(solvent:CDCl <sub>3</sub> ) 1.19(3H,t,J = 7.1Hz), 1.24(3H,t,J = 7.4Hz), 1.27 (3H,t,J = 7.8Hz), 2.59(3H,s), 2.70(2H,q,J = 7.2Hz), 2.85(1H,dd,J = 17.2, 4.6Hz), 3.02(1H,dd,J = 16.8, 4.6Hz), 3.72(2H,s), 4.10(2H, q,J = 7.2Hz), 4.20(2H,q,J = 7.1Hz), 4.85(1H,td, J = 4.9, 7.6Hz), 5.31(2H,s), 6.44(1H,s), 6.89(1H,s), 7.5(1H,s), 7.74(1H,d,J = 7.6Hz), 8.01(1H,dd,J = 7.6, 7.9Hz), 8.26(1H,d,J = 7.6Hz)	
75	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.5Hz), 2.59(3H,s), 2.69(2H,q,J = 7.3Hz), 3.26(2H,d,J = 5.0Hz), 3.70(2H,s), 4.70(1H,t,J = 5.0Hz), 5.33(2H,s), 6.48(1H,s), 6.95(1H,s), 7.05(1H,s), 7.50(1H,s), 7.76(1H,d,J = 8.0 Hz), 8.00(1H,dd,J = 8.0, 8.0Hz), 8.22(1H,d,J = 8.0 Hz)	

Table 82

Ex. No.	Structural formula
7 6	
7 7	
7 8	
7 9	
8 0	

**EP 0 516 069 A1**

Table 83

	<sup>1</sup> H-NMR	δppm
5	76 (solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.5Hz), 2.59(3H,s), 2.69(2H,q,J = 7.5Hz), 3.15(2H,t,J = 4.2Hz), 3.71(3H,s), 3.73(2H,s), 4.84(1H, dt, J = 7.3, 4.2Hz), 5.31(2H,s), 6.45(1H,s), 6.78(1H,s), 6.88(1H, s), 7.50(1H,s), 7.59(1H,s), 7.72(1H,d,J = 7.6Hz), 8.01(1H,dd,J = 7.9, 7.9Hz), 8.26(1H,d,J = 7.6Hz),	
10	77 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.5Hz), 1.9-2.5(4H, m), 2.0-2.5(4H, m), 2.60(3H,s), 2.71(2H,q,J = 7.5Hz), 3.70(2H,s), 4.56(1H,t,J = 4.0Hz), 5.35(2H,s), 6.49(1H,s), 6.94(1H,s), 7.36(1H,s), 7.77 (1H,d,J = 7.9Hz), 8.04(1H,dd,J = 7.6, 7.9Hz), 8.24(1H,d,J = 7.6Hz)	
15	78 (solvent:CDCl <sub>3</sub> ) 1.21(3H,t,J = 7.1Hz), 1.26(3H,t,J = 7.4Hz), 1.29 (3H,t,J = 7.6Hz), 1.9-2.4(4H,m), 2.59(3H,s), 2.70(2H,q,J = 7.4Hz), 3.70(2H,s), 4.09(2H,q,J = 7.2Hz), 4.19(2H,q,J = 6.9Hz), 4.63(1H, td,J = 3.7, 7.6Hz), 5.33(2H,s), 6.47(1H,s), 6.88(1H,s), 7.51(1H, s), 7.75(1H,d,J = 6.9Hz), 8.02(1H,dd,J = 6.9, 7.6Hz), 8.26(1H,d,J = 6.9Hz)	
20	79 (solvent:CDCl <sub>3</sub> ) 1.21(3H,t,J = 7.6Hz), 2.51(3H,s), 2.62(2H,q,J = 7.6Hz), 3.20(2H,br), 4.71(1H,t,J = 5.3Hz), 5.23(2H,s), 6.43(1H, s), 7.41(1H,s), 7.05(1H,s), 7.05(1H,d,J = 7.3Hz), 7.31(1H,s), 7.61(1H,dd,J = 7.9Hz), 7.67(1H,dd,J = 7.9, 7.9Hz), 7.90(1H,dd,J = 7.6, 7.6Hz), 8.12(1H,d,J = 7.3Hz), 8.19(1H,d,J = 8.3Hz),	
25	80 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.4Hz), 2.59(3H,s), 2.70(2H,q,J = 7.4Hz), 3.17(2H,d,J = 5.0Hz), 3.67(3H,s), 3.77(2H,s), 4.82(1H, dt,J = 6.9, 5.0 Hz), 5.22(2H,s), 6.35(1H,s), 6.71(1H,s), 7.07 (1H,d,J = 7.3Hz), 7.45(1H,s), 7.51(1H,s), 7.67(1H,d,J = 7.3Hz), 7.76(1H,dd,J = 7.9, 7.9Hz), 7.98(1H,dd,J = 7.9, 7.9Hz), 8.26(1H,d, J = 6.9Hz), 8.32(1H,d,J = 7.9Hz)	

30

35

40

45

50

55

Table 84

Ex. No.	Structural formula
8 1	
8 2	
8 3	
8 4	
8 5	

50






55

**EP 0 516 069 A1**

Table 85

	<sup>1</sup> H-NMR	$\delta$ ppm
81	(solvent:CDCl <sub>3</sub> ) 1.28(3H,t,J = 7.4Hz), 1.9-2.5(4H,m), 2.60(3H,s), 2.72(2H,q,J = 7.4Hz), 3.84(2H,s), 4.5-4.6(1H,m), 5.42(2H,s), 6.56(2H,s), 7.26(1H,d,J = 7.9Hz), 7.54(1H,s), 7.76(1H,d,J = 8.3 Hz, 7.94(1H,dd,J = 7.9, 7.9Hz), 8.03(1H,dd,J = 7.9, 7.6Hz), 8.24 (1H,d,J = 7.9Hz), 8.39(1H,d,J = 8.6Hz)	
82	(solvent:CDCl <sub>3</sub> ) 1.16(3H,t,J = 7.3Hz), 1.20(3H,t,J = 7.1Hz), 1.27 (3H,t,J = 7.4Hz), 2.59(3H,s), 2.71(2H,q,J = 7.4Hz), 2.0-2.4(4H,m), 3.74(2H,S), 4.03(2H,q,J = 7.1Hz), 4.1-4.3(2H,m), 4.65(1H,t,d,J = 7.6, 5.3Hz), 5.39(2H,s), 6.49(1H,s), 7.06(1H,d,J = 6.6Hz), 7.51 (1H,s), 7.71(1H,d,J = 7.3Hz), 7.73(1H,dd,J = 7.9, 7.9Hz), 7.99(1H, dd,J = 7.6, 7.9Hz), 8.27(1H,d,J = 7.9Hz), 8.34(1H,d,J = 7.9Hz)	
83	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.4Hz), 2.0-2.1(4H,m), 2.58(3H,s), 2.71(2H,q,J = 7.4Hz), 3.67(2H,m), 3.94(2H,d,J = 4.3Hz), 4.75(1H, d,J = 5.9Hz), 5.39(2H,s), 6.56(2H,s), 7.10(1H,d,J = 7.6Hz), 7.50 (1H,s), 7.71(1H,d,J = 7.9Hz), 7.78(1H,dd,J = 7.9, 7.9Hz), 7.98(1H, dd, J = 7.9, 7.6Hz), 8.24(1H,d,J = 7.6Hz), 8.37(1H,d,J = 8.3Hz)	
84	(solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.9-2.3(4H,m), 2.58(3H,s), 2.70(2H,q,J = 7.5Hz), 3.6-3.8(2H,m), 3.88(2H,s), 4.12(2H,q,J = 7.2 Hz), 4.63(1H,dd,J = 8.3, 3.6Hz), 5.17(2H,d,J = 7.9Hz), 5.31(2H,s), 6.47(1H s), 7.15(1H,d,J = 6.6Hz), 7.34(5H,m), 7.50(1H,s), 7.67 (1H,d,J = 7.6Hz), 7.68(1H,dd,J = 7.9, 7.6Hz), 7.97(1H,dd,J = 7.9, 7.6Hz), 8.26(1H,d,J = 6.9Hz), 8.30(1H,d,J = 8.3Hz)	
85	(solvent:CDCl <sub>3</sub> ) 1.28(3H,t,J = 7.4Hz), 2.60(3H,s), 2.72(2H,q,J = 7.4Hz), 3.79(2H,s), 3.8-4.1(2H,m), 4.59(1H,t,J = 3.5Hz), 5.39 (2H,s), 6.52(1H,s), 7.54(1H,s), 7.74(1H,d,J = 7.9Hz), 7.80(1H, dd,J = 7.6, 8.3Hz), 8.02(1H,dd,J = 7.9, 7.6Hz), 8.24(1H,d,J = 7.9 Hz), 8.31(1H,d,J = 8.2Hz), 7.15(1H,d,J = 7.3Hz)	

Table 86

Ex. No.	Structural formula
8 6	
8 7	
8 8	
8 9	
9 0	

**EP 0 516 069 A1**

Table 87

	<sup>1</sup> H-NMR	$\delta$ ppm
5	86 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.4Hz), 2.58(3H,s), 2.69(2H,q,J = 7.4Hz), 3.74(3H,s), 3.79(2H,s), 4.00(2H,d,J = 3.3Hz), 4.71(1H, dt,J = 7.3, 3.6Hz), 5.38(2H,s), 6.50(1H,s), 7.05(1H,d,J = 6.6Hz), 7.49(1H,s), 7.70(1H,d,J = 7.9Hz), 7.75(1H,dd,J = 7.6, 8.2Hz), 7.98(1H,dd,J = 7.9, 6.7Hz), 8.25(1H,d,J = 6.6Hz), 8.27(1H,d,J = 8.2Hz)	
10	87 (solvent:DMSO-d <sub>6</sub> ) 1.19(3H,t,J = 7.6Hz), 2.60(3H,s), 2.64(2H,q,J = 7.6Hz), 3.53(2H,s), 5.49(2H,s), 6.55(1H,s), 6.89(1H,s), 7.64 (1H,s), 8.04(1H,d,J = 5.0Hz), 9.05(1H,s) (DMSO-d <sub>6</sub> )	
15	88 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.29(3H,t,J = 7.3Hz), 2.58 (3H,s), 2.71(2H,q,J = 7.6Hz), 3.76(2H,s), 4.21(2H,q,J = 7.3Hz), 5.43(2H,s), 6.41(1H,s), 6.94(1H,s), 7.51(1H,s), 8.13(1H,d,J = 5.0Hz), 9.09(1H,d,J = 5.0Hz), 10.93(br), 12.64(1H,s)	
20	89 (solvent:DMSO-d <sub>6</sub> ) 1.22(3H,t,J = 7.6Hz), 2.59(2H,s), 2.67(2H,q, J = 7.6Hz), 3.73(2H,s), 5.56(2H,s), 6.71(1H,s), 7.20(1H,d,J = 7.6 Hz), 7.71(1H,s), 7.89(1H,dd,J = 7.6Hz,7.9Hz), 8.16(1H,d,J = 7.9 Hz), 9.08(1H,s), 9.32(1H,s), 10.22(1H,s), 12.58(1H,s)	
	90 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.28(3H,t,J = 7.3Hz), 2.60 (3H,s), 2.70(2H,q,J = 7.6Hz), 3.80(2H,s), 4.21(2H,q,J = 7.3Hz), 5.38(2H,s), 6.50(1H,s), 7.12(1H,dd,J = 0.7Hz,7.6Hz), 7.52(1H,s), 7.78(1H,t,J = 7.9Hz), 8.34(1H,d,J = 8.3Hz), 9.04(1H,s), 10.06(1H, s), 12.68(1H,s)	

25

30

35

40

45

50

55

Table 88

Ex. No.	Structural formula
9 1	
9 2	
9 3	
9 4	
9 5	

50

55

**EP 0 516 069 A1**

**Table 89**

	<sup>1</sup> H-NMR	$\delta$ ppm
5	91 (solvent:CDCl <sub>3</sub> ) 1.22(3H,t,J = 7.6Hz), 2.58(3H,s), 2.65(2H,q,J = 7.6Hz), 3.72(2H,s), 5.20(2H,s), 6.47(1H,s), 6.87(1H,s), 7.50 (1H,s), 7.58(1H,dd,J = 7.6, 7.6Hz), 7.69(1H,d,J = 7.6Hz), 7.98(1H, d,J = 7.6Hz), 8.09(1H,s)	
10	92 (solvent:CDCl <sub>3</sub> ) 1.22(3H,t,J = 7.4Hz), 1.28(3H,t,J = 7.1Hz), 2.58 (3H,s), 2.64(2H,q,J = 7.4Hz), 3.69(2H,s), 4.19(2H,q,J = 7.1Hz), 5.18(2H,s), 6.45(1H,s), 6.86(1H,s), 7.47(1H,s), 7.57(1H,dd,J = 7.6, 7.6Hz), 7.68(1H,d,J = 7.6Hz), 7.88(1H,d,J = 7.6Hz), 8.02(1H, s)	
15	93 (solvent:CDCl <sub>3</sub> ) 1.28(3H,t,J = 7.6Hz), 1.47(3H,d,J = 7.3Hz), 2.60 (3H,s), 2.72(2H,q,J = 7.6Hz), 3.89(2H,s), 4.50(1H,dt,J = 7.2, 7.3 Hz), 5.45(2H,s), 6.57(1H,s), 7.34(1H,d,J = 7.6Hz), 7.53(1H,s), 7.78(1H,d,J = 7.9Hz), 8.02(1H,dd,J = 7.6, 7.9Hz), 8.03(1H,dd,J = 7.6, 7.6Hz), 8.23(1H,d,J = 7.6Hz), 8.45(1H,d,J = 8.2Hz),	
20	94 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.43(3H,d,J = 7.3Hz), 2.59 (3H,s), 2.71(2H,q,J = 7.6Hz), 3.72(3H,s), 3.74(2H,s), 4.61(1H, qd,J = 7.1Hz), 5.39(2H,s), 6.49(1H,s), 7.06(1H,d,J = 7.3Hz), 7.51 (1H,s), 7.72(1H,d,J = 7.3Hz), 7.76(1H,dd,J = 7.9, 7.6Hz), 8.00(1H, dd,J = 7.9, 7.6Hz), 8.27(1H,d,J = 8.6Hz), 8.34(1H,d,J = 8.3Hz)	
25	95 (solvent:CDCl <sub>3</sub> /MeOD(4/1)) 1.28(3H,t,J = 7.6Hz), 2.60(3H,s), 2.72(2H,q,J = 7.6Hz), 3.77(2H,s), 3.97(2H,s), 3.99(2H,s), 5.38 (2H,s), 6.53(1H,s), 7.14(1H,d,J = 7.6Hz), 7.37(1H,s), 7.75(1H,d, J = 7.9Hz), 7.79(1H,dd,J = 7.6, 8.2Hz), 8.02(1H,dd,J = 7.6, 7.9Hz), 8.25(1H,d,J = 7.9Hz), 8.30(1H,d,J = 8.2Hz)	

25

30

35

40

45

50

55

Table 90

Ex. No.	Structural formula
9 6	
9 7	
9 8	
9 9	
1 0 0	

Table 91

	<sup>1</sup> H-NMR	δ ppm
96	(solvent:CDCl <sub>3</sub> ) 1.21(3H,t,J = 7.1Hz), 1.27(3H,t,J = 7.4Hz), 2.58 (3H,s), 2.71(2H,q,J = 7.4Hz), 3.78(2H,s), 4.0-4.1(4H,m), 4.12 (2H,q,J = 7.1Hz), 5.40(2H,s), 6.52(1H,s), 7.07(1H,d,J = 7.3Hz), 7.50((1H,s), 7.72(1H,d,J = 7.9Hz), 7.76(1H,t,J = 8.3, 7.6Hz), 7.99 (1H,dd,J = 7.9, 7.9Hz), 8.27(1H,d,J = 8.6Hz), 8.30(1H,d,J = 8.9Hz)	
97	(solvent:DMSO-d <sub>6</sub> ) 1.30(3H,t,J = 7.6Hz), 2.59(3H,s), 2.72(2H,q,J = 7.6Hz), 3.49(1H,s), 4.13(2H,s), 5.40(2H,s), 6.48(1H,s), 7.17 (1H,dd,J = 1.8Hz,7.9Hz), 7.51 (1H,s), 7.61(1H,d,J = 7.9Hz), 8.3Hz), 7.76(1H,d,J = 7.9Hz), 8.02(1H,dd,J = 7.9Hz, 7.9Hz), 8.26(1H,d,J = 8.6 Hz), 8.75(1H,dd,J = 1.8Hz,8.3Hz), 12.18(1H,br), 12.63(1H,s),	
98	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.31(1H,t,J = 7.1Hz), 2.58 (3H,s), 2.70(2H,q,J = 7.6Hz), 3.99(2H,s), 4.26(2H,q,q,J = 7.1Hz), 5.35(2H,s), 6.46(1H,s), 7.11(1H,dd,J = 1.7Hz,7.9Hz), 7.36(1H,dd,J = 7.9Hz,7.9Hz), 7.49(1H,s), 7.72(1H,dd,J = 1.0Hz,7.9Hz), 7.98 (1H,dd,J = 7.9Hz,7.9Hz), 8.23(1H,dd,J = 1.0Hz,7.9Hz), 8.63(1H,dd,J = 2.0Hz,8.6Hz), 12.29(1H,br), 12.62(1H,s),	
99	(solvent:CDCl <sub>3</sub> ) 1.29(3H,t,J = 7.4Hz), 2.57(3H,s), 2.72(2H,t,J = 7.4Hz), 2.98(1H,dd,J = 17.0, 4.5Hz), 3.09(1H,dd,J = 17.0, 4.5Hz), 3.77(2H,s), 4.85(1H,br), 5.49(2H,d,J = 3.3Hz), 6.72(1H,s), 7.02 (1H,d,J = 8.3Hz), 7.49(1H,s), 7.65(1H,d,J = 7.9Hz), 7.75(1H,dd,J = 7.6, 8.3Hz), 7.94(1H,dd,J = 7.6, 8.3Hz), 7.94(1H,dd,J = 7.9, 7.6 Hz), 8.19(1H,d,J = 7.6Hz), 8.32(1H,d,J = 8.3Hz)	
100	(solvent:CDCl <sub>3</sub> ) 1.10(3H,t,J = 7.0Hz), 1.17(3H,t,J = 7.1Hz), 1.28 (3H,t,J = 7.4Hz), 2.71(2H,q,J = 7.4Hz), 2.85(1H,dd,J = 17.0, 4.6Hz), 3.02(1H,d,J = 17.0, 4.6Hz), 3.75(2H,s), 4.00(2H, q,J = 7.1Hz), 4.16(2H,q,J = 7.0Hz), 4.85(1H,qt,J = 7.6, 4.6Hz), 5.39 (2H,s), 6.49(1H,s), 7.05(1H,d,J = 7.3Hz), 7.51(1H,s), 7.72(1H,d, J = 7.6Hz), 7.73(1H,dd,J = 7.3, 7.6Hz), 7.99(1H,dd,J = 7.6, 7.9Hz), 8.27(1H,d,J = 7.3Hz), 8.34(1H,d,J = 8.3Hz)	

Table 92

Ex. No.	Structural formula
1 O 1	
1 O 2	
1 O 3	
1 O 4	
1 O 5	

Table 93

	<sup>1</sup> H-NMR	δppm
101 (solvent:DMSO-d <sub>6</sub> )	1.17(3H,t,J = 7.6Hz), 2.56(3H,s), 2.59(1H,m), 2.69(1H,m), 3.59(2H,s), 3.6-4.3(2H,b), 4.56(1H,m), 5.28(2H, s, 6.60(1H,s), 6.96(1H,s), 7.56(1H,t,J = 7.9Hz), 7.64(1H,s), 7.68(1H,d,J = 7.9Hz), 8.07(1H,d,J = 7.9Hz), 8.19(1H,s), 8.23(1H,d,J = 7.6Hz), 12.6(1H,s)	
102 (solvent:CDCl <sub>3</sub> /DMSO-d <sub>6</sub> (10/1))	1.15-1.31(9H,m), 2.57(3H,s), 2.64(2H,q,J = 7.3Hz), 2.84(1H,dd,J = 17.2, 4.6Hz), 3.03(1H,dd,J = 17.2, 4.3Hz), 3.67(2H,s), 4.15-4.27(4H,m), 4.85(1H,ddd,J = 7.9, 4.6, 4.3Hz), 5.19(1H,s), 6.46(1H,s), 6.78(1H,s), 7.48(1H,s), 7.57(1H,t,J = 7.9Hz), 7.69(1H,d,J = 7.9Hz), 7.94(1H,brd,J = 8.3Hz), 7.97(1H,d,J = 7.9Hz), 8.10(1H,s), 12.68(1H,s)	
103 (solvent:DMSO-d <sub>6</sub> )	1.21(3H,t,J = 7.3Hz), 2.58(1H,s), 2.6-2.7(4H, m), 4.08(1H,s), 4.60(1H,m), 5.46(2H,s), 5.6-6.4(2H,br), 6.62 (1H,s), 7.68(1H,s), 7.80(2H,d), 8.15(2H,m), 8.78(1H,d,J = 7.9 Hz), 12.55(1H,s)	
104 (solvent:CDCl <sub>3</sub> )	1.23-1.65(9H,m), 2.59(3H,s), 2.70(2H,q,J = 7.3 Hz), 2.85(1H,dd,J = 17.2, 4.6Hz), 3.05(1H,dd,J = 17.2, 4.6Hz), 4.10(2H,s), 4.15(2H,q,J = 7.3Hz), 4.22(2H,q,J = 7.3Hz), 4.87(1H, dt,J = 7.9, 4.6Hz), 5.32(1H,s), 6.45(1H,s), 7.24(1H,brd), 7.52 (1H,s), 7.75(1H,d,J = 7.3Hz), 8.01(1H,t,J = 7.9Hz), 8.26(1H,d,J = 7.9Hz), 12.67 (1H,s)	
105 (solvent:DMSO-d <sub>6</sub> )	0.96(6H,m), 1.30(3H,t,J = 7.6Hz), 2.17(1H,m), 2.58(3H,s), 2.73(2H,q,J = 7.6Hz), 3.75(2H,m), 4.67(1H,m), 5.42 (2H,s), 6.83(1H,s), 7.02(1H,d,J = 7.9Hz), 7.51(1H,s), 7.65(1H,d, J = 7.9Hz), 7.75(1H,l,J = 7.9Hz), 7.95(1H,t,J = 7.9Hz), 8.22(1H,d,J = 7.9Hz), 8.32(1H,d,J = 7.9Hz), 8.91 (1H,brd), 10.87(1H,s)	

Table 94

Ex. No.	Structural formula
106	
107	
108	
109	
110	

**EP 0 516 069 A1**

Table 95

	<sup>1</sup> H-NMR	$\delta$ ppm
106	(solvent:CDCl <sub>3</sub> ) 0.91(3H,η), 1.27(3H,t,J = 7.3Hz), 2.18(1H,m), 2.59(3H,s), 2.71(2H,q,J = 7.3Hz), 3.71(3H,s), 3.76(2H,s), 4.60 (1H,s), 5.34(2H,s), 6.46(1H,s), 7.05(1H,d,J = 7.6Hz), 7.51(1H, s), 7.73(1H,t,J = 7.6Hz), 7.78(1H,d,J = 7.9Hz), 7.97(1H,br), 8.00 (1H,t,J = 7.9Hz), 8.27(1H,d,J = 7.9Hz), 8.35(1H,d,J = 7.9Hz), 10.54 (1H,s), 12.62(1H,s)	
107	(solvent:DMSO-d <sub>6</sub> ) 1.31(3H,t,J = 7.6Hz), 2.01(3H,s), 2.15(1H,m), 2.35(1H,m), 2.55(2H,m), 2.58(3H,s), 2.74(2H,q,J = 7.6Hz), 3.80 (1H,d,J = 15.8Hz), 3.68(1H,d,J = 15.8Hz), 4.73(1H,m), 5.48(2H,s), 6.83(1H,s), 7.02(1H,d,J = 7.6Hz), 7.51(1H,s), 7.63(1H,d,J = 7.6 Hz), 7.75(1H,t,J = 7.6Hz), 7.94(1H,t,J = 7.6Hz), 8.22(1H,d,J = 7.6 Hz), 8.33(1H,d,J = 7.6Hz), 9.08(1H,brd), 10.87(1H,s)	
108	(solvent:CDCl <sub>3</sub> ) 1.1-1.3(6H,m), 2.00(3H,s), 2.05-2.2(2H,m), 2.47(2H,m), 2.59(3H,s), 2.70(2H,q,J = 7.3Hz), 3.74(2H,s), 4.16 (2H,m), 5.40(2H,s), 6.50(1H,s), 7.08(1H,d,J = 7.6 Hz), 7.51(1H,s), 7.75(1H,t,J = 7.6Hz), 7.77(1H,d,J = 7.9Hz), 7.96 (1H,br), 8.00(1H,t,J = 7.6Hz), 8.27(1H,d,J = 7.3Hz), 8.34(1H,d,J = 8.3Hz), 10.53(1H,s), 12.63(1H,s)	
109	(solvent:DMSO-d <sub>6</sub> ) 1.21(3H,t,J = 7.3Hz), 2.51(3H,s), 2.63(4H,m), 3.89(2H,s), 4.59(1H,m), 5.42(2H,s), 6.63(1H,s), 7.29 (1H,d,J = 8.3Hz), 7.44(1H,t,J = 8.3Hz), 7.65(1H,s), 7.83(1H,d,J = 7.3Hz), 8.18(1H,dd,J = 7.3Hz), 8.23(1H,brd), 8.47(1H,d,J = 8.3Hz), 8.59(1H, d,J = 7.3Hz), 12.16(1H,s), 12.51(1H,s), 12.6(2H,br)	
110	(solvent:CDCl <sub>3</sub> ) 1.15(3H,t,J = 7.3Hz), 1.17(3H,t,J = 7.3Hz), 1.27 (3H,t,J = 7.3Hz), 2.59(3H,s), 2.71(1H,q,J = 7.3Hz), 2.83(1H,dd,J = 16.8Hz,5.3Hz), 2.94(1H,dd,J = 16.8Hz,5.3Hz), 3.96(1H,d,J = 13.5 Hz), 4.07(1H,d,J = 13.5Hz), 4.11(2H,q,J = 7.3Hz), 4.12(2H,q,J = 7.3Hz), 5.39(2H,s), 6.48(1H,s), 7.18(1H, dd,J = 7.9Hz,1.7Hz), 7.41(1H,t,J = 7.9Hz), 7.50(1H,s), 7.76(1H,d, J = 7.9Hz), 8.01(1H,t,J = 7.9Hz), 8.25(1H,d,J = 7.9Hz), 8.63(1H,dd, J = 7.4Hz,1.7Hz), 8.68(1H,d, J = 8.2Hz), 12.32(1H,s), 12.6(1H,s)	






Table 96

Ex. No.	Structural formula
1 1 1	
1 1 2	
1 1 3	
1 1 4	
1 1 5	

Table 97

	<sup>1</sup> H-NMR	δ ppm
111 (solvent:DMSO-d <sub>6</sub> )	1.12(3H,d,J = 6.6Hz), 1.22(3H,t,J = 7.6Hz), 2.30 (1H,dd,J = 15.2Hz,7.3Hz), 2.46(1H,dd,J = 15.2Hz,7.3Hz), 2.58(3H, s), 2.67(2H,q,J = 7.6Hz), 3.56(2H,s), 4.10(1H,m), 5.47(2H,s), 6.84(2H,s), 7.13(1H,d,J = 7.6Hz), 7.69(1H,s), 7.80-7.86(2H,m), 8.10-8.30(4H,m), 10.35(1H,s), 12.17(1H,s), 12.56(1H,s)	
112 (solvent:CDCl <sub>3</sub> )	1.26(6H,m), 2.53(2H,d,J = 5.3Hz), 2.59(3H,s), 2.71 (3H,s), 2.71(2H,m), 3.55(3H,s), 3.68(2H,s), 4.36(1H,m), 5.36(2H,s), 6.47(1H,s), 7.06(1H,d,J = 7.6Hz), 7.42(1H,brd,J = 7.9 Hz), 7.5(1H,s), 7.70(1H,d,J = 7.6Hz), 7.75(1H,t,J = 7.6Hz), 7.99 (1H,t,J = 7.6Hz), 8.27(1H,d,J = 7.6Hz), 8.31(1H,d,J = 7.6Hz), 10.48 (1H,s), 12.65(1H,s)	
113 (solvent:DMSO-d <sub>6</sub> )	1.23(3H,t,J = 7.3Hz), 2.14(1H,m), 2.6(1H,m), 2.58(3H s), 2.67(2H,q,J = 7.3Hz), 3.45-3.70(2H,m), 3.83(1H,m), 4.22(1H,m), 5.02(0.4H m), 4.57(0.6H m), 5.48(2H,s), 6.65(1H s), 7.14(1H m), 7.69(1H s), 7.65-7.90(2H,m), 8.15-8.30(3H,m), 10.32(0.6H s), 10.34(0.4H s), 12.55(1H s), 12.90(1H br)	
114 (solvent:CDCl <sub>3</sub> )	1.27(3H,t,J = 7.6Hz), 2.20-2.40(1H,m), 2.5-2.7 (1H,m), 2.59(3H,s), 2.71(2H,q,J = 7.6Hz), 3.64(0.4H s), 3.68(0.6 H,s), 3.77(0.6H s), 3.80(0.4H s), 4.05-4.40(2H,m), 4.79(0.6H m), 4.95(0.4H m), 5.34(2H,s), 6.48(1H,s), 7.13(0.4H,d,J = 7.6 Hz), 7.19(0.6H,d,J = 7.6Hz), 7.51(1H,s), 7.70(1H,d,J = 7.6Hz), 7.75(1H,m), 7.98(1H,t,J = 7.6Hz), 8.27(1H,d,J = 7.6Hz), 8.32(1H,d,J = 7.6Hz), 10.34(1H,s), 12.67(1H,s)	
115 (solvent:CDCl <sub>3</sub> )	1.28(3H,t,J = 7.6Hz), 2.58(3H,s), 2.72(2H,q,J = 7.6Hz), 2.91(2H,t,J = 5.7Hz), 3.87(2H,s), 3.92(2H,t,J = 5.7Hz), 5.46(2H,s), 6.60(1H,s), 6.88(1H,d,J = 7.3Hz), 7.12(1H,d,J = 6.6 Hz), 7.50(1H,s), 7.62(1H,dd,J = 7.6, 8.3Hz), 7.73(1H,d,J = 7.9Hz), 7.78(1H,dd,J = 7.6, 8.3Hz), 7.98(1H,dd,J = 7.6, 7.9Hz), 8.06(1H,d, J = 8.3Hz), 8.27(1H,d,J = 7.9Hz), 8.40(1H,d,J = 7.6Hz)	

Table 98

Ex. No.	Structural formula
1 1 6	
1 1 7	
1 1 8	
1 1 9	
1 2 0	

**EP 0 516 069 A1**

Table 99

	<sup>1</sup> H-NMR	$\delta$ ppm
5	116 (solvent:CDCl <sub>3</sub> /MeODC(1/4)) 1.28(3H,t,J = 7.6Hz), 2.60(3H,s), 2.72(2H,q,J = 7.6Hz), 2.88(2H,t,J = 6.3Hz), 3.86(2H,t,J = 6.3Hz), 3.97(2H,s), 5.39(2H,s), 6.52(1H,s), 6.68(1H,s), 7.19(1H,d,J = 7.6Hz), 7.55(1H,s), 7.76(1H,d,J = 7.9Hz), 7.83(1H,dd,J = 8.2,7.6Hz), 8.05(1H,dd,J = 7.6,J = 7.9Hz), 8.25(1H,d,J = 7.6Hz), 8.33(1H,d,J = 8.2Hz)	
10	117 (solvent:CDCl <sub>3</sub> ) 1.0-1.3(5H,m), 2.59(2H,s), 2.71(2H,q,J = 7.5Hz), 3.4-3.9(6H,m), 3.4-3.9(6H,m), 3.93(2H,s), 5.35(2H,s), 6.49(1H,s), 7.0-7.2(1H,m), 7.51(1H,s), 7.6-8.4(5H,m)	
15	118 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.4Hz), 2.58(3H,s), 2.70(2H,q,J = 7.4Hz), 3.6-4.0(8H,m), 4.00(2H,s), 5.35(2H,s), 6.51(1H,s), 7.11(1H,d,J = 7.6Hz), 7.50(1H,s), 7.70(1H,d,J = 7.6Hz), 7.76(1H,dd,J = 7.6,7.6Hz), 7.97(1H,dd,J = 7.6,7.9Hz), 8.24(1H,d,J = 7.9Hz), 8.32(1H,d,J = 7.6Hz)	
20	119 (solvent:CDCl <sub>3</sub> ) 1.28(3H,t,J = 7.4Hz), 2.60(3H,s), 2.71(2H,q,J = 7.4Hz), 3.42(2H,t,J = 6.6Hz), 3.68(2H,t,J = 6.6Hz), 3.71(2H,s), 5.37(2H,s), 6.50(1H,s), 7.13(1H,d,J = 7.6Hz), 7.53(1H,s), 7.74(1H,d,J = 7.6Hz), 7.76(1H,dd,J = 8.2,7.6Hz), 8.02(1H,dd,J = 7.6,7.6Hz), 8.25(1H,d,J = 7.6Hz), 8.27(1H,d,J = 8.2Hz)	
	120 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.4Hz), 2.59(3H,s), 2.71(2H,q,J = 7.4Hz), 2.93(2H,t,J = 6.8Hz), 4.48(2H,t,J = 6.8Hz), 5.32(2H,s), 6.31(1H,d,J = 8.1Hz), 6.45(1H,d,J = 8.1Hz), 7.03(1H,d,J = 7.6Hz), 7.29(1H,d,J = 8.1,8.1Hz), 7.69(1H,d,J = 7.6Hz) 7.71(1H,dd,J = 7.6,7.6Hz), 7.97(1H,dd,J = 7.6,7.6Hz), 8.26(1H,d,J = 7.6Hz), 8.33(1H,d,J = 7.6Hz)	

25

30

35

40

45

50

55

Table 100

Ex. No.	Structural formula
1 2 1	
1 2 2	
1 2 3	
1 2 4	
1 2 5	

50

55

**EP 0 516 069 A1**

Table 101

	<sup>1</sup> H-NMR	δ ppm
121 (solvent:CDCl <sub>3</sub> )	1.28(3H,t,J = 7.4Hz), 2.59(3H,s), 2.71(2H,q,J = 7.4Hz), 2.96(2H,t,J = 5.5Hz), 3.96(2H,t,J = 5.5Hz), 5.39(2H,s), 6.45(1H,s), 6.73(1H,s), 7.51(1H,s), 7.72(1H,d,J = 6.9Hz), 8.00(1H,dd,J = 7.9,7.6Hz), 8.25(1H,dd,J = 7.6Hz)	
122 (solvent:DMSO-d <sub>6</sub> )	0.41(3H,t,J = 7.6Hz), 1.30(3H,t,J = 7.6Hz), 1.71-1.9(2H,m), 2.57(3H,s), 3.74(2H,ABq,J = 15.4Hz,5.5Hz), 4.66(1H,m), 5.46(2H,s), 6.83(1H,s), 7.02(1H,d,J = 7.6Hz), 7.51(1H,s), 7.63(1H,d,J = 7.6Hz), 7.75(1H,t,J = 7.6Hz), 7.94(1H,t,J = 7.6Hz), 8.22(1H,d,J = 7.6Hz), 8.32(1H,d,J = 7.6Hz), 8.94(1H,m), 10.86(1H,s)	
123 (solvent:CDCl <sub>3</sub> )	0.88(3H,t,J = 7.3Hz), 1.27(3H,t,J = 7.6Hz), 1.71-1.9(2H,m), 2.59(3H,s), 2.71(2H,q,J = 7.6Hz), 3.71(3H,s), 3.74(2H,s), 4.63(1H,m), 5.37(2H,s), 6.47(1H,s), 7.06(1H,d,J = 7.6Hz), 7.71(1H,d,J = 7.6Hz), 7.75(1H,t,J = 7.6Hz), 7.86(1H,m), 8.00(1H,t,J = 7.6Hz), 8.27(1H,d,J = 7.6Hz), 8.35(1H,m,J = 7.6Hz), 10.53(1H,s), 12.63(1H,s)	
124 (solvent:DMSO-d <sub>6</sub> )	1.19(3H,t,J = 7.6Hz), 2.59(3H,s), 2.65(2H,q,J = 7.6Hz), 3.89(2H,s), 5.53(2H,s), 6.73(1H,s), 7.37(1H,d,J = 7.9Hz), 7.51(1H,t,J = 7.9Hz), 7.69(1H,s), 8.46(1H,d,J = 7.9Hz), 9.13(1H,s), 11.96(1H,s), 12.50(1H,br), 12.54(1H,s)	
125 (solvent:CDCl <sub>3</sub> )	1.26(3H,t,J = 7.6Hz), 1.31(3H,t,J = 7.3Hz), 2.60(3H,s), 2.69(2H,q,J = 7.6Hz), 3.98(3H,s), 4.25(2H,q,J = 7.3Hz), 5.39(2H,s), 6.47(1H,s), 7.15(1H,dd,J = 8.3Hz, 2.0Hz), 7.39(1H,t,J = 8.3Hz), 7.52(1H,s), 8.61(1H,dd,J = 8.3Hz,2.0Hz), 9.07(1H,s), 9.46(1H,s), 12.12(1H,s), 12.65(1H,s)	

Table 102

Ex. No.	Structural formula
1 2 6	
1 2 7	
1 2 8	
1 2 9	
1 3 0	

Table 103

	<sup>1</sup> H-NMR	δppm
126	(solvent:CDCl <sub>3</sub> ) 1.28(3H,t,J = 7.4Hz), 2.58(3H,s), 2.71(2H,q,J = 7.4Hz), 3.02(2H,t,J = 5.5Hz), 4.05(2H,t,J = 5.5Hz), 5.34(2H,s), 6.49(1H,s), 6.98(1H,d,J = 7.6Hz), 7.50(1H,s), 7.70(1H,d,J = 7.9Hz), 7.72(1H,dd,J = 7.9,7.9Hz), 7.98(1H,d,J = 7.9,7.6Hz), 8.27(1H,d,J = 7.6Hz), 8.30(1H,d,J = 8.2Hz)	
127	(solvent:CDCl <sub>3</sub> ) 1.10(3H,t,J = 7.1Hz), 1.17(3H,t,J = 7.3Hz), 1.27(3H,t,J = 8.1Hz), 2.59(3H,s), 2.71(2H,q,J = 7.2Hz), 2.84(1H,dd,J = 16.8,4.6Hz), 3.02(1H,dd,J = 16.8,4.3Hz), 3.75(2H,s), 4.00(2H,q,J = 7.1Hz), 4.16(2H,q,J = 7.0Hz), 4.85(1H,dt,J = 7.9,4.6Hz), 5.39(2H,s), 6.49(1H,s), 7.05(1H,dd,J = 7.6,0.6Hz), 7.51(1H,s), 7.72(1H,d,J = 7.6Hz), 7.75(1H,dd,J = 7.9,7.9Hz), 7.99(1H,dd,J = 7.6,7.9Hz), 8.26(1H,dd,J = 8.6,1.0Hz), 8.34(1H,dd,J = 8.2,0.7Hz)	
128	(solvent:DMSO-d <sub>6</sub> ) 0.90(3H,d,J = 7.6Hz), 0.91(3H,d,J = 7.6Hz), 1.19(3H,t,J = 7.3Hz), 2.07(1H,m), 2.58(3H,s), 2.65(2H,q,J = 7.3Hz), 3.92(2H,ABq,J = 21.8,15.5Hz), 4.18(1H,dd,J = 8.3,5.6Hz), 5.42(2H,s), 6.62(1H,s), 7.29(1H,dd,J = 8.3,2.0Hz), 7.48(1H,t,J = 8.3Hz), 7.68(1H,s), 7.85(1H,m), 8.20(2H,m), 8.45(1H,dd,J = 8.3,2.0Hz), 8.46(1H,d,J = 8.3Hz), 12.17(1H,s), 12.51(1H,s), 12.60(1H,s)	
129	(solvent:CDCl <sub>3</sub> ) 0.88(3H,t,J = 7.3Hz), 0.98(3H,t,J = 7.3Hz), 1.27(3H,t,J = 7.6Hz), 2.18(1H,m), 2.59(3H,s), 2.71(2H,q,J = 7.6Hz), 3.65(3H,s), 4.04(2H,ABq,J = 17.5,13.2Hz), 4.40(1H,m), 5.36(2H,s), 6.45(1H,s), 7.18(1H,dd,J = 8.3,2.0Hz), 7.41(1H,t,J = 8.3Hz), 7.51(1H,s), 7.74(1H,d,J = 7.9Hz), 8.00(1H,t,J = 7.9Hz), 8.25(1H,d,J = 8.3,2.0Hz), 8.78(1H,d,J = 8.6Hz), 12.38(1H,s), 12.62(1H,s)	
130	(solvent:DMSO-d <sub>6</sub> ) 1.10(3H,d,J = 7.3Hz), 1.22(3H,t,J = 7.6Hz), 2.58(3H,s), 2.67(2H,q,J = 7.6Hz), 3.76(2H,ABq,J = 20.5,14.9Hz), 4.17(1H,dt), 4.26(1H,m), 4.95(1H,m), 5.47(2H,s), 6.63(1H,s), 7.20(1H,d,J = 7.6Hz), 7.69(1H,s), 7.82(2H,m), 8.18(4H,m), 10.36(1H,s), 12.50(1H,br), 12.55(1H,s)	

Table 104

Ex. No.	Structural formula
1 3 1	
1 3 2	
1 3 3	
1 3 4	
1 3 5	

Table 105

	<sup>1</sup> H-NMR	δ ppm
131	(solvent:CDCl <sub>3</sub> ) 1.16(3H,t,J = 7.3Hz), 1.26(3H,t,J = 7.6Hz), 2.57(3H,s), 2.69(2H,q,J = 7.6Hz), 3.01(1H,br), 3.69(3H,s), 4.05(2H,ABq,J = 20.1Hz,ABq,J = 8.3Hz), 4.50(1H,m), 4.54(1H,m), 5.36(2H,s), 6.49(1H,s), 7.20(1H,dd,J = 8.3Hz,1.7Hz), 7.41(1H,t,J = 8.3Hz), 7.48(1H,s), 7.72(1H,d,J = 7.9Hz), 7.98(1H,t,J = 7.9Hz), 8.21(1H,d,J = 7.9Hz), 8.51(1H,d,J = 8.6Hz), 8.60(1H,dd,J = 8.3,1.7Hz), 12.34(1H,s), 12.64(1H,s)	
132	(solvent:DMSO-d <sub>6</sub> ) 1.19(3H,t,J = 7.3Hz), 1.31(3H,d,J = 7.3Hz), 2.58(3H,s), 2.64(2H,q,J = 7.6Hz), 3.85(2H,m), 4.24(1H,m), 5.43(2H,s), 6.68(1H,s), 7.31(1H,dd,J = 8.3,1.7Hz), 7.47(1H,t,J = 8.3Hz), 7.68(1H,s), 7.85(1H,m), 8.21(2H,m), 8.46(1H,dd,J = 8.3,1.7Hz), 8.54(1H,d,J = 7.9Hz), 12.15(1H,s), 12.50(1H,s), 12.55(1H,br)	
133	(solvent:DMSO-d <sub>6</sub> ) 0.92(3H,t,J = 7.6Hz), 1.20(3H,t,J = 7.6Hz), 1.6-1.9(1H,m), 2.58(3H,s), 2.65(2H,q,J = 7.6Hz), 3.89(2H,ABq,J = 20.8,15.8Hz), 4.17(1H,m), 5.42(2H,s), 6.63(1H,s), 7.30(1H,dd,J = 8.3Hz,2.0Hz), 7.47(1H,t,J = 8.3Hz), 7.68(1H,s), 7.85(2H,m), 8.45(1H,dd,J = 8.3,2.0Hz), 8.50(1H,d,J = 7.9Hz), 12.16(1H,s), 12.50(1H,s), 12.55(1H,br)	
134	(solvent:CDCl <sub>3</sub> ) 0.89(3H,t,J = 7.3Hz), 1.27(3H,t,J = 7.6Hz), 1.70-1.85(2H,m), 2.59(3H,s), 2.71(2H,q,J = 7.6Hz), 3.66(3H,s), 4.02(2H,ABq,J = 18.8,13.2Hz), 4.45(1H,m), 5.38(2H,s), 6.48(1H,s), 7.18(1H,dd,J = 7.9,2.0Hz), 7.41(1H,t,J = 7.9Hz), 7.50(1H,s), 7.75(1H,d,J = 7.9Hz), 8.00(1H,t,J = 7.9Hz), 8.25(1H,d,J = 7.9Hz), 8.61(1H,brd), 8.63(1H,dd,J = 7.9Hz,2.0Hz), 12.33(1H,s), 12.63(1H,s)	
135	(solvent:DMSO-d <sub>6</sub> ) 1.20(3H,t,J = 7.6Hz), 2.58(3H,s), 2.65(2H,q,J = 7.6Hz), 2.7-2.9(2H,m), 3.87(2H,s), 4.58(1H,m), 5.43(2H,s), 6.64(1H,s), 7.30(1H,dd,J = 8.3,2.0Hz), 7.47(1H,t,J = 8.3Hz), 7.68(1H,s), 7.84(1H,m), 8.21(1H,m), 8.46(1H,dd,J = 8.3Hz,2.0Hz), 8.61(1H,d,J = 7.9Hz), 12.14(1H,s), 12.51(1H,s), 12.55(2H,br)	



Table 106

Ex. No.	Structural formula
1 3 6	
1 3 7	
1 3 8	
1 3 9	
1 4 0	

Table 107

	<sup>1</sup> H-NMR	δ ppm
136	(solvent:CDCl <sub>3</sub> ) 1.15(3H,t,J = 7.3Hz), 1.17(3H,t,J = 7.3Hz), 1.27(3H,t,J = 7.6Hz), 2.59(3H,s), 2.71(2H,q,J = 7.6Hz), 2.80-2.95(2H,m), 3.93-4.16(6H,m), 4.81(1H,m), 5.39(2H,s), 6.47(1H,s), 7.18(1H,d,J = 8.3Hz), 7.41(1H,t,J = 8.3Hz), 7.51(1H,s), 7.76(1H,d,J = 7.9Hz), 8.01(1H,t,J = 7.9Hz), 8.25(1H,d,J = 7.9Hz), 8.62(1H,dd,J = 8.3,1.7Hz), 8.69(1H,d,J = 7.9Hz), 12.31(1H,s), 12.61(1H,s)	
137	(solvent:DMSO-d <sub>6</sub> ) 1.09(3H,d,J = 7.6Hz), 1.20(3H,t,J = 7.6Hz), 2.58(3H,s), 2.66(2H,q,J = 7.6Hz), 3.96(2H,ABq,J = 20.8,15.8Hz), 4.10(1H,br), 4.24(1H,m), 4.90(1H,m), 5.42(2H,s), 6.63(1H,s), 7.31(1H,dd,J = 7.9,2.0Hz), 7.48(1H,t,J = 7.9Hz), 7.68(1H,s), 7.85(1H,m), 8.17-8.30(3H,m), 12.16(1H,s), 12.50(1H,s), 12.55(1H,br)	
138	(solvent:CDCl <sub>3</sub> ) 1.18(2H,d,J = 6.6Hz), 1.27(3H,t,J = 7.6Hz), 2.58(3H,s), 2.69(2H,q,J = 7.6Hz), 3.72(3H,s), 4.34(4H,m), 4.61(1H,m), 5.37(2H,s), 6.49(1H,s), 7.06(1H,d,J = 7.9Hz), 7.49(1H,s), 7.70(1H,d,J = 7.9Hz), 7.76(1H,t,J = 7.9Hz), 7.97(1H,t,J = 7.9Hz), 8.25(1H,d,J = 7.9Hz), 8.29(1H,d,J = 7.9Hz), 8.46(1H,brd,J = 8.3Hz), 10.57(1H,s), 12.70(1H,s)	
139	(solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.41(3H,d,J = 7.3Hz), 2.59(3H,s), 2.71(2H,q,J = 7.6Hz), 3.66(3H,s), 4.01(2H,ABq,J = 29.7Hz,13.2Hz), 4.51(1H,m), 5.40(2H,s), 6.50(1H,s), 7.18(1H,dd,J = 8.3,2.0Hz), 7.41(1H,t,J = 8.3Hz), 7.50(1H,s), 7.75(1H,d,J = 7.9Hz), 8.00(1H,t,J = 7.9Hz), 8.26(1H,d,J = 7.9Hz), 8.52(1H,d,J = 7.6Hz), 8.64(1H,dd,J = 8.3,2.0Hz), 12.31(1H,s), 12.63(1H,s)	
140	(solvent:DMSO-d <sub>6</sub> ) 1.20(3H,t,J = 7.6Hz), 1.90-2.52(4H,m), 2.58(3H,s), 2.66(2H,q,J = 7.6Hz), 3.70(2H,m), 3.99(2H,ABq,J = 29.7,16.2Hz), 4.29(1H,m), 5.24(2H,s), 6.63(1H,s), 7.33(1H,dd,J = 7.6,2.0Hz), 7.47(1H,t,J = 8.3Hz), 7.68(1H,s), 7.85(1H,dd,J = 5.6,3.3Hz), 8.20(2H,s), 8.46(1H,dd,J = 8.3,2.0Hz), 12.14(1H,s), 12.51(1H,s)	

Table 108

Ex. No.	Structural formula
10 1 4 1	
15 1 4 2	
20	
25	
30	
35	
40	
45	
50	

**EP 0 516 069 A1**

**Table 109**

	<sup>1</sup> H-NMR	$\delta$ ppm
5	<b>141</b> (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.9-2.3(4H,m), 2.59(3H,s), 2.71(2H,q,J = 7.6Hz), 3.73(3H,s), 3.6-3.9(2H,m), 3.87(2H,m), 4.55(1H,m), 5.33(2H,s), 6.47(1H,s), 7.18(1H,d,J = 7.9Hz), 7.51(1H,s), 7.69(1H,d,J = 7.9Hz), 7.74(1H,t,J = 7.9Hz), 7.98(1H,t,J = 7.9Hz), 8.27(1H,d,J = 7.9Hz), 8.31(1H,d,J = 7.9Hz), 10.34(1H,s), 12.67(1H,s)	
10	<b>142</b> (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 1.9-2.3(4H,m), 2.58(3H,s), 2.70(2H,q,J = 7.6Hz), 3.74(3H,s), 3.7-3.9(2H,m), 3.90(1H,d,J = 15.8Hz), 4.26(1H,d,J = 15.8Hz), 4.61(1H,m), 5.35(2H,s), 6.46(1H,s), 7.25(1H,brd), 7.37(1H,t,J = 7.9Hz), 7.50(1H,s), 7.73(1H,d,J = 7.9Hz), 7.98(1H,t,J = 7.9Hz), 8.24(1H,d,J = 7.9Hz), 8.59(1H,d,J = 7.9Hz), 12.29(1H,s), 12.65(1H,s)	
15		

20

25

30

35

40

45

50

55

Table 110

Ex. No.	Structural formula
1 4 3	
1 4 4	
1 4 5	
1 4 6	
1 4 7	

50

55

Table 111

	<sup>1</sup> H-NMR δppm
143	(solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.4Hz), 1.27(3H,t,J = 7.4Hz), 1.30(3H,t,J = 7.0Hz), 2.58(3H,s), 2.69(2H,q,J = 7.4Hz), 2.97(1H,dd,J = 16.8,4.6Hz), 3.13(1H,dd,J = 16.8,4.0Hz), 4.19(2H,qd,J = 7.3,3.0Hz), 4.27(2H,q,J = 7.3,3.0Hz), 5.06(1H,id,J = 8.3,5.0Hz), 5.27(1H,s), 6.46(1H,s), 7.49(1H,s), 7.64(1H,dd,J = 7.6,1.0Hz), 7.91(1H,dd,J = 7.6,7.6Hz), 8.14(1H,dd,J = 7.6,1.0Hz)
144	(solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.32(3H,t,J = 7.3Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 4.24-4.3(4H,m), 5.26(2H,s), 6.45(1H,s), 7.49(1H,s), 7.64(1H,d,J = 7.6Hz), 7.92(1H,dd,J = 6.9,7.6Hz), 8.15(1H,d,J = 6.9Hz), 12.66(1H,s)
145	(solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 1.28(3H,t,J = 7.3Hz), 2.6-2.7(4H,m), 3.7-3.8(2H,m), 4.1-4.2(2H,q,J = 7.3Hz), 5.24(2H,s), 6.45(1H,s), 7.49(1H,s), 7.61(1H,d,J = 6.6,7.9Hz), 8.14(1H,d,J = 6.6,7.9Hz), 8.42(1H,br), 12.66(1H,s)
146	(solvent:CDCl <sub>3</sub> ) 1.02(6H,dd,J = 4.0Hz,6.9Hz), 1.26(3H,t,J = 7.6Hz), 2.2-2.4(1H,m), 2.58(3H,s), 2.69(2H,q,J = 7.6Hz), 3.78(3H,s), 4.75(1H,dd,J = 5.3,9.2Hz), 5.29(2H,s), 6.49(1H,s), 7.50(1H,s), 7.64(1H,d,J = 7.9Hz), 7.91(1H,dd,J = 7.9,7.9Hz), 8.15(1H,d,J = 7.9Hz), 8.44(1H,d,J = 9.2Hz), 12.66(1H,s)
147	(solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.85(3H,s), 4.0-4.2(2H,m), 4.8-4.9(1H,m), 5.29(2H,s), 6.51(1H,s), 7.49(1H,s), 7.65(1H,d,J = 7.6Hz), 7.92(1H,dd,J = 7.6,7.9Hz), 8.15(1H,d,J = 7.9Hz), 8.80(1H,d,J = 7.9Hz), 12.70(1H,s)

Table 112

Ex. No.	Structural formula
1 4 8	
1 4 9	
1 5 0	
1 5 1	
1 5 2	

**EP 0 516 069 A1**

Table 113

	<sup>1</sup> H-NMR	$\delta$ ppm
5	148 (solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.32(3H,t,J = 7.3Hz), 2.0-2.2(1H,m), 2.12(3H,s), 2.3-2.4(1H,m), 2.5-2.7(4H,m), 2.58(3H,s), 4.26(2H,q,J = 7.3Hz), 4.8-5.0(1H,m), 5.29(2H,s), 6.47(1H,s), 7.50(1H,s), 7.64(1H,dd,J = 1.0,7.6Hz), 7.91,(1H,dd,J = 7.6,7.6Hz), 8.14(1H,dd,J = 1.0Hz,7.6Hz), 8.52(1H,d,J = 8.6Hz), 12.66(1H,s)	
10	149 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 2.58(3H,s), 2.67(2H,q,J = 7.6Hz), 3.26(2H,dd,J = 1.8Hz,6.3Hz), 3.75(3H,s), 5.07(1H,dt,J = 8.3,6.3Hz), 5.22(2H,s), 6.45(1H,s), 7.1-7.4(5H,m), 7.50(1H,s), 7.62(1H,d,J = 7.3Hz), 7.89(1H,dd,J = 6.9Hz,7.3Hz), 8.11(1H,d,J = 6.9Hz), 8.41(1H,d,J = 8.3Hz), 12.67(1H,s)	
15	150 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.1-3.2(2H,m), 3.76(3H,s), 5.02(1H,dt,J = 8.6Hz,5.9Hz), 5.21(2H,d,J = 2.0Hz), 6.09(1H,s), 6.42(1H,s), 6.76(1H,dd,J = 2.3Hz,8.9Hz), 7.02(1H,d,J = 8.9Hz), 7.50(1H,s), 7.61(1H,d,J = 7.6Hz), 7.88(1H,dd,J = 7.5Hz,7.6Hz), 8.10(1H,d,J = 7.5Hz), 8.40(1H,d,J = 8.6Hz), 12.63(1H,s)	
20	151 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.30(2H,d,J = 5.6Hz), 3.79(3H,s), 5.0-5.1(1H,m), 5.27(2H,d,J = 4.62Hz), 6.42(1H,s), 6.86(1H,d,J = 1.3Hz), 7.49(1H,s), 7.6-7.7(2H,m), 7.89(1H,dd,J = 7.6Hz,7.6Hz), 8.12(1H,dd,J = 1.0Hz,7.9Hz), 8.8-8.9(1H,m), 12.80(1H,s)	
25	152 (solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.57(3H,d,J = 6.9Hz), 2.58(3H,s), 2.69(2H,q,J = 7.6Hz), 3.80(3H,s), 4.82(1H,dq,J = 6.9Hz,8.3Hz), 5.28(2H,s), 6.47(1H,s), 7.50(1H,s), 7.63(1H,dd,J = 1.0Hz,7.9Hz), 7.91(1H,dd,J = 7.9Hz,7.9Hz), 8.14(1H,dd,J = 1.0,7.9Hz), 8.43(1H,d,J = 8.3Hz), 12.66(1H,s)	

30

35






40

45

50

55

Table 114

Ex. No.	Structural formula
1 5 3	
1 5 4	
1 5 5	
1 5 6	
1 5 7	

50

55

**EP 0 516 069 A1**

**Table 115**

	<sup>1</sup> H-NMR	$\delta$ ppm
5	153 (solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 1.57(3H,d,J = 7.3Hz), 2.58(3H,s), 2.69(2H,q,J = 7.6Hz), 3.80(3H,s), 4.82(1H,dq,J = 7.3Hz,7.9Hz), 5.28(2H,s), 6.45(1H,s), 7.50(1H,s), 7.63(1H,d,J = 7.6Hz), 7.91(1H,dd,J = 7.6,7.6Hz), 8.14(1H,d,J = 7.6Hz), 8.43(1H,d,J = 7.9Hz), 12.66(1H,s)	
10	154 (solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 2.1-2.5(4H,m), 2.58(3H,s), 2.69(2H,q,J = 7.6Hz), 3.66(3H,s), 3.70(3H,s), 4.8-4.9(1H,m), 5.29(2H,s), 6.48(1H,s), 7.50(1H,s), 7.64(1H,dd,J = 1.0Hz,7.6Hz), 7.91(1H,dd,J = 7.6Hz,7.6Hz), 8.13(1H,dd,J = 1.0,7.6Hz), 8.47(1H,d,J = 8.6Hz), 12.65(1H,s)	
15	155 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.3Hz), 1.26(3H,t,J = 7.6Hz), 2.58(3H,s), 2.69(2H,q,J = 7.6Hz), 3.68(2H,d,J = 1.0Hz), 4.17(2H,q,J = 7.3Hz), 4.42(2H,d,J = 6.3Hz), 5.26(2H,s), 6.45(1H,s), 6.82(1H,t,J = 1.0Hz), 7.50(1H,s), 7.69(1H,d,J = 7.9Hz), 7.96(1H,dd,J = 7.9Hz,8.9Hz), 8.63(1H,br), 9.80(1H,br), 12.67(1H,s)	
20	156 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 2.97(1H,dd,J = 6.3Hz,15.8Hz), 3.09(1H,dd,J = 6.6,15.8Hz), 3.64(3H,s), 5.27(2H,s), 5.64(1H,ddd,J = 6.3Hz,6.6Hz,8.9Hz), 6.49(1H,s), 7.2-7.5(5H,m), 7.49(1H,s), 7.63(1H,d,J = 7.3Hz), 7.90(1H,dd,J = 7.3Hz,7.3Hz), 8.15(1H,d,J = 7.3Hz), 8.80(1H,d,J = 8.9Hz), 12.66(1H,s)	
	157 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 1.9-2.1(2H,m), 2.45(2H,t,J = 7.6Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.54(2H,m), 3.68(3H,s), 5.25(2H,s), 6.47(1H,s), 7.50(1H,s), 7.61(1H,d,J = 7.6Hz), 7.90(1H,dd,J = 7.6Hz,7.9Hz), 8.10(1H,br), 8.15(1H,d,J = 7.9Hz)	

25

30

35






40

45

50

55

Table 116

Ex. No.	Structural formula
158	
159	
160	
161	
162	

50

55

**EP 0 516 069 A1**

**Table 117**

	<sup>1</sup> H-NMR	$\delta$ ppm
5	158 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 1.3-1.5(2H,m), 1.6-1.8(4H,m), 2.34(2H,t,J = 7.6Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.4-3.5(2H,m), 3.67(3H,s), 5.25(2H,s), 6.47(1H,s), 7.49(1H,s), 7.51(1H,d,J = 7.9Hz), 7.90(1H,dd,J = 7.9Hz,7.9Hz), 8.02(1H,br), 8.16(1H,d,J = 7.9Hz), 12.67(1H,s)	
10	159 (solvent:DMSO-d <sub>6</sub> ) 1.19(3H,t,J = 7.6Hz), 2.52(3H,s), 2.60(2H,q,J = 7.6Hz), 3.5-3.7(2H,m), 4.6-4.8(1H,m), 5.36(2H,s), 5.57(1H,d,J = 4.3Hz), 6.58(1H,s), 6.6-6.7(1H,m), 6.8-6.9(2H,m), 7.1-7.2(1H,m), 7.7-7.8(2H,m), 7.9-8.2(2H,m), 8.5-8.6(1H,m), 9.34(1H,s), 12.56(1H,s)	
15	160 (solvent:DMSO-d <sub>6</sub> ) 1.25(3H,t,J = 7.6Hz), 2.59(3H,s), 2.67(2H,q,J = 7.6Hz), 2.73(1H,t,J = 5.4Hz), 3.6-3.7(2H,m), 3.8-3.9(2H,m), 5.25(2H,m), 6.49(1H,s), 7.49(1H,s), 7.62(1H,d,J = 7.6Hz), 7.91(1H,dd,J = 7.6Hz,7.6Hz), 8.16(1H,d,J = 7.6Hz), 8.40(1H,br), 12.69(1H,s)	
20	161 (solvent:DMSO-d <sub>6</sub> ) 1.24(3H,t,J = 7.6Hz), 2.59(3H,s), 2.68(2H,q,J = 7.6Hz), 3.6-4.0(9H,m), 5.25(2H,s), 5.84(1H,t,J = 4.6Hz), 6.43(1H,s), 7.49(1H,s), 7.62(1H,d,J = 7.6Hz), 7.81(1H,d,J = 7.6Hz), 7.95(1H,dd,J = 7.6Hz,7.6Hz), 12.62(1H,s)	
	162 (solvent:DMSO-d <sub>6</sub> ) 1.25(3H,t,J = 7.6Hz), 1.8-1.9(2H,m), 2.58(3H,s), 2.67(2H,q,J = 7.6Hz), 3.30(1H,t,J = 6.4Hz), 5.25(2H,s), 6.50(1H,s), 7.63(1H,d,J = 7.6Hz), 7.91(1H,dd,J = 7.6Hz,7.6Hz), 8.16(1H,d,J = 7.6Hz), 8.30(1H,br), 12.71(1H,s)	

25

30

35

40

45

50

55

Table 118

Ex. No.	Structural formula
163	
164	
165	
166	
167	

**EP 0 516 069 A1**

Table 119

	<sup>1</sup> H-NMR	δppm
5	163 (solvent:DMSO-d <sub>6</sub> ) 1.25(3H,t,J = 7.6Hz), 1.32(3H,t,J = 7.1Hz), 2.57(3H,s), 2.68(2H,q,J = 7.6Hz), 3.4-4.0(6H,m), 5.25(2H,s), 6.45(1H,s), 7.49(1H,s), 7.5-7.9(3H,m), 12.61(1H,s)	
10	164 (solvent:CDCl <sub>3</sub> ) 1.22(3H,t,J = 7.4Hz), 1.32(3H,t,J = 7.1Hz), 2.57(3H,s), 2.63(2H,q,J = 7.4Hz), 4.26(2H,s), 4.27(2H,q,J = 7.1Hz), 5.13(2H,s), 6.44(1H,s), 7.46(1H,s), 7.49(1H,dd,J = 7.6,7.6Hz), 7.59(1H,d,J = 7.6Hz), 7.77(1H,d,J = 7.6Hz), 7.90(1H,s)	
15	165 (solvent:CDCl <sub>3</sub> ) 1.22(3H,t,J = 7.4Hz), 1.54(2H,d,J = 7.0Hz), 2.57(3H,s), 2.63(2H,q,J = 7.4Hz), 3.80(3H,s), 4.82(1H,q,J = 7.0Hz), 5.14(2H,s), 6.44(1H,s), 7.46(1H,s), 7.48(1H,dd,J = 7.6,7.6Hz), 7.58(1H,q,J = 7.6Hz), 7.76(1H,d,J = 7.6Hz), 7.88(1H,s)	
20	166 (solvent:CDCl <sub>3</sub> ) 1.22(3H,t,J = 7.6Hz), 1.26(3H,t,J = 7.1Hz), 1.29(3H,t,J = 7.1Hz), 2.57(3H,s), 2.64(2H,q,J = 7.4Hz), 2.97(1H,dd,J = 17.2,4.3Hz), 3.14(1H,dd,J = 17.2,4.3Hz), 4.16(2H,q,J = 7.1Hz), 4.27(2H,q,J = 7.1Hz), 5.04(1H,td,J = 4.3,7.9Hz), 5.15(1H,s), 6.45(1H,s), 7.46(1H,s), 7.49(1H,dd,J = 7.6,7.6Hz), 7.59(1H,d,J = 7.6Hz), 7.77(1H,d,J = 7.6Hz), 7.90(1H,s)	
25	167 (solvent:CDCl <sub>3</sub> ) 1.22(3H,t,J = 7.4Hz), 2.57(3H,s), 2.63(2H,q,J = 7.4Hz), 3.83(3H,s), 4.1-4.2(2H,br), 4.89(1H,dt,J = 7.3,3.6Hz), 5.14(2H,s), 6.44(1H,s), 7.47(1H,s), 7.49(1H dd,J = 7.6,7.6Hz), 7.60(1H,d,J = 7.6Hz), 7.80(1H,d,J = 7.6Hz), 7.91(1H,s)	

25

30

35






40

45

50

55

Table 120

Ex. No.	Structural formula
168	
169	
170	
171	
172	

50

55

Table 121

	<sup>1</sup> H-NMR	δ ppm
168	(solvent:CDCl <sub>3</sub> ) 0.98(3H,t,J = 7.3Hz), 1.27(3H,t,J = 7.3Hz), 1.30(3H,t,J = 7.1Hz), 1.5-1.7(2H,m), 2.59(3H,s), 2.76(2H,t,J = 7.6Hz), 2.98(1H,dd,J = 16.8,4.9Hz), 3.14(1H,dd,J = 16.8,4.9Hz), 4.1-4.4(4H,m), 5.06(1H,dt,J = 8.6,4.9Hz), 5.32(2H,s), 6.50(1H,d,J = 8.9Hz), 7.61(1H,d,J = 8.9Hz), 7.66(1H,d,J = 8.9Hz), 7.66(1H,d,J = 7.9Hz), 7.91(1H,dd,J = 7.6,7.9Hz), 8.13(1H,d,J = 7.6Hz)	
169	(solvent:CDCl <sub>3</sub> ) 1.02(3H,t,J = 7.4Hz), 1.27(3H,t,J = 7.1Hz), 1.30(3H,t,J = 7.1Hz), 1.6-1.7(2H,m), 2.62(3H,t), 2.74(2H,t,J = 7.9Hz), 2.97(1H,dd,J = 17.0,4.9Hz), 3.13(1H,dd,J = 17.0,4.9Hz), 4.1-4.4(4H,m), 5.06(1H,dt,J = 8.3,4.9Hz), 5.29(2H,s), 6.74(1H,d,J = 8.8Hz), 7.57(1H,d,J = 8.8Hz), 7.66(1H,d,J = 7.9Hz), 7.91(1H,dd,J = 7.6,7.9Hz), 8.14(1H,d,J = 7.6Hz)	
170	(solvent:CDCl <sub>3</sub> ) 1.02(3H,t,J = 7.3Hz), 1.32(3H,t,J = 7.3Hz), 1.56(3H,d,J = 7.3Hz), 1.6-1.7(2H,m), 2.62(3H,s), 2.75(2H,t,J = 7.9Hz), 3.78(3H,s), 4.26(2H,q,J = 7.2Hz), 4.79(1H,qd,J = 7.8,7.8Hz), 5.29(2H,s), 6.73(1H,d,J = 7.6Hz), 7.57(1H,d,J = 8.6Hz), 7.64(1H,d,J = 7.9Hz), 7.91(1H,dd,J = 7.6,7.9Hz), 8.14(1H,d,J = 7.6Hz)	
171	(solvent:CDCl <sub>3</sub> ) 1.24(3H,t,J = 7.2Hz), 11.32(3H,t,J = 7.1Hz), 1.56(3H,d,J = 1.0Hz), 2.58(3H,s), 2.69(2H,q,J = 7.5Hz), 3.88(3H,s), 4.26(2H,q,J = 7.2Hz), 4.81(1H,qd,J = 7.7,7.7Hz), 5.32(2H,s), 6.51(1H,s), 7.72(1H,s), 7.70(1H,d,J = 8.3Hz), 7.93(1H,dd,J = 9.7,7.6Hz), 8.15(1H,d,J = 7.9Hz)	
172	(solvent:CDCl <sub>3</sub> ) 1.24(3H,t,J = 7.5Hz), 1.6-2.2(4H,m), 2.57(3H,s), 2.67(2H,q,J = 7.5Hz), 3.5-5.4(7H,m), 6.44-6.46(2H,m), 7.5-8.0(4H,m)	

Table 122

Ex. No.	Structural formula
1 7 3	
1 7 4	
1 7 5	
1 7 6	
1 7 7	

**EP 0 516 069 A1**

Table 123

	<sup>1</sup> H-NMR	$\delta$ ppm
5	173 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.5Hz), 1.7-2.1(5H,m), 2.57(3H,s), 2.67(2H,q,J = 7.5Hz), 3.0-3.3(2H,m), 3.72(3H,s), 3.8-4.0(2H,m), 4.5-4.7(2H,m), 5.24(2H,s), 6.44(1H,s), 7.48(1H,s), 7.53(1H,d,J = 7.6Hz), 7.56(1H,d,J = 7.6Hz), 7.84(1H,dd,J = 7.9,7.9Hz)	
10	174 (solvent:CDCl <sub>3</sub> ) 1.25(3H,td,J = 7.6,2.0Hz), 1.5-2.0(4H,m), 2.57(3H,s), 2.68(2H,q,J = 7.6Hz), 3.61(1.5H,s), 3.73(1.5H,s), 2.5-5.0(5H,m), 5.24(2H,s), 6.44(1H,s), 7.48(1H,s), 7.5-8.0(3H,m)	
15	175 (solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.4Hz), 1.38(2H,d,J = 6.9Hz), 2.58(3H,s), 2.5-2.7(4H,m), 3.72(3H,s), 4.5-4.6(1H,m), 5.27(2H,s), 6.48(1H,s), 7.49(1H,s), 7.61(1H,d,J = 7.9Hz), 7.89(1H,dd,J = 7.9,7.6Hz), 8.15(1H,d,J = 7.6Hz)	
20	176 (solvent:CDCl <sub>3</sub> ) 1.22(3H,t,J = 6.9Hz), 1.25(3H,t,J = 7.1Hz), 1.29(3H,t,J = 7.1Hz), 2.57(3H,s), 2.68(2H,q,J = 7.4Hz), 2.78(1H,t,J = 7.1Hz), 3.44(1H,q,J = 7.1Hz), 3.58(1H,q,J = 7.1Hz), 3.70(1H,t,J = 7.4Hz), 3.79(1H,t,J = 7.4Hz), 4.10(1H,q,J = 7.1Hz), 4.18(1H,q,J = 7.1Hz), 5.21(1H,s), 5.23(1H,s), 6.43(1H,s), 7.48(1H,s), 7.5-7.9(3H,m), 2.84(1H,t,J = 7.1Hz)	
25	177 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.4Hz), 1.29(3H,d,J = 6.3Hz), 2.58(3H,s), 2.69(2H,q,J = 7.4Hz), 4.4-4.6(1H,m), 4.7-4.9(1H,m), 5.30(2H,s), 6.50(1H,s), 7.50(1H,s), 7.66(1H,d,J = 7.6Hz), 7.93(1H,dd,J = 7.6,7.6Hz), 8.13(1H,d,J = 7.6Hz)	

25

30

35


40

45

50

55

Table 124

Ex. No.	Structural formula
1 7 8	
15	
20	
25	
30	
35	
40	
45	
50	

**EP 0 516 069 A1**

Table 125

	<sup>1</sup> H-NMR	$\delta$ ppm
5	<b>178</b> (solvent:CDCl <sub>3</sub> ) 1.23(1.2H,t,J = 7.6Hz), 1.26(1.8H,t,J = 7.6Hz), 2.1-2.6(2H,m), 2.59(3H,s), 2.8-3.0(2H,m), 3.8-4.8(3H,m), 5.3-5.4(3H,m), 6.44(0.6H,s), 6.48(0.4H,s), 7.5-8.1(3H,s)	
10		

15

20

25

30

35

40

45

50

55

Table 126

	<sup>1</sup> H-NMR	$\delta$ ppm
1 7 9		5 10 15 20 25 30 35 40 45 50
1 8 0		15 20 25 30 35 40 45
1 8 1		25 30 35 40 45
1 8 2		35 40 45
1 8 3		40 45

Table 127

	<sup>1</sup> H-NMR	$\delta$ ppm
5	179 (solvent: CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 1.26(3H,t,J = 7.4Hz), 2.60(3H,s), 2.70(2H,q,J = 7.4Hz), 2.97(1H,dd,J = 17.5,4.8Hz), 3.15(1H,dd,J = 17.5,4.8Hz), 5.00(1H,t,J = 8.9Hz), 5.29(2H,s), 6.47(1H,s), 7.53(1H,s), 7.68(1H,d,J = 7.9Hz), 7.95(1H,dd,J = 7.9,7.6Hz), 8.11(1H,d,J = 7.6Hz)	
10	180 (solvent:d <sub>6</sub> -DMSO) 1.18(3H,t,J = 7.6Hz), 2.58(3H,S), 2.62(2H,q,J = 7.6Hz), 4.00(2H,d,J = 5.9Hz), 5.36(2H,s), 6.57(1H,s), 7.69(1H,s), 7.73(1H,d,J = 6.3Hz), 8.01(1H,d,J = 6.3Hz), 8.10(1H,dd,J = 6.3Hz,6.3Hz), 8.88(1H,t,J = 5.9Hz), 12.55(1H,s)	
15	181 (solvent:d <sub>6</sub> -DMSO) 1.18(3H,s,J = 7.6Hz), 2.58(3H,s), 2.61(2H,q,J = 7.6Hz), 2.69(2H,q,J = 7.6Hz), 3.4-3.5(2H,m), 5.35(2H,s), 6.57(1H,s) 7.69(1H,s), 7.70(1H,dd,J = 1.0Hz,7.6Hz), 7.99(1H,dd,J = 1.0Hz,7.6Hz), 8.07(1H,dd,J = 7.6Hz,7.6Hz), 8.72(1H,t,J = 5.9Hz), 12.54(1H,br)	
20	182 (solvent:d <sub>6</sub> -DMSO) 0.91(6H,t,J = 6.4Hz), 1.18(3H,t,J = 7.6Hz), 2.1-2.2(1H,m), 2.57(3H,s), 2.63(1H,q,J = 7.6Hz), 4.41(1H,dd,J = 5.1Hz,8.9Hz), 5.42(2H,s), 6.63(1H,s), 7.68(1H,s), 7.76(1H,d,J = 6.6Hz), 8.01(1H,d,J = 6.9Hz), 8.11(1H,dd,J = 6.6Hz,6.9Hz), 8.38(1H,d,J = 8.9Hz), 12.55(1H,s)	
25	183 (solvent:d <sub>6</sub> -DMSO) 1.19(3H,t,J = 7.6Hz), 2.58(3H,s), 2.63(2H,q,J = 7.6Hz), 3.77(1H,dd,J = 3.6Hz,10.9Hz), 3.91(1H,dd,J = 3.6Hz,10.9Hz), 4.4-4.5(1H,s) 5.39(2H,s) 6.61(1H,s), 7.69(1H,s), 7.75(1H,d,J = 7.6Hz), 8.03(1H,dd,J = 1.0Hz,7.6Hz), 8.11(1H,dd,J = 7.6Hz,7.6Hz), 8.63(1H,d,J = 8.3Hz), 12.55(1H,s)	

25

30

35

40

45

50

55

Table 128

Ex. No.	Structural formula
1 8 4	
1 8 5	
1 8 6	
1 8 7	
1 8 8	

50

55

**EP 0 516 069 A1**

Table 129

	<sup>1</sup> H-NMR	$\delta$ ppm
5	184 (solvent: $d_6$ -DMSO) 1.18(3H,t,J = 7.6Hz), 2.04(3H,s), 2.1-2.2(2H,m), 2.4-2.5(2H,m), 2.58(3H,s), 2.62(2H,q,J = 7.6Hz), 4.5-4.6(1H,m), 5.40(2H,s), 6.60(1H,s), 7.69(1H,s), 7.74(1H,d,J = 7.6Hz), 7.99(1H,d,J = 6.6Hz), 8.09(1H,dd,J = 6.6Hz,7.6Hz), 8.74(1H,d,J = 8.2Hz), 12.55(1H,s)	
10	185 (solvent: $d_6$ -DMSO) 1.16(3H,t,J = 7.6Hz), 2.59(3H,s), 2.63(2H,q,J = 7.6Hz), 3.1-3.4(2H,m), 4.6-4.7(1H,m), 5.34(2H,s), 6.60(1H,s), 7.1-7.3(5H,m), 7.68(1H,s), 7.71(1H,d,J = 7.6Hz), 7.97(1H,dd,J = 1.0Hz,7.6Hz), 8.07(1H,dd,J = 7.6Hz,7.6Hz), 8.61(1H,d,J = 8.2Hz), 12.56(1H,s)	
15	186 (solvent: $d_6$ -DMSO) 1.17(3H,t,J = 7.6Hz), 2.58(3H,s), 2.61(2H,q,J = 7.6Hz), 3.5-3.6(2H,m), 4.6-4.7(1H,m), 5.36(1H,s), 6.62(2H,d,J = 8.5Hz), 6.99(2H,d,J = 8.5Hz), 7.69(1H,s), 7.73(1H,dd,J = 1.0Hz,7.6Hz), 7.96(1H,dd,J = 1.0Hz), 7.6Hz) 8.08(1H,dd,J = 7.6Hz,7.6Hz), 8.52(1H,d,J = 8.3Hz), 9.21(1H,br), 12.56(1H,s)	
20	187 (solvent: $d_6$ -DMSO) 1.17(3H,t,J = 7.6Hz), 2.58(3H,s), 2.62(2H,q,J = 7.6Hz), 3.20(2H,d,J = 6.3Hz), 4.7-4.8(1H,m), 5.37(2H,s), 6.60(1H,s), 7.12(1H,s), 7.69(1H,s), 7.72(1H,d,J = 7.6Hz), 7.98(1H,dd,J = 0.7Hz,7.6Hz) 8.08(1H,dd,J = 7.6Hz,7.6Hz), 8.28(1H,s), 8.99(1H,d,J = 8.3Hz), 12.54(1H,br).	
	188 (solvent: $d_6$ -DMSO) 1.89(3H,t,J = 7.6Hz), 1.43(3H,d,J = 7.3Hz), 2.58(3H,s), 2.63(2H,q,J = 7.6Hz), 4.4-4.5(1H,m), 5.39(2H,s), 6.59(1H,s), 7.69(1H,s), 7.73(1H,d,J = 7.6Hz), 8.00(1H,d,J = 7.6Hz), 8.09(1H,dd,J = 7.6Hz,7.6Hz), 8.67(1H,d,J = 7.9Hz), 12.55(1H,s)	

25

30

35






40

45

50

55

Table 130

Ex. No.	Structural formula
1 8 9	
1 9 0	
1 9 1	
1 9 2	
1 9 3	

**EP 0 516 069 A1**

Table 131

	<sup>1</sup> H-NMR	$\delta$ ppm
5	189 (solvent: $d_6$ -DMSO) 1.89(3H,t,J = 7.6Hz), 1.43(3H,d,J = 7.3Hz), 2.58(3H,s), 2.63(2H,q,J = 7.6Hz), 4.4-4.5(1H,m), 5.39(2H,s), 6.59(1H,s), 7.69(1H,s), 7.73(1H,d,J = 7.6Hz), 8.00(1H,d,J = 7.6Hz), 8.09(1H,dd,J = 7.6Hz,7.6Hz), 8.67(1H,d,J = 7.9Hz), 12.55(1H,s)	
10	190 (solvent: $d_6$ -DMSO) 1.86(3H,t,J = 7.6Hz), 1.9-2.3(4H,m), 2.58(3H,s), 2.63(2H,q,J = 7.6Hz), 4.4-4.5(1H,m), 5.40(2H,s), 6.60(1H,s), 7.69(1H,s), 7.73(1H,d,J = 7.6Hz), 8.00(1H,d,J = 7.6Hz), 8.10(1H,dd,J = 7.6Hz,7.6Hz), 8.70(1H,d,J = 8.6Hz), 12.55(1H,s)	
15	191 (solvent: $d_6$ -DMSO) 1.19(3H,t,J = 7.6Hz), 2.58(3H,s), 2.63(2H,q,J = 7.6Hz), 3.60(2H,s), 4.24(2H,d,J = 5.9Hz), 5.38(2H,s), 6.58(1H,s), 6.96(1H,s), 7.70(1H,s), 7.75(1H,d,J = 7.6Hz), 8.02(1H,d,J = 7.6Hz), 8.10(1H,dd,J = 7.6Hz,7.6Hz), 8.98(1H,d,J = 5.9Hz), 12.34(1H,br), 12.55(1H,s)	
20	192 (solvent: $d_6$ -DMSO) 1.17(3H,t,J = 7.6Hz), 2.58(3H,s), 2.62(2H,q,J = 7.6Hz), 2.88(1H,dd,J = 6.3Hz,16.2Hz), 4.0-4.2(1H,m), 5.39(2H,s), 5.4-5.5(1H,m), 6.60(1H,s), 7.2-7.7(5H,m), 7.69(1H,s), 7.72(1H,d,J = 7.6Hz), 7.98(1H,d,J = 7.3Hz), 8.07(1H,dd,J = 7.3Hz,7.6Hz), 9.13(1H,d,J = 8.9Hz), 12.32(1H,br), 12.56(1H,s)	
25	193 (solvent: $d_6$ -DMSO) 1.18(3H,t,J = 7.6Hz), 1.7-1.8(2H,m), 2.26(2H,t,J = 7.6Hz), 2.58(3H,s), 2.62(2H,q,J = 7.6Hz), 3.3-3.5(2H,m), 5.36(2H,s), 6.57(1H,s), 7.69(1H,s), 7.70(1H,d,J = 7.6Hz), 7.98(1H,d,J = 7.6Hz), 8.06(1H,dd,J = 7.6Hz,7.6Hz), 8.68(1H,d,J = 5.6Hz), 12.00(1H,br), 12.55(1H,br)	

25

30

35

40

45

50

55

Table 132

Ex. No.	Structural formula
194	
195	
196	
197	
198	

## EP 0 516 069 A1

Table 133

	<sup>1</sup> H-NMR	$\delta$ ppm
5	194 (solvent:DMSO-d <sub>6</sub> ) 1.18(3H,t,J = 7.6Hz), 1.2-1.3(2H,m), 1.5-1.7(4H,m), 2.21(2H,t,J = 7.3Hz), 2.58(3H,s), 2.62(2H,q,J = 7.6Hz), 5.36(2H,s), 6.57(1H,s), 7.68(1H,d,J = 7.6Hz), 7.69(1H,s), 7.98(1H,d,J = 7.6Hz), 8.06(1H,dd,J = 7.6Hz,7.6Hz), 8.61(1H,m), 12.55(1H,br)	
10	195 (solvent:CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 1.21(3H,t,J = 7.6Hz), 2.58(3H,s), 2.64(2H,q,J = 7.6Hz), 4.18(2H,d,J = 1.7Hz), 5.16(2H,s), 6.46(1H,s), 7.49(1H,s), 7.50(1H,dd,J = 7.6,7.6Hz), 7.61(1H,d,J = 7.6Hz), 7.81(1H,d,J = 7.6Hz), 7.91(1H,s)	
15	196 (solvent:CD <sub>3</sub> OD:CDCl <sub>3</sub> = 1:4) 1.22(3H,t,J = 7.4Hz), 1.55(3H,d,J = 6.9Hz), 2.58(3H,s), 2.64(2H,q,J = 7.4Hz), 4.72(1H,td,J = 5.9,7.3Hz), 5.17(2H,s), 6.46(1H,s), 7.50(1H,dd,J = 7.9,7.6Hz), 7.61(1H,d,J = 7.9Hz), 7.80(1H,d,J = 7.6Hz), 7.90(1H,s)	
20	197 (solvent:CD <sub>3</sub> OD:CDCl <sub>3</sub> = 1:4) 1.22(3H,td,J = 7.6,0.9Hz), 2.65(2H,q,J = 7.6Hz), 2.98(1H,dd,J = 17.2,5.0Hz), 3.11(1H,dd,J = 17.5,5.0Hz), 4.99(1H,dt,J = 4.3,8.6Hz), 5.18(2H,s), 6.47(1H,s), 7.51(1H,dd,J = 7.6,8.3Hz), 7.63(1H,d,J = 8.3Hz), 7.81(1H,d,J = 7.6Hz), 7.92(1H,s), 2.59(3H,s), 7.51(1H,s)	
	198 (solvent:CD <sub>3</sub> OD:CDCl <sub>3</sub> = 1:4) 1.22(3H,t,J = 7.4Hz), 2.58(3H,s), 2.64(2H,q,J = 7.4Hz), 3.97(1H,dd,J = 11.6,3.5Hz), 4.10(1H,dd,J = 11.2,3.9Hz), 4.67(1H,t,J = 3.6Hz), 5.17(1H,s), 6.46(1H,s), 7.50(1H,s), 7.51(1H,dd,J = 7.6,7.6Hz), 7.62(1H,d,J = 7.6Hz), 7.85(1H,d,J = 7.6Hz)	

25

30

35

40

45

50

55

Table 134

Ex. No.	Structural formula
199	
200	
201	
202	
203	

## EP 0 516 069 A1

Table 135

	<sup>1</sup> H-NMR	$\delta$ ppm
5	199 (solvent:CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 0.99(3H,t,J = 7.6Hz), 1.5-1.7(2H,m), 2.60(3H,s), 2.70(2H,t,J = 7.8Hz), 3.0-3.3(2H,m), 5.1-5.2(1H,m), 5.27(2H,s) 6.76(2H,d,J = 8.9Hz), 7.53(2H,d,J = 8.9Hz), 7.64(1H,d,J = 7.9Hz), 7.90(1H,dd,J = 7.9,7.6Hz), 8.11(1H,d,J = 7.6Hz)	
10	200 (solvent:CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 0.98(3H,t,J = 7.3Hz), 1.5-1.7(2H,m), 2.57(3H,s), 2.75(2H,t,J = 7.6Hz), 3.0-3.3(2H,m), 3.75(3H,s), 5.1-5.2(1H,m), 5.31(2H,s), 6.50(1H,d,J = 8.9Hz), 7.60(1H,d,J = 8.9Hz), 7.67(1H,d,J = 7.6Hz), 7.92(1H,dd,J = 7.6,7.3Hz), 8.14(1H,d,J = 7.3Hz)	
15	201 (solvent:CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 1.01(3H,t,J = 7.3Hz), 1.63(3H,d,J = 7.3Hz), 1.5-1.7(2H,m), 2.62(3H,s), 2.74(2H,t,J = 7.6Hz), 3.78(3H,s), 4.80(1H,t,J = 7.3Hz), 5.29(2H,s), 6.73(1H,d,J = 8.9Hz), 7.55(1H,d,J = 8.9Hz), 7.66(1H,d,J = 7.6Hz), 7.93(1H,dd,J = 7.6,7.6Hz), 8.15(1H,d,J = 7.6Hz)	
20	202 (solvent:CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 1.23(3H,t,J = 7.4Hz), 1.62(3H,d,J = 7.3Hz), 2.58(3H,s), 2.69(2H,q,J = 7.4Hz), 3.87(3H,s), 4.82(1H,q,J = 7.3,7.3Hz), 5.31(2H,s), 6.49(1H,s), 7.71(1H,d,J = 7.9Hz), 7.71(1H,s), 7.94(1H,dd,J = 7.6,7.9Hz), 8.16(1H,d,J = 7.6Hz)	
	203 (solvent: CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 1.24(3H,t,J = 7.6Hz), 1.7-2.2(4H,m), 2.57(3H,s), 2.6-2.8(1H,m), 2.67(2H,q,J = 7.6Hz), 3.0-3.3(2H,m), 3.8-4.0(1H,m), 4.4-4.6(1H,m), 5.25(2H,s), 6.44(1H,s), 7.47(1H,s), 7.54(1H,d,J = 7.6Hz), 7.57(1H,d,J = 7.0Hz), 7.85(1H,dd,J = 7.6,7.9Hz)	

25

30

35






40

45

50

55

Table 136

Ex. No.	Structural formula
204	
205	
206	
207	
208	

**EP 0 516 069 A1**

Table 137

	<sup>1</sup> H-NMR	$\delta$ ppm
5	204 (solvent:CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 1.25(3H,t,J = 7.4Hz), 1.5-2.3(5H,m), 2.57(3H,s), 2.67(2H,q,J = 7.4Hz), 2.7-2.9(1H,m), 3.1-4.8(4H,m), 5.25(2H,s), 6.44(1H,s), 7.47(1H,s), 7.5-7.7(2H,m), 7.85(1H,dd,J = 7.6,7.9Hz)	
10	205 (solvent: CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 1.24(3H,t,J = 7.6Hz), 1.43(3H,d,J = 6.6Hz), 2.58(3H,s), 2.67(2H,q,J = 7.4Hz), 2.74(2H,dd,J = 5.6,3.0Hz), 4.5-4.6(1H,m), 5.25(2H,s), 6.51(1H,s), 7.48(1H,s), 7.61(1H,d,J = 7.9Hz), 7.89(1H,dd,J = 7.6,7.9Hz), 8.14(1H,d,J = 7.6Hz)	
15	206 (solvent:CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/4)) 1.2-1.3(6H,m), 2.57(1H,s), 2.67(2H,q,J = 7.5Hz), 2.8-3.0(2H,m), 3.4-3.8(4H,m), 5.24(2H,s), 6.4-6.5(1H,m), 7.48(1H,s), 7.5-7.7(2H,m), 7.85(1H,dd,J = 7.6,7.9Hz),	
20	207 (solvent:CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/9)) 1.25(3H,t,J = 7.4Hz), 1.29(3H,d,J = 6.3Hz), 2.58(3H,s), 2.69(2H,q,J = 7.4Hz), 4.4-4.6(1H,m), 4.7-4.9(1H,m), 5.30(2H,s), 6.50(1H,s), 7.50(1H,s), 7.66(1H,d,J = 7.6Hz), 7.93(1H,dd,J = 7.6,7.6Hz), 8.13(1H,d,J = 7.6Hz)	
	208 (solvent: CD <sub>3</sub> OD/CDCl <sub>3</sub> (1/9)) 1.23(1.2H,t,J = 7.6Hz), 1.26(1.8H,t,J = 7.6Hz), 2.1-2.6(2H,m), 2.59(3H,s), 2.8-3.0(2H.m), 3.8-4.8(3H,m), 5.3-5.4(3H,m), 6.44(0.6H,s), 6.48(0.4H,s), 7.5-8.1(3H,s),	

25

30

35

40

45

50

55

Table 138

Ex. No.	Structural formula
209	
210	
211	
212	
213	

Table 139

	<sup>1</sup> H-NMR	$\delta$ ppm
209	(solvent:CDCl <sub>3</sub> /MeOD(9/1)) 1.26(3H,t,J = 7.4Hz), 1.9-2.1(1H,m), 2.2-2.4(1H,m), 2.59(3H,s), 2.70(1H,q,J = 7.4Hz), 3.6-3.9(1H,m), 4.84(1H,dt,J = 4,3.4,6Hz), 5.30(2H,s), 6.49(1H,s), 7.53(1H,s), 7.69(1H,d,J = 7.6Hz), 7.98(1H,dd,J = 7.6,7.6Hz), 8.11(1H,d,J = 7.6Hz)	
210	(solvent:DMSO-d <sub>6</sub> ) 1.19(3H,t,J = 7.6Hz), 2.57(3H,s), 2.63(2H,q,J = 7.6Hz), 3.78(2H,s), 4.02(2H,s), 5.36(2H,s), 6.56(1H,s), 7.67(1H,s), 7.71(1H,d,J = 7.3Hz), 8.03(1H,dd,J = 6.6,5.9Hz), 8.09(1H,d,J = 6.6Hz),	
211	(solvent:CDCl <sub>3</sub> /MeOD(4/1)) 1.26(3H,t,J = 7.6Hz), 1.29(3H,t,J = 7.3Hz), 2.59(3H,s), 2.69(2H,q,J = 7.5Hz), 3.68(2H,s), 4.05(2H,s), 4.20(2H,q,J = 7.3Hz), 5.29(2H,s), 6.46(1H,s), 7.52(1H,s), 7.67(1H,d,J = 7.9Hz), 7.95(1H,dd,J = 7.6,7.9Hz), 8.11(1H,d,J = 7.6Hz)	
212	(solvent:DMSO-d <sub>6</sub> ) 1.25(3H,t,J = 7.6Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.50(1H,m), 3.78(1H,m), 4.74(1H,m), 5.30(2H,s), 5.46(1H,d,J = 2.0Hz), 6.49(1H,s), 6.69(1H,m), 6.85(1H,d,J = 7.9Hz), 7.91(1H,s), 7.13(1H,t,J = 7.9Hz), 7.56(1H,s), 7.67(1H,d,J = 7.6Hz), 7.98(1H,t,J = 7.6Hz), 8.08(1H,d,J = 7.6Hz), 8.51(1H,m), 9.08(1H,s), 12.61(1H,s)	
213	(solvent:DMSO-d <sub>6</sub> ) 1.19(3H,t,J = 7.6Hz), 2.58(3H,s), 2.64(2H,q,J = 7.6Hz), 3.85(2H,m), 4.55(1H,m), 5.34(1H,br), 5.39(2H,s), 6.60(1H,s), 7.68(1H,s), 7.74(1H,d,J = 7.6Hz), 8.05(1H,t,J = 7.6Hz), 8.12(1H,d,J = 7.6Hz), 8.63(1H,d,J = 8.3Hz), 12.55(1H,s), 12.90(1H,br)	

Table 140

Ex. No.	Structural formula
2 1 4	
2 1 5	
2 1 6	
2 1 7	
2 1 8	

Table 141

	<sup>1</sup> H-NMR	$\delta$ ppm
5	214 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.85(3H,s), 4.11(2H,m), 4.88(1H,m), 5.29(2H,s), 6.52(1H,s), 7.49(1H,s), 7.65(1H,d,J = 8.3Hz), 7.91(1H,t,J = 8.3Hz), 8.15(1H,d,J = 8.3Hz), 8.80(1H,d,J = 8.3Hz) 12.69(1H,s)	
10	215 (solvent:DMSO-d <sub>6</sub> ) 1.18(3H,t,J = 7.3Hz), 2.51(3H,s), 2.63(2H,q,J = 7.3Hz), 3.79(1H,dd,J = 11.2Hz,3.9Hz), 3.91(1H,dd,J = 11.2Hz,3.9Hz), 4.55(1H,m), 5.48(2H,s), 6.68(1H,s), 7.70(1H,s), 8.58(1H,d,J = 7.9Hz), 9.05(1H,s), 9.21(1H,s), 12.57(1H,s)	
15	216 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.3Hz), 2.59(3H,br), 2.89(3H,s), 2.68(2H,q,J = 7.3Hz), 3.85(3H,s), 4.06(1H,dd,J = 11.2Hz,3.6Hz), 4.18(1H,dd,J = 11.2Hz,3.6Hz), 4.90(1H,m), 5.34(2H,s), 6.52(1H,s), 7.51(1H,s), 8.58(1H,m), 9.00(1H,s), 9.37(1H,s), 12.71(1H,s),	
20	217 (solvent:CDCl <sub>3</sub> ) 1.27(3H,t,J = 7.6Hz), 2.60(3H,s), 2.71(2H,q,J = 7.6Hz), 3.79(2H,s), 3.85-4.10(4H,m), 4.64-4.80(2H,m), 5.33(2H,s), 6.49(1H,s), 7.57(1H,s), 7.72(1H,d,J = 7.6Hz), 8.00(1H,t,J = 7.6Hz), 8.10(1H,d,J = 7.6Hz)	
	218 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 2.57(3H,s), 2.67(2H,q,J = 7.6Hz), 3.2-3.7(2H,m), 3.70(s,1.2H), 3.81(s,1.8H), 4.0-4.3(2H,m), 4.37(0.6H,m), 4.90(0.4H,m), 5.24(2H,s), 6.44(1H,s), 7.48(1H,s), 7.5-7.9(3H,m), 12.63(1H,s)	

25

30

35






40

45

50

55

Table 142

Ex. No.	Structural formula
2 1 9	
2 2 0	
2 2 1	
2 2 2	
2 2 3	

50

55

Table 143

	<sup>1</sup> H-NMR	$\delta$ ppm
5	219 (solvent:CDCl <sub>3</sub> ) 1.00(3H,t,J = 7.6Hz), 1.24(3H,t,J = 7.6Hz), 1.81(2H,q,J = 7.6Hz), 2.58(3H,s), 2.67(2H,q,J = 7.6Hz), 3.72(2H,m), 3.94-4.06(4H,m), 5.27(2H,s), 6.56(1H,s), 7.48(1H,s), 7.63(1H,d,J = 7.6Hz), 7.93(1H,t,J = 7.6Hz), 8.15(1H,d,J = 7.6Hz), 8.52(1H,brs), 12.73(1H,s),	
10	220 (solvent:CDCl <sub>3</sub> ) 1.24(3H,t,J = 7.3Hz), 1.38(3H,s), 2.58(3H,s), 2.67(2H,q,J = 7.3Hz), 3.7-4.1(6H,m), 5.27(2H,s), 6.56(1H,s), 7.48(1H,s), 7.64(1H,d,J = 7.6Hz), 7.92(1H,t,J = 7.6Hz), 8.14(1H,d,J = 7.6Hz), 8.49(1H,s), 12.73(1H,s)	
15	221 (solvent:CDCl <sub>3</sub> ) 1.22(3H,t,J = 7.6Hz), 2.57(3H,s), 2.65(2H,q,J = 7.6Hz), 3.83(8H,s), 5.29(2H,s), 6.66(1H,s), 7.46(1H,s), 7.65(1H,d,J = 6.6Hz), 7.93(1H,t,J = 7.6Hz), 8.14(1H,d,J = 7.9Hz), 9.12(1H,s), 12.82(1H,s)	
20	222 (solvent:CDCl <sub>3</sub> ) 1.26(3H,t,J = 7.6Hz), 2.58(3H,s), 2.67-2.72(2H,m), 3.75-3.82(2H,m), 3.83-3.95(2H,m), 4.14-4.20(1H,m), 4.20-4.26(2H,m), 5.27(2H,s), 6.45(1H,s), 7.50(1H,s), 7.62(1H,d,J = 6.9Hz), 7.92(1H,t,J = 6.9Hz), 8.13(1H,d,J = 6.9Hz), 8.53(1H,d,J = 7.9Hz), 12.66(1H,s)	
25	223 (solvent:DMSO-d <sub>6</sub> ) 1.21(3H,t,J = 7.6Hz), 2.58(3H,s), 2.65(2H,q,J = 7.6Hz), 3.7-3.9(4H,m), 4.61(1H,m), 5.05(1H,br), 5.37(2H,s), 6.58(1H,s), 7.65(1H,s), 7.71(1H,dd,J = 6.8Hz,2.1Hz), 8.02-8.25(2H,m), 8.39(1H,t,J = 5.8Hz), 8.62(1H,d,J = 8.3Hz), 12.54(1H,s),	

25

30

35

40

45

50

55

Table 144


Ex. No.	Structural formula
224	
225	
226	

Table 145

	<sup>1</sup> H-NMR	$\delta$ ppm
5	224 (solvent:DMSO-d <sub>6</sub> ) 1.21(3H,t,J = 7.6Hz), 2.57(3H,s), 2.64(2H,q,J = 7.6Hz), 3.54(1H,m), 3.72(1H,m), 4.19(1H,m), 5.34(2H,s), 5.59(1H,br), 6.55(1H,s), 7.63(1H,s), 7.69(1H,dd,J = 6.1Hz,2.8Hz), 8.05(2H,m), 8.51(1H,t,J = 6.1Hz), 12.55(1H,s), 12.65(1H,br)	
10	225 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 1.26(3H,t,J = 7.3Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.10(1H,dd,J = 8.9Hz,5.6Hz), 3.80-3.88(1H,m), 4.06(2H,d,J = 5.6Hz), 4.20(2H,q,J = 7.3Hz), 4.25-4.35(1H,m), 4.70(1H,m), 5.28(2H,s), 6.45(1H,s), 7.15(1H,br), 7.49(1H,s), 7.63(1H,d,J = 6.9Hz), 7.92(1H,t,J = 6.9Hz), 8.15(1H,d,J = 6.9Hz), 8.85(1H,d,J = 7.6Hz), 12.66(1H,s)	
15	226 (solvent:CDCl <sub>3</sub> ) 1.25(3H,t,J = 7.6Hz), 2.58(3H,s), 2.68(2H,q,J = 7.6Hz), 3.57(1H,d,J = 5.3Hz), 3.83(3H,s), 3.88(2H,m), 4.44(1H,m), 5.25(2H,s), 6.47(1H,s), 7.49(1H,s), 7.63(1H,d,J = 7.6Hz), 7.91(1H,t,J = 7.6Hz), 8.14(1H,d,J = 7.6Hz), 8.36(1H,br), 12.68(1H,s)	

## Claims

20 1. A compound represented by the formula :



wherein

A is a C<sub>1</sub>-C<sub>5</sub> alkylene chain;35 B is a phenylene or 6 membered heteroaromatic group which is constituted by carbon atoms and one or two nitrogen atoms, and B may be, optionally substituted with one or two substituents selected from the group, consisting of a C<sub>1</sub>-C<sub>5</sub> alkyl group, a C<sub>1</sub>-C<sub>5</sub> alkoxy group, a hydroxyl group, a carboxyl group, a nitro group and a halogen atom;R<sup>1</sup> is a C<sub>1</sub>-C<sub>5</sub> alkyl group;R<sup>2</sup> is a hydroxyl group or a C<sub>1</sub>-C<sub>5</sub> alkoxy group;40 R<sup>3</sup> and R<sup>4</sup> are each independently a hydrogen atom, a C<sub>1</sub>-C<sub>5</sub> alkyl group, a C<sub>2</sub>-C<sub>5</sub> alkenyl group or a C<sub>2</sub>-C<sub>5</sub> alkynyl group;R<sup>5</sup> is a hydrogen atom, a C<sub>1</sub>-C<sub>5</sub> alkyl group or a hydroxy C<sub>1</sub>-C<sub>5</sub> alkyl group;R<sup>6</sup> is a group of the formula:45 -X-Y-Z-R<sup>6</sup>'wherein X is a phenylene group or a monocyclic 5~6 membered hetero aromatic group, and X is optionally substituted with one or two substituents selected from the group consisting of a C<sub>1</sub>-C<sub>5</sub> alkyl group, a hydroxyl group, a carboxyl group, a nitro group and a halogen atom;

50 Y is a single bond or an oxygen atom;

Z is a single bond or a C<sub>1</sub>-C<sub>5</sub> alkylene chain;

provided that when Y is an oxygen atom,

X is a phenylene group and Z is a C<sub>1</sub>-C<sub>5</sub> alkylene chain;55 R<sup>6</sup>' is a COOR<sup>7</sup> group,  
a CONR<sup>8</sup>R<sup>9</sup> group,  
a CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOR<sup>7</sup> group,  
a CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>CONR<sup>8</sup>R<sup>9</sup> group,  
a CONHCHR<sup>20</sup>CONHCHR<sup>22</sup>CO<sub>2</sub>R<sup>7</sup> group or

a sulfamoyl group,

wherein R<sup>7</sup> is a hydrogen atom, a benzyl group, a C<sub>1</sub>-C<sub>5</sub> alkyl group or an C<sub>1</sub>-C<sub>5</sub> alkyl group substituted with an aminoheteroaromatic group wherein the heteroaromatic group is a monocyclic 5-6 membered heteroaromatic group;

<sup>5</sup> R<sup>8</sup> and R<sup>9</sup> are each independently a hydrogen atom, a C<sub>1</sub>-C<sub>5</sub> alkyl group, hydroxy C<sub>1</sub>-C<sub>5</sub> alkyl group, a hydroxyethylpyridyl group or a hydroxyethylthiazolyl group, or the group of the formula:

-NR<sup>8</sup>R<sup>9</sup>

**10** represents a pyrrolidino, a piperidino or a morpholino group;

$R^{20}$  is a hydrogen atom, a hydroxyl group, a  $C_1$ - $C_5$  alkyl group, a phenyl group, a hydroxyphenyl group, a benzyl group, a hydroxy benzyl group or a substituted  $C_1$ - $C_5$  alkyl group wherein the substituent is selected from the group consisting of a hydroxyl group, a  $C_1$ - $C_5$  alkoxy group, a mercapto group, a methylthio group, an amino group, an indolyl group, an imidazolyl group, a carboxyl group, a  $C_1$ - $C_5$  alkoxycarbonyl group, a carbamoyl group and a guanidino group;

75 group, a C<sub>1</sub>-C<sub>5</sub> alkoxy carbonyl group, a carbamoyl group and a guanidino group;

$n$  is 0, 1, 2, 3, 4 or 5; and

R<sup>22</sup> is a hydrogen atom, a C<sub>1</sub>-C<sub>5</sub> alkyl group or a C<sub>1</sub>-C<sub>5</sub> hydroxyalkyl group;

or R<sup>6</sup> is a CHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOR<sup>7</sup> group,

a  $\text{CH}_2\text{CHR}^{20}\text{COOR}^7$  group,

a  $\text{CHR}^{20}(\text{CH}_2)_n\text{CONR}^8\text{R}^9$  group.

a  $\text{CH}_2\text{CHR}^{20}\text{CONR}^8\text{R}^9$  group

a  $\text{CHR}^{20}(\text{CH}_2)_n\text{OH}$  group,

a CR<sup>20</sup>R<sup>22</sup>(CH<sub>2</sub>)<sub>n</sub>OH group,

a  $\text{CH}_2\text{CHR}^{20}\text{OH}$  group, or

a  $\text{CHR}^{20}\text{CONHCHR}^{22}\text{CO}_2\text{R}^7$  group.



35 represents an azetidino group, pyrrolidino group, a piperidino group or a homopiperidino group, which is optionally substituted with one to two substituents selected from the group consisting of a hydroxyl group, a C<sub>1</sub>-C<sub>5</sub> hydroxyalkyl group, carboxyl group, C<sub>1</sub>-C<sub>5</sub> alkoxy carbonyl group and benzyloxy carbonyl group; or pharmaceutically acceptable salts thereof.

2. The compound according to claim 1, wherein R<sup>1</sup> is a methyl group and R<sup>2</sup> is a hydroxyl group.
  3. The compound according to claim 1, wherein R<sup>3</sup> is a hydrogen atom and A is a methylene group.
  4. The compound according to claim 1, wherein R<sup>1</sup> is a methyl group, R<sup>2</sup> is a hydroxyl group, R<sup>3</sup> is a hydrogen atom and A is a methylene group.
  5. The compound according to claim 4, wherein B is a 2,6-pyridinediyl, a 2,4-pyrimidinediyl or a 2,6-pyridinediyl N-oxide group.
  6. The compound according to claim 4, wherein R<sup>6</sup> is a group of the formula:

X-Y-Z-R<sup>6</sup>


(wherein X, Y, Z and R<sup>6</sup> are as defined in claim 1).

- 55 7. The compound according to claim 4, wherein R<sup>6</sup> is a group of the formula:

$$\text{CHR}^{20}(\text{CH}_2)_n\text{COOR}'$$

(wherein R<sup>20</sup>, R<sup>7</sup> and n are as defined in claim 1).

8. The compound according to claim 4, wherein R<sup>6</sup> is a group of the formula:



(wherein R<sup>20</sup>, R<sup>8</sup>, R<sup>9</sup> and n are as defined in claim 1).

9. The compound according to claim 4, wherein R<sup>6</sup> is a group of the formula:



(wherein R<sup>20</sup>, R<sup>22</sup>, R<sup>7</sup> and n are as defined in claim 1).

- 15 10. The compound according to claim 4, wherein R<sup>4</sup> is an ethyl group.

11. The compound according to claim 5, wherein X is a 2,6-pyridinediyl group.

12. The compound according to claim 10, wherein R<sup>6'</sup> is a group of the formula:



(wherein R<sup>7</sup> is as defined in claim 1).


- 25 13. The compound according to claim 13, wherein R<sup>6'</sup> is a carboxyl group.

14. The compound according to claim 10, wherein R<sup>6'</sup> is a group of the formula:




(wherein R<sup>20</sup>, R<sup>7</sup> and n are as defined in claim 1).

- 35 15. A compound of the formula:




45

16. A compound of the formula:




17. A compound of the formula:



18. A compound of the formula:


15



19. A compound of the formula:

30

35



40 20. A compound of the formula:

45


50




21. A process for producing a compound as claimed in claim 1 which comprises:  
(a) to produce a compound of the formula:

55


EP 0 516 069 A1




reacting a compound of the formula:




with a compound of the formula:




(b) hydrolyzing a compound of the formula:




to produce a compound of the formula:




55 (c) reacting a compound of the formula:




with a compound of the formula:




20 to produce a compound of the formula:




(d) hydrolyzing a compound of the formula:




45 to produce a compound of the formula:



(e) oxidizing a compound of the formula:




to produce a compound of the formula:




or

(f) hydrolyzing a compound of the formula.



35

to produce a compound of the formula:



wherein R¹, R², R³, R⁴, R⁵, R⁶, R²⁰, A, B, X, Y and Z are as defined in claim 1,  
R¹¹ is the same as R⁶, but it does not mean free carboxylic group;

50 R¹² is a group of the formula:

X-Y-Z-COOR⁷,  
X-Y-Z-CONHCHR²⁰(CH₂)ₙCOOR⁷,  
X-Y-Z-CONHCHR²⁰CONHCHR²²CO₂R⁷,  
55 CHR²⁰(CH₂)ₙCOOR⁷,  
CH₂CHR²⁰COOR⁷, or  
CHR²⁰CONHCHR²²COOR⁷,

wherein X, Y, Z, R<sup>20</sup>, R<sup>22</sup> and n are as defined above, and R<sup>7'</sup> is the same as R<sup>7</sup> but it does not mean a hydrogen atom,

R<sup>13</sup> is a group of the formula:

- 5        X-Y-Z-COOH,  
X-Y-Z-CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub> COOH,  
X-Y-Z-CONHCHR<sup>20</sup>CONHCHR<sup>22</sup>CO<sub>2</sub>H,  
CHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOH,  
CH<sub>2</sub>CHR<sup>20</sup>COOH, or  
10      CHR<sup>20</sup>CONHCHR<sup>22</sup>COOH,

wherein X, Y, Z, R<sup>20</sup>, R<sup>22</sup> and n are as defined above.

R<sup>14</sup> is a group of the formula:

- 15      (CH<sub>2</sub>)<sub>n</sub>COOR<sup>7'</sup>, or  
CONHCHR<sup>22</sup>COOR<sup>7'</sup>,

wherein R<sup>7'</sup>, R<sup>22</sup> and n are as defined above.

R<sup>15</sup> is a group of the formula:

- 20      COOR<sup>7'</sup>,  
CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOR<sup>7'</sup>, or  
CONHCHR<sup>20</sup>CONHCHR<sup>22</sup>CO<sub>2</sub>R<sup>7'</sup>,

25      wherein R<sup>7'</sup>, R<sup>20</sup>, R<sup>22</sup> and n are as defined above.

R<sup>16</sup> is a group of the formula:

- 30      COOH,  
CONHCHR<sup>20</sup>(CH<sub>2</sub>)<sub>n</sub>COOH, or  
CONHCHR<sup>20</sup>CONHCHR<sup>22</sup>CO<sub>2</sub>H,

wherein R<sup>20</sup>, R<sup>22</sup> and n are as defined above.

R<sup>26</sup> is a group of the formula:

- 35      (CH<sub>2</sub>)<sub>n</sub>COOH, or  
CONHCHR<sup>22</sup>COOH,

wherein R<sup>22</sup> and n are as defined above.

40      22. A pharmaceutical composition useful as an antiinflammatory agent or an antiallergic agent, which comprises an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier or diluent.

45      23. A method of treating inflammatory or allergic states which comprises administering a pharmaceutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to a patient.

24. A compound of claim 1 for use as a medicament as an active therapeutic substance.

50

55



European Patent  
Office

### PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

EP 92 10 8916

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
Y	US-A-4 672 066 (M. CARSON et al.) * Claims 1-4, 6, 15, 16, 30; examples 31-38 * ---	1-5, 22, 24	C 07 D 213/81 C 07 D 277/46 C 07 D 401/06 C 07 D 401/12 C 07 D 401/14 C 07 D 417/12 C 07 D 417/14 C 07 D 241/24 C 07 C 233/82 A 61 K 31/44 A 61 K 31/425
Y	CHEMICAL ABSTRACTS, vol. 111, no. 11, 11th September 1989, page 729, abstract no. 97094e, Columbus, Ohio, US; & JP-A-01 29 363 (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD) 31-01-1989 * Abstract * ---	1-5, 22, 24	
X	* CAS RN 122151-73-9 * ---	1-5, 22, 24	
A	CHEMICAL ABSTRACTS, vol. 112, no. 3, 15th January 1990, page 494, abstract no. 20906j, Columbus, Ohio, US; & JP-A-01 104 052 (YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD) 21-04-1989 * Abstract * ---	1-22, 24	
		-/-	TECHNICAL FIELDS SEARCHED (Int. Cl. 5)
			C 07 D C 07 C A 61 K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p><b>Remark:</b> Although claim 23 is directed to a method of treatment of (diagnostic method practised on) the human/animal body (Art. 52(4) EPC) the search has been carried out and based on the alleged effects of the compound/composition.</p>			
Place of search  THE HAGUE	Date of completion of the search  01-09-1992	Examiner  BOSMA P.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	
<small>EPO FORM 1500 (03.82 (PWO))</small>			



European Patent  
Office

### PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 92 10 8916

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
A,D	EP-A-0 276 065 (ELI LILLY AND CO.) * Claims 1-7; examples * ----	1-20,22 ,24	
A	EP-A-0 174 770 (MERCK FROSST CANADA INC.) * Whole document * -----	1-22,24	



(19) Eur pâisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number: 0 516 069 A1

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 92108916.5

(51) Int. Cl.<sup>5</sup>: C07D 213/81, C07D 277/46,  
C07D 401/06, C07D 401/12,  
C07D 401/14, C07D 417/12,  
C07D 417/14, C07D 241/24,  
C07C 233/82, A61K 31/44,  
A61K 31/425

(22) Date of filing: 27.05.92

(30) Priority: 31.05.91 JP 157725/91

(71) Applicant: SUMITOMO PHARMACEUTICALS  
COMPANY, LIMITED  
2-8, Doshomachi 2-chome, Chuo-ku  
Osaka-shi Osaka 541(JP)

(43) Date of publication of application:

02.12.92 Bulletin 92/49


(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IT LI NL PT SE

(72) Inventor: Nagata, Hideo  
2-29-7, Ooike  
Ibaraki-shi, Osaka 567(JP)  
Inventor: Kawakami, Hajime  
6-32-702, Fukazu-cho  
Nishinomiya-shi, Hyogo 663(JP)

(74) Representative: von Kreisler, Alek,  
Dipl.-Chem. et al  
Patentanwâlte Von Kreisler-Selting-Werner,  
Delchmannhaus am Hauptbahnhof  
W-5000 Köln 1(DE)

(54) Leukotriene B<sub>4</sub> antagonist.

(57) Leukotriene B<sub>4</sub> antagonists of the formula:



wherein each symbol is as defined in the specification, processes for producing them, and pharmaceutical compositions containing them. The compounds of the present invention are very useful as the drugs for the treatment of allergic and inflammatory diseases.

EP 0 516 069 A1

pfs no=91157725 cc=JP ls

NO : 91 157725 CC : JP

FAMILY MEMBERS

CC	PUBDAT	KD	DOC.NO.	CC	PR.DAT	YY	PR.NO.
					JP 1991/05/31	91	157725

AT 1996/05/15 E 137223

AU 1993/03/11 A1 1719392

AU 1993/11/04 B2 643140

CA 1992/12/01 AA 2069667

DE 1996/05/30 C0 69210091

DE 1996/10/02 T2 69210091

DK 1996/05/13 T3 516069

EP 1992/12/02 A1 516069

DC : AT BE CH DE DK ES FR GB GR IT LI NL PT SE

EP 1996/04/24 B1 516069

DC : AT BE CH DE DK ES FR GB GR IT LI NL PT SE

ES 1996/07/01 T3 2086579

GR 1996/08/31 T3 3020050

JP 1993/09/17 A2 5239004

MX 1993/01/20 A1 9202612

US 1993/07/06 A 5225422